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Abstract 
There are several challenges associated with current strategies for drug and vaccine delivery. 
These include the need for multiple-dose administrations, which can hinder patience 
compliance, the requirements for specific storage conditions due to the fragile structure of 
protein-based molecules, and the need for additional excipients to enhance protein stability or 
adjuvant the immune response. This work has focused on the development of a high 
throughput, combinatorial approach to optimize degradable polymeric biomaterials, 
specifically polyanhydrides, to overcome these challenges associated with drug and vaccine 
delivery. We have developed high throughput techniques to rapidly fabricate polymer film 
and nanoparticle libraries to carry out detailed investigations of protein/biomaterial, 
cell/biomaterial, and host/biomaterial interactions. By developing and employing a highly 
sensitive fluorescence-based assay we rapidly identified that protein release kinetics are 
dictated by polymer chemistry, pH, and hydrophobicity, and thus can be tailored for the 
specific application to potentially eliminate the need for multiple-dose treatments. Further 
investigation of protein/biomaterial interactions identified polymer chemistry, pH, 
hydrophobicity, and temperature to be integral factors controlling protein stability during 
fabrication of the delivery device, storage, and delivery. Amphiphilic polymer chemistries 
were specifically identified to preserve the structure of both robust and fragile proteins from 
device fabrication to release. Our investigations of cell/biomaterial interactions revealed that 
all nanoparticle and polymer film chemistries studied were non-toxic at concentrations 
expected for human use. Furthermore, cellular activation studies were carried out with 
antigen presenting cells co-incubated with the polymer libraries which indicated that polymer 
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films do not possess immune stimulating properties; however, the nanoparticles do, in a 
chemistry dependent manner. Combining these insights with informatics analysis, we 
discovered the molecular basis of the “pathogen-mimicking” behavior of amphiphilic 
polyanhydride nanoparticles. Specific molecular descriptors that were identified for this 
pathogen-mimicking behavior include alkyl ethers, % hydroxyl end groups, backbone 
oxygen content, and hydrophobicity. These findings demonstrated the stealth properties of 
polyanhydride films for tissue engineering and the pathogen-mimicking adjuvant properties 
of the nanoparticles for vaccine delivery. Finally, host/biomaterial interactions were studied, 
which indicated that polymer chemistry and administration route affect nanoparticle 
biodistribution and mucoadhesion. Amphiphilic nanoparticles were identified to reside 
longest at parenteral administration routes and adhere best to mucosal surfaces. These results 
point to their ability to provide a long-term antigen depot in vivo. In summary, the studies 
described in this thesis have created a rational design paradigm for materials selection and 
optimization for use as drug delivery vehicles and vaccine adjuvants, which will overcome 
the challenges associated with administration frequency, protein instability, and insufficient 
immune stimulation. 
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Chapter 1: Introduction 
1.1 Introduction 
Biodegradable polymers have the advantage of delivering biological molecules at controlled 
rates, thereby limiting the need for repeated treatments [1-10] . This has beneficial implications 
in both vaccine and drug delivery, where multiple treatments are usually required to achieve 
the desired outcome. In many cases, several doses are necessary to gain full protection 
against pathogens such as Bacillus anthracis, hepatitis B virus, etc [11, 12]. Many conventional 
methods include frequent inoculations with the antigen or administration of the therapeutic 
drug to achieve protection against the pathogen or disease treatment. When these 
administrations are performed via injections, they are often painful and lead to poor patient 
compliance [13, 14]. Additionally, concerning vaccines, it is suggested that the best way to 
achieve vaccine efficacy is by vaccinating through the same route that the pathogen uses to 
infect the host [15]. Thus, vaccines and therapeutics need to be tailored to use the best 
adjuvant, administration route, treatment dose, and exposure or controlled release of the 
antigen/drug. There is a need for controlled delivery systems for vaccines and therapeutic 
drugs that can meet the desired specifications for disease prevention and treatment. 
 
Current advancements in medicine have led to the development of protein-based drugs for 
cancer, bacterial, viral and autoimmune diseases. The poster child of these drugs is 
recombinant insulin for diabetic patients, which was approved by the United States FDA 
(Food and Drug Administration) approximately 27 years ago [16]. Many other protein-based 
biomolecules have also emerged as vaccine antigen candidates (H1N1: influenza, rPA: 
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anthrax, rF1V: pneumonic plague, TT: tetanus, IPV: polio, etc) and as therapeutic drugs 
(anti-toxins: animal venom, penicillin: bacterial infection, insulin: diabetes, IL-2: metastatic 
cancer, IFN-γ: chronic granulomatous, γ-globulin: x-linked agammagolbulinemia, etc.) [17]. 
However, many of these proteins are fragile and sensitive to structural instability upon 
storage and administration. The effect of storage on drug stability is even more pronounced 
in developing countries with limited resources for the necessary storage conditions. To 
overcome these challenges, polymer-based drug carriers have emerged as frontrunners. Some 
of these carriers are unique in that they can be fabricated into different device geometries 
(e.g., films for tissue engineering scaffolds [18, 19] , implant coatings [20-24], drug eluting stents 
[25, 26]; microparticles for injectable localized drug delivery [2-7, 9, 27-30]; or nanoparticles for 
inhalable or injectable systemic drug delivery [8, 21, 22, 31-41]) to best fit the desired application 
of disease treatment. Additionally, many of these polymeric drug carriers are capable of 
providing protein stabilizing environments as well as controlled release kinetics to both 
preserve the drug functionality as well as deliver it in a manner to best fit disease treatment [3, 
4, 6-9, 37]. Their role in drug delivery has shown great promise due to their biocompatibility and 
highly tunable behavior resulting in control over release kinetics [42], immune modulation [5, 
22, 30, 35, 38, 40], protein stability, and responsiveness to environmental changes such as pH . The 
primary goal with these polymeric devices is to eliminate multi-dose administration as well 
as preserve protein-based drugs in less favorable environments leading to a more viable 
method for drug and vaccine administration. 
 
Current research in this field has focused on versatile groups of polymeric biomaterials with 
a broad range of properties including: acid-catalyzed polymers (polyacetals, polyketals and 
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polyorthoesters), polyesters, polyethers, and polyanhydrides. Many of these biomaterials 
haven demonstrated the ability to successfully deliver therapeutic drug-based therapeutics. 
For example, several polyesters have FDA approval for human use and are commercially 
available, making them ideal for research in drug delivery. Polyanhydrides have shown many 
benefits in their ability to stabilize proteins, control the rate of drug release, as well as 
enhance/modulate the immune response to vaccine antigens [3, 4, 6-9, 22, 29, 35-38, 40, 43]. 
Polyanhydrides composed of 1-6 bis(p-carboxyphenoxy)hexane (CPH) (Figure 1.1), sebacic 
acid (SA) (Figure 1.2) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) (Figure 
1.3) have been studied extensively in a conventional format for use as drug delivery devices. 
The Gliadel® wafer, a U.S. FDA approved polyanhydride based drug delivery system, has 
been used in the treatment of brain tumors [44]. Their history of positive impact for human use 
[45] along with their chemical diversity makes polyanhydrides ideal candidates for protein and 
vaccine delivery. Today, many preferred drugs and antigens are proteins, but they are more 
susceptible to various forms of deactivation due to their chemical and physical environments 
[3, 37, 46]. To ensure protein stability and functionality, it is necessary to provide stable 
microenvironments for these protein-based drugs during storage, encapsulation and in vivo 
delivery. Due to their versatile chemistries and degradation rates, polyanhydrides are 
excellent candidates for protein stabilization and delivery. 
 
The rational design and optimization of polymeric biomaterials is achievable by tailoring 
their properties and experimental conditions to ensure their function for the specific 
application. This is typically carried out through careful and time-consuming “conventional” 
(i.e., one experiment-at-a-time) methods to study the effect of multiple parameters with each 
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parameter differentially affecting the experimental outcome. For example, these parameters 
could include polymer properties (e.g., chemistry, degradation mechanisms and kinetics, 
glass transition temperature, melting temperature, surface molecules, etc.), experimental 
conditions (e.g., temperature, buffers, pH), protein/polymer interactions (e.g., release 
kinetics, stability, etc.), cell/polymer interactions (e.g., cytotoxicity, proliferation, adhesion, 
etc.) and host/polymer interactions (e.g., biodistribution, residence time, mucoadhesion, etc.). 
Often this trial-and-error process, which involves testing one variable at a time, can become 
expensive, time-consuming, and potentially non-reproducible. The rational design of 
polymeric biomaterials is a multi-variant problem in which efficient methods enabling 
numerous variables to be tested simultaneously are needed to rapidly advance their 
development for drug and vaccine delivery applications [47, 48].  
 
The combinatorial approach to discovery was initially propelled into research by the 
pharmaceutical industry [49]. Difficulties in efficiently evaluating complex combinations of 
proteins, biomolecules, and biological components directed the focus on combinatorial 
techniques that have led to the development of biological assays and high throughput 
automated sampling and data quantification (e.g., auto samplers and plate readers). More 
recently, the combinatorial approach has been applied to biomaterials development focusing 
on parallel synthesis and characterization, and optimization of the properties best suited for 
specific biomedical applications [8, 21, 22, 36, 38, 43, 48, 50-54]. The design of biomaterials for drug 
delivery involves complex interplay between the material, the drug/antigen, the processing 
conditions, and the in vivo/in vitro conditions into which the material is applied or delivered. 
Optimizing these variables to administer a drug or an antigen at a desired rate to a specific 
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organ, or to deliver an antigen to a specific cell type to elicit the desired immune response are 
daunting challenges that could significantly benefit by the use of combinatorial techniques. 
This methodology also plays a central role in the subsequent biological screening of cellular 
and host interactions with biomaterials. The versatility of the combinatorial methodology 
makes it amenable to numerous applications and processes allowing for accelerated 
discovery, optimization, and reduced experimental and user variability. However, the central 
role of the combinatorial method is to function as a screening tool for the rapid identification 
of “hot spots” or areas of interest in a multi-variant parameter space. The identified key areas 
must then be further investigated and validated through conventional experimentation. In 
summary, the generality of the technique paves the path for rational design and development 
of biomaterials for specific applications in drug/vaccine delivery. With this in mind, the 
overall goal of the research described in this thesis is the rational design and development of 
polyanhydrides as drug and vaccine delivery devices using combinatorial and high 
throughput methodologies. 
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1.3 List of Figures 
 
 
 
Figure 1.1: The chemical structure of poly(CPH) 
 
 
 
 
Figure 1.2: The chemical structure of poly(SA) 
 
 
 
 
 
Figure 1.3: The chemical structure of poly(CPTEG) 
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Chapter 2: Literature Review 
2.1 Summary 
Current research in the field of polymeric biomaterials for drug and vaccine delivery has 
focused on versatile groups of degradable materials including: acid-catalyzed polymers 
(polyacetals, polyketals and polyorthoesters), polyesters, polyethers, and polyanhydrides. 
These biomaterials have been used as therapeutic delivery vehicles, vaccine adjuvants, tissue 
engineering constructs, drug eluting stents, and multi-component implants. Due to their non-
toxic, biocompatible, and bioresorbable properties, these biodegradable polymers are 
excellent candidates for use as protein-based drug delivery devices. Additionally, they have 
tunable parameters which can be optimized to meet treatment requirements, including 
tailored release kinetics, protein stabilization, and immune modulation. Section 2.2 gives a 
brief overview of polymeric biomaterials and their use in drug delivery applications. Section 
2.3 demonstrates the ability of polymers to differentially modulate the immune system based 
upon polymer chemistry, particle size and particle shape. As a result of the large parameter 
space to be evaluated and optimized to study these protein/polymer and cell/polymer 
interactions, there is a need for a more rapid, multi-parametric approach to be integrated into 
the design and development of these biomaterials. These approaches are discussed in Section 
2.4, which provides an overview of combinatorial approaches used to design and discover 
biomaterials and the need for these studies to more efficiently develop therapeutic and 
prophylactic medical treatments. 
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2.2  Polymeric Biomaterials: Drug Delivery Applications 
2.2.1 Introduction 
Polymeric biomaterials have been studied for many decades. Initial applications of these 
materials originated in the textile industry in the 1910’s. Polyanhydrides and polyesters 
demonstrated robust mechanical properties upon being spun into fibers and were initially 
intended for use in the fabrication of textiles and clothing. However, these degradable 
polymers were soon deemed unusable for such applications. Steps were taken to make these 
polymers more durable and long-lasting by incorporating carboxylic rings into their 
backbone [1-3]. While these modified materials showed slower rates of degradation these 
materials were found to be less stable and therefore their use as fibers in the textile industry 
was short lived. 
 
In the 1960’s, researchers discovered alternative uses for these biomaterials in biomedical 
applications for drug delivery. Poly(glycolic acid) (PGA) (Figure 2.2.1), a member of the 
polyester family, was employed for use as surgical sutures and biomedical implants [4-6]. 
While this class of polyesters is biocompatible and non-toxic and has demonstrated much 
success in the field of biomaterials, their use in protein delivery has some limitations. 
Commonly used copolymers of PGA and poly(lactic acid) (PLA) (Figure 2.2.1) have non-
tunable protein release kinetics, which results in either rapid or very slow protein release [7-
17]. Effective drug delivery is demonstrated by controlled release kinetics which is difficult to 
achieve with polyesters. In addition, they undergo bulk erosion which results in diffusion-
controlled protein release, as shown in Figure 2.2.2 [7]. These polymers also degrade into 
highly acidic degradation products (pH ~3.5-3.6) which can lead to acid-induced hydrolysis 
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of encapsulated therapeutic protein-based drugs intended for drug deliver y [18-24]. 
 
These limitations prompted further design and development of biomaterials with alternative 
degradation mechanisms. In the early 1980’s two classes of polymeric biomaterials were 
developed, acid-catalyzed polymers (Figure 2.2.3) and polyanhydrides (Figure 2.2.4) [25-30]. 
These polymeric systems undergo surface erosion which enables protein release kinetics to 
mimic the polymer degradation, as shown in Figure 2.2.4. In the case of polyanhydrides, the 
degradation rates can be tailored to suit specific applications by changing the chemistry [30-41]. 
This method of controlled protein release has been used in a wide range of applications 
including the treatment of Alzheimer disease and several forms of cancer as well as vaccine 
delivery of both DNA and protein based treatments [34, 42-47].  
 
Additional polymeric biomaterials which also emerged as drug delivery devices in the early 
1980’s include polyethers (Figure 2.2.5), which have demonstrated use in a wide range of 
applications due to their high drug loading capabilities and easy administration [48-51]. 
However, the stability of this polymeric device in water degradation poses challenges and is 
achieved through enzymatic means, oxidation, or device disassociation and extraction [51].  
 
In the following sections, a brief overview of polymeric biomaterials and their applications in 
drug delivery will be discussed Section 2.2.2 deals with acid-catalyzed polymers 
(polyacetals, polyketals and polyorthoesters), Section 2.2.3 with polyesters, Section 2.2.4 
with polyanhydrides, and Section 2.2.5 with polyethers. 
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2.2.2 Acid-Catalyzed Polymers 
Acid-catalyzed polymers emerged in the field of biomaterials for use in drug delivery in the 
last thirty years [25-29]. The need for surface eroding polymers led to the discovery of several 
versatile acid-catalyzed polymers including polyacetals, polyketals and polyorthoesters, as 
shown in Figure 2.2.3.  
 
While non-degradable polyacetals (e.g., Delrin®) have been used in the medical field for 
many years [52-56], only recently have degradable polyacetals and polyketals been developed 
for applications in drug delivery and tissue engineering [51, 57]. They have been investigated in 
this field in the form of thermoresponsive gels [58], microparticles [59, 60] and poly-
functionalized polymers with specialized structures [61, 62], all of which have differential 
protein release profiles based upon release environment pH [18, 19, 51, 63]. Due to their 
responsiveness to pH they have been used as tumor targeting vehicles, enabling site-specific 
drug release at the more acidic tumor location [18, 19, 51, 58, 63, 64]. Polyacetal microparticles with 
polyethylene glycol (PEG) incorporated into their backbone were able to provide prolonged, 
sustained drug delivery as a result of the increased hydrophilicity of the microparticle device 
inhibiting cellular uptake. They also have been shown to have minimal effects on local pH 
environments, limiting their overall effect on inflammation and immune aggravation. Thus, 
these materials demonstrated biologically inert properties important for drug delivery 
applications in tissue engineering and administration of local therapeutics in which immune 
activation is not desired [51]. Additionally, polyacetals have been utilized as therapeutic 
delivery agents by incorporating anti-cancer drugs, non-steroidal oestrogen 
diethylstilboestrol (DES), into the polyacetal backbone, thus enabling DES release upon 
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polymer degradation [51, 58]. 
 
Another group of acid-catalyzed polymers similar to polyacetals and polyketals are 
polyorthoesters. They have been fabricated into microparticles and medical implants but their 
applications in drug delivery demonstrate a much broader range of therapeutics capabilities 
including the delivery of cancer chemotherapeutics, periodontal therapeutics, anti-
inflammatory agents, intraocular therapeutics, anesthetics, and DNA [65-74]. While 
polyorthoesters lack the ability to provide a long-term sustained drug release, researchers 
have synthesized polyorthoester-amines, which are capable of providing a more sustained 
drug release profile [75]. This rapidly advancing field of acid-catalyzed polymeric 
biomaterials is enabling the optimization of drug delivery vehicles and tissue engineering 
constructs with biologically inert properties [51]. 
 
2.2.3 Polyesters 
The most widely investigated degradable polymeric biomaterials are polyesters, specifically 
those based on copolymers of lactic and glycolic acids (PLA, PGA, and PLGA) and poly(ε-
caprolactone) (PCL) (Figure 2.2.1) with wide ranging applications in drug delivery and tissue 
engineering constructs [10, 12-17, 20-23, 51, 71, 76-107]. A significant amount of research has been 
carried out in the past several decades to investigate these materials for biomedical 
applications. They have favorable properties including their biocompatibility and low 
cytotoxicity which is a result of their degradation into cellular metabolites, readily taken up 
by surrounding cells [51, 108, 109]. 
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PGA is a hydrophilic polymer with a highly crystalline structure and has been most 
commonly used in the medical field as resorbable sutures [51, 110]. Upon degradation it 
undergoes bulk erosion (Figure 2.2.2) in which it rapidly loses most of its mechanical 
properties and results in a burst release of an encapsulated drug [7, 110]. To compensate for this 
structural loss often times PGA is copolymerized with the hydrophobic semi-crystalline 
poly(lactic acid) (PLA) resulting in PLGA copolymers [17, 22, 23, 51, 77, 84-86, 90, 93, 96, 99-101, 103, 105, 
107, 111, 112].  
 
PCL, which is FDA approved for applications in drug delivery and biodegradable sutures, is 
another member of the polyester family which is semi-crystalline in structure, similar to PLA 
[51]. However, PCL has a much slower degradation profile ranging from one to three years in 
vivo [113-117]. Due to this prolonged degradation rate it has been utilized in blends or 
copolymers to expedite the degradation rate [51, 77, 118-127].  
 
While all polyesters undergo bulk erosion due to the stability of their ester bonds, controlled 
drug delivery becomes a difficult task due to several limitations. Despite the incorporation of 
lactic acid (from 50 to 100%) into the PLGA copolymer, they possess a very limited range of 
release kinetics [8-10]. Additionally, the ingress of water into the bulk of the polymer network 
exposes encapsulated protein to low microenvironment pH levels and allows for significant 
residence time with the surrounding water [20, 22, 128]. Both mechanisms have demonstrated to 
be detrimental factors in preserving protein stability [20, 22, 89, 90, 128]. To compensate for these 
problems, basic compounds such as Mg(OH)2 and MgCO3 have been incorporated into the 
polyester particles or devices and have demonstrated a less acidic release environment upon 
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protein release; however, additional components can complicate the delivery of fragile 
therapeutic drugs by affecting the release profiles, biocompatibility, and in vivo side effects 
[93, 129]. These limitations demonstrate significant hurdles for the use of polyesters in drug 
delivery. 
 
2.2.4 Polyethers 
Polyethers have been investigated for drug delivery applications. The most common 
polyethers are poly(ethylene glycol) (PEG) and poly(propylene glycol) (PPG) (Figure 2.2.5). 
They have been used in conjunction with several of the other polymeric biomaterials 
discussed in this chapter . The incorporation of PEG into the backbone of many of these 
materials (e.g., polyanhydrides, PCL, and acid-catalyzed polymers) allows for a more 
amphiphilic environment and in many cases alters the degradation rate, (e.g., reduces the 
year-long degradation profile of PCL) [77, 78, 121, 130, 131]. Additional studies have demonstrated 
the ability of PEG to oppose interactions with the host by acting as a phagocytosis and 
cellular adhesion inhibitor [132, 133]. This can be used as a coating for polymeric micro- and 
nanoparticles intended for drug delivery in which cellular adhesion or phagocytosis is not 
desirable. 
 
An additional polyether commonly used in drug delivery applications is the triblock 
copolymer ([PEG]n-[PPG]m-[PEG]n) known as Pluronic®. This copolymer has unique 
micelle forming properties, via self assembly in water, due to the hydrophilic PEG and 
hydrophobic PPG, enabling the formation of nanometer sized particles [134]. In addition, the 
amphiphilicity of this copolymer enables for high drug loading, on the order of 30%, of 
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hydrophobic molecules and allows for many cell/polymer interactions including hydrophobic 
surfaces and cellular membranes [48].  
 
Despite the unique properties and significant advantages of the polyether system, there are 
hurdles which must be overcome. Specifically, polyethers do not undergo water induced 
hydrolysis because of their hydrolytically stable ether bond and therefore require the use of 
alternate components (i.e. enzymes) for degradation or surgical extraction [51]. In addition, the 
slow in vivo degradation of high molecular weight polyethers like PEG, can lead to 
accumulation and subsequent immune activation. By minimizing the polymer molecular 
weight and utilizing non-invasive degradation mechanisms, this polymeric biomaterial holds 
much promise for future applications in drug delivery. 
 
2.2.5 Polyanhydrides 
Polyanhydrides are a class of versatile biomaterials and can often be grouped into three 
primary classes: 1) aliphatic, 2) unsaturated and fatty-acid derived and 3) aromatic 
polyanhydrides [31]. Polyanhydrides have been studied extensively for use as drug and 
delivery devices and vaccine adjuvants [32-37, 39, 40, 135-150]. Modulation of the stability and 
release of an encapsulated protein drug is a critically important advantage of these polymeric 
devices and is credited to the unique chemistry and tunable release kinetics, with the ability 
to mimic the polymer degradation in an aqueous environment [7]. Polyanhydrides have been 
shown to degrade by surface, bulk, and combined erosion (Figure 2.2.2) mechanisms via 
hydrolysis into acidic monomers over a period of years to weeks to days [31, 37, 136]. These 
degradation times are directly related to the release rates of encapsulated proteins and can be 
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modulated by synthesizing copolymers with various combinations of monomers as dictated 
by application. These polymers also possess important protein stabilization properties, which 
is a significant problem with other drug delivery devices (i.e. polyesters). They are 
biocompatible (at concentrations up to 5000 μg/mL in vivo) as they degrade into non-toxic, 
non-mutagenic degradation products capable of being metabolized intracellularly [46, 139, 151]. 
In 1996, the U.S. FDA approved the use a polyanhydride drug delivery system, the Gliadel™ 
wafer, for the treatment of brain tumors. The wafer is composed of poly((1,3-bis(p-
carboxyphenoxy)propane) and (sebacic acid)) (CPP:SA) in a 20:80 molar ratio encapsulating 
a chemotherapeutic agent, 1,3-bis[2-chlororthyl]-1-nitro-sourea (BCNU), otherwise known 
as carmustine [42]. 
 
The most common aliphatic polyanhydrides include poly(SA) and poly(adipic acid) (AA), 
which are semi-crystalline polymers that exhibit surface erosion [31]. Poly(SA) was first 
synthesized in 1987 and is often used in coordination with other polyanhydrides [30]. Some 
unsaturated and fatty acid derived polyanhydrides include poly(fumaric acid) (FA) and 
acetylenedicarboxylic acid (ACDA) [31]. They contain significant mechanical strength and 
when copolymerized together with SA, they are able to increase the bioavailability of orally 
delivered proteins. Finally the third class is a group of aromatic polyanhydrides, which 
encompasses poly(isophthalic acid) (IPA), poly(terephthalic acid) (TA), 1-6 bis(p-
carboxyphenoxy)hexane (CPH) and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
[31]. With the exception of CPTEG, the degradation of these hydrophobic, surface eroding 
polymers can exceed one year and are therefore often copolymerized with more rapidly 
eroding aliphatic polyanhydrides. 
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Polyanhydrides based on CPP, CPH, SA, and CPTEG have been well studied (Figure 2.2.4). 
These polyanhydrides have highly tunable properties when polymerized together as 
copolymers (CPH:SA or CPTEG:CPH) allowing for tailored release kinetics, protein 
stability, and immunomodulatory capabilities [32-36, 39, 139, 142, 143, 145-149]. Narasimhan and 
colleagues have extensively studied these polyanhydrides and have demonstrated their 
excellent characteristics for use as drug and protein carriers. They have demonstrated the 
ability of these polyanhydrides to be fabricated into multiple device geometries including 
films, nanoparticles, microparticles, and tablets [32-36, 39, 40, 46, 47, 136, 139, 142-149, 151-158]. This 
allows for their use in a broad range of drug delivery applications including injectable 
microparticle delivery, inhalable/injectable nanoparticle delivery, implantable tablets, drug 
eluting stents, multi-component implants, and tissue engineering constructs.  
 
As previously mentioned, polyanhydrides can undergo surface, bulk, or a combination of 
degradation mechanisms, with CPTEG undergoing bulk and CPH and SA undergoing surface 
erosion [38, 39]. However, these monomers can be copolymerized together to allow for tunable 
protein release kinetics. As to be expected, the less hydrophobic copolymers (CPTEG and 
SA rich) tend to degrade more quickly than more hydrophobic copolymers (CPH rich). 
CPTEG-rich systems tend to exhibit an initial burst of protein whereas the CPH and SA-rich 
systems demonstrate a much smaller initial burst [33-36, 39, 147]. This is also observed with high 
protein loading. This polymer degradation and subsequent protein release have been well 
documented in the literature for several proteins, including bovine serum albumin (BSA), 
ovalbumin, tetanus toxoid, the protective antigen for anthrax, lipocalin-2, and the 
recombinant F1-V antigen [32, 34-36, 39, 143, 144]. Release kinetics between proteins can differ 
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based upon their affinity for the homopolymer or microphase separated regions of the 
copolymer [37, 38]. It has been reported by Carrillo-Conde et al. that antigens for pneumonic 
plague, F1–V fusion protein and the F1B2T1–V10, release differently from 50:50 
CPTEG:CPH nanoparticles, which is likely a result of differential affinity for the copolymer 
[32]. 
 
In addition to protein release kinetics it has been reported that protein stability is 
differentially affected by the polyanhydride copolymer chemistry [32-35, 39, 142-144, 146]. 
Specifically, CPTEG:CPH copolymers are of key interest because their amphiphilic 
properties have been shown to provide an excellent environment for protein stabilization, 
securing both protein structure and function [32-35, 39, 146]. The structure of the CPTEG 
monomer differs from that of the CPH monomer in that it has oligomeric ethylene glycols in 
its backbone. This is what creates the more amphiphilic environment favorable for 
encapsulating proteins. SA-rich copolymers have been demonstrated to provide a much less 
favorable protein environment due to their degradation into monomers resulting in an acidic 
microenvironment, which is harmful to the function of many protein-based drugs [33, 35, 142, 143, 
146, 159].  
 
While some polyanhydrides possess limitations (e.g., SA-rich materials lead to protein 
hydrolysis), many of these problems can be overcome due to the availability of a large library 
of polyanhydrides to copolymerize together allowing for optimization of the desirable 
polymer system. This class of biomaterials has demonstrated success in terms of 
biocompatibility, protein stability, and tunable protein release kinetics; additionally, they 
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have also shown the unique ability to modulate the immune system based upon copolymer 
chemistry, which will be discussed in the next Section. 
 
2.3 Polymeric Biomaterials: Vaccine Adjuvants 
2.3.1 Introduction 
Vaccination is one of the most successful medical interventions for eliminating infectious 
diseases in the past 200 years [160]. It is estimated that for every $1 spent on vaccination, 
another $5-10 is saved for what would have been spent on disease treatment [161]. The 
effectiveness of vaccination has been demonstrated through the world-wide eradication of 
human small pox virus and the elimination of the polio virus in the US, Europe, and the 
Western Pacific [162]. 
 
Despite the benefits and effectiveness of many vaccines available today, infectious disease 
still remains a leading cause of death worldwide [163, 164]. It is estimated by the World Health 
Organization that approximately 14% of childhood deaths are caused by vaccine preventable 
diseases [165]. Problems associated with vaccine administration and disease prevention are 
often associated with the need for multi-dose administration, poor patient compliance, poor 
immunogenicity of vaccine antigens, and rapidly evolving/mutating pathogens [166, 167]. Full 
protection from a pathogen through vaccination often requires multiple doses to be 
administered incrementally. Often times, the immune system will produce a response to the 
initial vaccine dose which involves antigen presenting cells and many other naïve immune 
cells while later vaccine doses are able to promote the long term memory required for full 
protection. It has been reported that in developing countries that as much as 70% of vaccine 
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patients drop out after the first administration and are therefore not fully protected [13]. In 
addition, many current diseases lack FDA approved vaccines because available vaccine 
antigens for those diseases are not highly immunogenic and are not able to result in the 
development of protective immunity; however, vaccines remain the most cost effective 
method to combat infectious disease [168]. 
 
These problems associated with preventive vaccine protection could be addressed with the 
use of controlled delivery devices and vaccine adjuvants. Controlled delivery devices such as 
polymeric biomaterials could allow for tunable antigen release, which is able to mimic the 
multi-dose regimen with a single injection of the soluble antigen plus antigen encapsulated 
into the polymeric delivery device [46, 169]. Additionally, the prolonged residence time of these 
materials in vivo would provide continual antigen (specific-stimulation) exposure to antigen 
presenting cells (APCs) to fully activate adaptive and innate immune responses. This has 
been investigated with a host of polymers including acid-catalyzed polymers (polyketals and 
polyorthoesters, polyesters (PLA, PGA, PLGA, poly(ester-amide) (PEA), and PCL), 
polyethers (PEG), and polyanhydrides (SA, CPTEG, and CPH)) [14, 46, 47, 58, 88, 170-176]. In 
addition to their function as vaccine/drug delivery devices, as discussed in Section 2.2, they 
have also been investigated as vaccine adjuvants [46, 47, 79, 80, 86-88, 94, 103, 105, 139, 145, 147-149, 158, 170, 
177, 178]. An adjuvant is an agent capable of stimulating the immune system without having 
any inherent antigenic properties [171, 179, 180]. Such agents are able to encapsulate the desired 
antigen and deliver it to immune cells while enhancing and modulating the immune response 
over what the antigen could achieve when administered alone [171, 178, 181-183]. In addition, 
adjuvant agents could be encapsulated into polymeric biomaterials to synergistically enhance 
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the immune response [87, 180]. Currently there are several polymeric adjuvants under 
investigation for use in vaccination; however, only PLGA microparticles are currently 
undergoing clinical trials for human use [184]. In addition, there is a wide range of non-
polymeric adjuvants (e.g., cytokines, virosomes, oil emulsions, alum, MPLA) in current 
clinical trials but only one (alum) is approved for human use in the U.S. [171, 180, 184, 185].  
 
When designing vaccine adjuvants to enhance a specific immune response, it is important to 
understand the multi-faceted aspects of both the innate and adaptive immune responses and 
the different branches that stem from these responses (Th1, Th2, Th17, Th0). Innate and 
adaptive immune systems work in concert to make up the body’s defense mechanism against 
infectious disease [186]. The innate system is the first line of defense and is responsible for 
recognizing foreign pathogens or agents. Cells from the innate system would the primary 
target for vaccine adjuvants since they are the initial responders to pathogenic antigens and 
determine the robustness of the primary response to the antigen. Much of the foreign body 
recognition of these cells is triggered through interaction of pattern recognition receptors 
(PRRs) such as Toll-like receptors (TLRs) with pathogen-associated molecular patters 
(PAMPs) [187]. These PAMPs are comprised of bacterial components such as 
lipopolysaccharide (LPS) which is found on the surface of gram-negative bacteria [188]. 
Depending upon the effectiveness of the innate immune response, engagement of the 
adaptive immune response is conditional.  
 
Dendritic cells (DCs) are primary APCs and play key roles in both innate and adaptive 
immunity [189]. DCs can be found in all body tissues and are often in an immature state 
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allowing for antigen sampling through phagocytosis, endocytosis, micropinocytosis, or 
receptor-mediated uptake (mannose, complement, or Fc receptors) [190]. There are several 
subsets of DCs which include but are not limited to Langerhans’, interstitial, myeloid (DC1), 
or lymphoid (DC2) [191]. Each subset plays a different role in the immune system from 
antigen processing and presentation to the induction of tolerance (the act of identifying self-
antigens which should not be responded upon by the immune system) [191]. As the DCs 
undergo activation upon encountering a foreign antigen they process the antigen, undergo a 
maturation process, and then migrate to the draining lymph nodes. The DCs will internalize 
the foreign antigen and present it on its surface via major histocompatibility complexes 
(MHC) I or II depending upon the location of the foreign pathogen (MHC I: endogenous 
pathogen, MHC II: exogenous pathogen) [179, 192]. Additional co-stimulatory molecules 
(CD80, CD86 and CD40) will be expressed on the cell surface for interaction with naïve T 
cells, either CD4+ or CD8+. Interactions with each T cell type are dependent upon the cell 
surface molecule by which the antigen is presented (MHC I or MHC II) [193, 194]. Upon 
processing of an endogenous pathogen the DC will present the pathogen via MHC I cell 
surface molecules which results in the maturation and activation of cytotoxic CD8+ T cells 
[193]. This is an important component of cell-mediated immunity because activation of CD8+ 
T cells enables them to directly kill infected cells. Conversely, when exogenous antigen is 
taken up by the DCs and presented via the MHC II cell surface molecule, CD4+ T cells are 
stimulated. The CD4+ T cell response encompasses both cell-mediated as well as humoral 
immunity. There are many CD4+ T cell subtypes including Th1, Th2, Th17, and Treg cells 
[195-197]. Upon activation by the MHC II-antigen complex, a Th2 immune response is 
characterized by the production of IL-4, IL-5, IL-10, and IL-13, as well as the secretion of 
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IgG1 and IgE, resulting in a humoral response. Th1 immune responses are dictated by 
interaction with the MHC II-antigen complex and production of INF-γ and TNF-β as well as 
secretion of IgG2a which leads to a cell-mediated response characterized by the activation of 
macrophages [198]. This network of immune responses is illustrated in Figure 2.3.1. Less is 
known about Th17 responses; however, they are considered to be pro-inflammatory and can 
be characterized by the production of IL-17 [195]. Treg cells are T cells responsible for 
regulating the immune system and controlling over-stimulation through production of 
cytokines such as IL-10. 
 
As discussed before, the immune system is a complex network of pathways; however, when 
designing vaccine adjuvants, it is important to understand the basic directions the immune 
system can take upon encountering foreign pathogens to enable the design of these materials 
to better mimicking the natural infection. The following sections will investigate the use of 
polymeric vaccine adjuvants acid-catalyzed polymers (polyketals and polyorthoesters 
(Section 2.3.2), polyesters (PLA, PGA, PLGA, PEA and PCL) (Section 2.3.3), polyethers 
(PEG) (Section 2.3.4), and polyanhydrides (SA, CPTEG, and CPH) (Section 2.3.5). 
 
2.3.2 Acid-Catalyzed Polymer Adjuvants 
The use of acid-catalyzed polymer adjuvants has recently gained interest in the field of 
vaccinology. These surface eroding polymers are amendable for use as vaccine delivery 
devices because they are capable of encapsulating and releasing encapsulated antigens [51]. In 
addition, they can be fabricated into particles enabling non-invasive administration. Two 
groups of acid-catalyzed polymers, polyketals and polyorthoesters, have demonstrated 
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promising vaccine adjuvant properties to enable an enhanced Th1 modulated immune 
response. 
 
Recently, polyketals were investigated for their effect upon DCs and the subsequent priming 
of IFN-γ producing CD8+ T cells [199]. The polyketals were administered in the form of 
microspheres and encapsulated a hydrophobic complex, the antigen, ovalbumin, and a TLR3 
agonist, double-stranded RNA analog poly(inosinic acid)–poly(cytidylic acid) (poly(I:C)), 
both of which were ion-paired to cetyltrimethylammonium bromide (CTAB). The results 
demonstrated the ability of the antigen-loaded polyketal microparticles to induce a higher 
percentage of CD8+ T cells and promote more production of TNF-α and IL-2 than the 
antigen complex administered alone [199]. 
 
The use of DNA vaccines is another vaccine strategy employed in current vaccinology 
studies because these vaccines are able to elicit both cell-mediated (CD8+ and CD4+ Th1) 
and humoral (CD4+ Th2) immune responses [200]. DNA vaccines are not effective when 
administered alone due to the rapid degradation of DNA in vivo. Thus, polyorthoesters have 
been recently studied for use in the delivery of DNA to protect the vaccine from degradation. 
It has been demonstrated that polyorthoesters have the ability to increase the cell-mediated 
immune response through activation of CD69+ CD8+ T cells as well as the humoral immune 
response through enhanced antibody production both before and after antigenic challenge 
[200]. To better demonstrate this combined immune response activated by the delivery of DNA 
vaccines through polyorthoesters, pre-immunized mice were challenged with tumors 
expressing a specific antigenic epitope and demonstrated restricted tumor growth compared 
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to mice immunized with the DNA vaccine alone or with non-immunized mice [200].  
 
Acid-catalyzed polymers are under current investigation as polymer adjuvants and vaccine 
delivery vehicles and have demonstrated much promise due to their non-acidic and non-toxic 
degradation products enabling antigen preservation and cellular viability. Polyketals also 
exhibited the ability to shift the immune response to cell-mediated immunity through the 
activation of CD8+ T cells. These materials have proven to be viable vehicles for the 
development of efficacious vaccine delivery should be further investigated for such 
applications. 
 
2.3.3 Polyester Adjuvants 
Polyesters have been investigated for use in vaccine delivery and adjuvant properties to 
enhance immune stimulation as well as modulate the immune response. They have 
encompassed several different vaccine strategies including antigen-loaded particles, DNA 
vaccines, as well as particle-based vaccines employing additional adjuvant agents (e.g. 
MPLA, CpG) [86-88]. However, due to their limited range of release kinetics and acidic 
monomer degradation products, antigen release and stability have been of primary concern. 
Despite these limitations several polyesters have been investigated in depth for use in vaccine 
delivery and administration including PLGA, PLA, PGA, PCL and PEA [15, 79-81, 83, 86-88, 92, 94, 
100, 102, 103, 105, 129, 170, 177, 178, 201-210]. 
 
PLA, PGA and copolymers of the lactic and glycolic acid subunits (PLGA) have been 
studied extensively for use in vaccine applications for the past 15 years [15, 79-81, 83, 86-88, 92, 94, 
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100, 102, 103, 105, 129, 170, 177, 178, 205-210]. They are well characterized and FDA approved for drug 
delivery applications and thus are likely candidates as vaccine adjuvants. Much research has 
been carried out to examine the adjuvant properties of PLGA microparticles on dendritic 
cells in vitro [79-81, 83, 88, 94, 103, 105, 170, 207]. Studies have shown that PLGA microparticles can 
enhance the expression of the cell surface marker CD86 and the production of cytokines [105, 
177]. Additional studies have shown that PLGA microspheres encapsulating antigens have 
demonstrated the ability to enhance antigen presentation via MHC I resulting in an increased 
activation of antigen specific CD8+ T cells; however, some of these studies included MPLA 
which is known to have a Th1 bias [80, 86, 88].  
 
To provide a better basis for human vaccination, several studies have also been carried out in 
vivo with antigen encapsulated into PLGA, PLA, and PGL microspheres to successfully 
produce an immune response towards Vibrio cholera antigens, Y. pestis antigens, B. pertussis 
antigens, measles virus antigen, influenza virus antigens, ovalbumin antigen, diphtheria 
toxin, type II collagen, malarial antigens, tetanus toxoid (TT), ricin toxoid cancer targeted 
antigens, E. Coli adhesion proteins, hepatitis B viral antigens, and HIV gp140 [177, 198, 205, 208, 
209, 211-215]. These immune responses were characterized by induction of mucosal IgA, serum 
antibodies, antibody isotype switching, and cell-mediated responses. Numerous studies have 
been carried out investigating the encapsulation and release of TT from PLGA 
microparticles. Some studies demonstrate the ability of TT loaded microparticles to elevate 
antibody titers over that of soluble antigen as well as antigen + alum [205]. Contrasting results 
were found with TT loaded microparticles, which did not demonstrate elevated antibody 
titers over that of TT + alum [209]. In addition, PLGA microspheres have been investigated to 
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modulate the in vivo immune response and have proven successfully in several cases [178, 206, 
216]. When encapsulating the HIV protein, gp 120, PLGA microspheres were shown to induce 
a shift from a Th2 dominant, to a combined Th1/Th2, to a Th1 dominant immune response 
[216]. Other research has suggested that upon encapsulation of the Th2-strong hepatitis B 
antigen into PLGA microparticles + MPLA, a shift to Th1 immunity is observed [178]. It is 
important to note that the adjuvant, MPLA, alone demonstrates a Th1 dominant response. 
Moreover, an additional study for vaccination against malaria provided evidence of the 
ability of Montanide ISA-720-loaded PLGA microparticles to induce a Th1 immune 
response as evidence by IgG isotype class switching [206]. While microspheres based on PLA, 
PGL, and PGLA have shown much success in the development of vaccine adjuvants and 
vaccine carriers, there still remains contradicting evidence which lead to inconclusive results 
for the efficacy of vaccine adjuvants based upon these polymers. 
 
In addition to the lactic and glycolic acid based polyester vaccine adjuvants, PCL has been 
investigated for applications in this field. Recent studies demonstrate the difference between 
micro and nano sized particles for efficacious vaccination [204]. Antigen loaded PCL was 
fabricated into microparticles and nanoparticles and administered for immunization to mice. 
Upon infectious agent challenge, mice immunized with nanoparticles demonstrated 
significant protection when compared to the microparticle- and soluble antigen-vaccinated 
and non-vaccinated controls. Although, additional agents were required for the stabilization 
of the antigen in the PCL particles, this study confirms the capabilities of PCL as a vaccine 
delivery device as well as the importance of particle size for induction of the necessary 
immune response [204]. 
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Finally, PEA, which is a unique biodegradable polymer that degrades via enzymatic 
degradation [202, 203] has been studied as a vaccine adjuvant. It is mechanically robust due to 
its amide components, yet its ester bonds allow for flexibility and hydrolytic vulnerability. 
Due to its degradation mechanism, PEA has unlimited shelf life and storage capabilities and 
is only triggered for degradation upon administration. This polymer has been conjugated with 
multiple antigenic peptides for vaccine applications against human melanoma, HIV, and 
influenza A. The responses demonstrated a significant shift to cell-mediated immunity 
through MHC I and MHC II driven T cell responses [202, 203]. 
 
As described in this Section, there are numerous areas of research on the use of polyesters as 
vaccine adjuvants and vaccine delivery devices. They have limitations, yet their commercial 
availability and acceptance in the field of biomaterials has driven researchers to overcome 
these hurdles to produce vaccine delivery vehicles. From the most common PLGA to the less 
known PEA, polyesters have and will continue to be a primary focus of research for drug and 
vaccine delivery. 
 
2.3.4 Polyether Adjuvants 
Polyethers have been studied to a limited degree as vaccine adjuvants and delivery vehicles 
with more widespread use in drug delivery. The only polyether reported for use in such 
applications is PEG. As is the case for many drug delivery applications employing PEG, 
studies in vaccine delivery have also incorporated other polymers in conjunction with PEG. 
Recently, poly(propylene sulfide) (PPS) nanoparticles were fabricated in combination with 
PEG in varying sizes [217, 218]. The PPS was the core of the nanoparticle with the PEG 
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providing a stabilizing corona. These blank particles were administered in vivo and found to 
readily traffic to the draining lymph node at which point there were taken up by 
approximately ~40-50% of the antigen presenting cells. Even after 4 days post injection the 
particles appeared to reside in lymph node APC and actually as the time increased the 
number of particle containing APCs increased, indicating the infiltration of more cells to the 
nanoparticle site [217, 218]. While these particles appear to be possible candidates for vaccine 
and immunotherapy applications targeting DCs in the lymph node, further studies need to be 
carried out to assess their viability as drug/vaccine adjuvants or delivery vehicles. 
 
2.3.5 Polyanhydride Adjuvants 
Polyanhydrides are a class of biomaterials that have demonstrate much promise as vaccine 
adjuvants and vaccine delivery vehicles. They possess important properties for vaccine 
delivery including protein stabilization, controlled release, and biocompatibility. In addition, 
they are capable of modulating the immune response [46, 139, 145, 147-149, 154]. This versatile class 
of vaccine adjuvants includes poly(fumaric acid) (FA), poly(methyl vinyl ether-co-maleic 
anhydride) (MVE-co-MA) and copolymers based on CPTEG:CPH and CPH:SA [46, 139, 145, 
147-149, 219, 220]. 
 
FA copolymerized with SA has demonstrated efficacy in oral vaccination. This copolymer 
was fabricated into microspheres and administered orally to rats [219]. The microspheres 
demonstrated strong adhesive interactions with the mucosal layer of the gastrointestinal tract. 
These prolonged interactions with the mucosal layer would provide extended antigen release 
necessary for protective immunity. Additional studies encapsulating plasmid DNA and the 
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anti-coagulant, dicumarol, in support of the previous work, demonstrated enhanced gene 
activity as well as plasma drug levels. These results indicate the potential viability for use of 
poly(FA-co-SA) in vaccine delivery applications [219]. 
 
Polyanhydrides based upon poly(SA) and CPTEG:CPH and CPH:SA copolymers have 
shown much promise as vaccine adjuvants and drug delivery. Significant in vitro work has 
indicated that these polyanhydrides when fabricated into nanoparticles are able to modulate 
the immune response by influencing cell marker expression and cytokine production of DCs 
[139, 145, 147, 149]. Cell surface marker expression of CD40, MHC I, MHC II, and CD209 was 
controlled by polymer hydrophobicity. Expression of these markers increased as the polymer 
chemistry shifted from CPH-rich to SA- and CPTEG-rich polymer chemistries (i.e. decrease 
in hydrophobicity) [139, 145, 147, 149]. Additionally, the production of cytokines, IL-6 and IL-
12p40, were also controlled by polymer chemistry. Production of both cytokines was 
enhanced upon incubation with SA-rich or CPTEG-rich copolymer chemistries [139, 145, 147, 
149]. Additional work has been carried out to investigate the effect of polyanhydride 
microparticles on immune activation of DCs. Again, the expression of cell surface markers 
and production of cytokines was enhanced over the non stimulated control [148]. Due to the 
abundance of –COOH terminated end groups, these nanoparticles can also be surface 
modified to target specific cellular receptors and immune pathways to modulate the immune 
response [145]. Furthermore, recent work has demonstrated that amphiphilic polyanhydride 
nanoparticles, based on 50:50 CPTEG:CPH, possess many properties similar to LPS and 
bacteria which explained their similarity in internalization and DC activation [145, 147, 149]. 
However, while influencing DC behavior in a pathogen-mimicking manner, 50:50 
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CPTEG:CPH nanoparticles do not induce the toxicity and inflammatory response of 
bacteria/LPS [46, 47, 139, 147, 149, 151, 180] and therefore, provide a novel strategy for vaccination in 
a non-toxic, pathogen-mimicking approach. In vivo work investigating the use of 
polyanhydride microparticles as vaccine adjuvants has demonstrated the ability of CPH:SA 
particles to encapsulate and delivery TT antigen while modulating the immune response [46]. 
When antigen was delivered alone or in a 20:80 CPH:SA copolymer a Th2 dominant 
response was induced; however, the delivery of TT encapsulated into 50:50 CPH:SA 
microparticles resulted in a shift from the Th2 dominant response to a balanced Th1/Th2 
response [46]. More recently, long-term protection against a lethal challenge of Y. pestis was 
achieved with a single-dose intranasal vaccine composed of antigen-encapsulated 50:50 
CPTEG:CPH nanoparticles [47]. This group of polyanhydrides has demonstrated much 
promise for use as vaccine adjuvants and continues to be the focus of further in vivo studies 
for vaccine protection. 
 
An additional polyanhydride copolymer based upon poly(methyl vinyl ether-co-maleic 
anhydride) (MVE-co-MA), Gantraz ®, has investigated the ability to protect against 
Salmonella enteritidis infection via vaccine strategies [220]. In these studies an immunogenic 
subcellular extract obtained from heat-killed S. enteritidis cells (HE) was loaded into (MVE-
co-MA) nanoparticles and used to immunize mice. When challenged 49 days post-
immunization approximately 80% of the mice which received the nanoparticle vaccine 
survived the infection. While serum antibody titers resemble a Th1 dominant response in the 
initial stages after immunization, later stages reveal a Th2 dominant response, indicating the 
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importance of a balanced combination of the two immune responses for disease prevention 
[220]. 
 
Polyanhydrides encompass a wide range of promising characteristics for use in vaccine 
delivery and administration. They are able to encapsulate, stabilize and provide a depot for a 
vaccine antigen, they are able to be administered via any injection route, and they have been 
shown to enhance and modulate the immune response, dictated by polymer chemistry and 
hydrophobicity. When fine-tuned, this polymer system can provide ideal properties to 
enhance vaccine efficacy as needed based upon limitations with vaccine antigens. 
 
2.4 Combinatorial Design of Biomaterials for Drug Delivery: Opportunities and 
Challenges 
A review article published in Expert Opinion on Drug Delivery 2008, 5(8), 1-10 
Latrisha K. Petersen and Balaji Narasimhan 
 
2.4.1 Introduction 
Polymeric biomaterials are used in a wide range of biomedical applications from bio-
absorbable prostheses [221] and drug delivery [37, 222-224] to tissue scaffolding [225] and sutures. 
Their role in drug delivery has emerged with great success due to their biocompatibility and 
highly tunable behavior that results in control over release kinetics [37, 143], immune 
modulation [46], protein stability [39, 142, 143], and responsiveness to environmental changes 
such as pH [226]. The rational design of key polymer properties and controlled experimental 
conditions is essential to fulfill their promise in these applications. This is typically carried 
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out through careful, time-consuming conventional (i.e., one experiment-at-a-time) design and 
development with multiple varying parameters, including polymer properties (e.g., 
chemistry, degradation mechanisms and kinetics, glass transition temperature, melting 
temperature), experimental conditions (e.g., temperature, buffers, pH, ionic strength), and 
polymer/cell interactions (e.g., cytotoxicity, proliferation, adhesion) with each variable 
differentially affecting the resulting experimental outcomes. Often this trial-and-error 
process, with testing one variable at a time, can become an expensive and non-reproducible 
proposition, in which experiments take a considerable amount of time. This is a multi-variant 
problem and efficient methods enabling numerous variables to be tested simultaneously are 
needed to advance the development of biomaterials for applications in drug delivery and 
tissue engineering [227].  
 
The combinatorial approach to discovery was initially propelled into the spotlight by the 
pharmaceutical industry [221, 228]. Difficulty in efficiently evaluating complex combinations of 
proteins, biomolecules, and biological components directed the focus on combinatorial 
techniques including biological assays and high throughput automated sampling and data 
quantification (i.e., auto samplers and plate readers). The combinatorial approach has been 
applied to biomaterials and drug delivery development and has focused on the synthesis, 
characterization, and optimization of the biomaterial properties best suited for specific 
applications in drug delivery. Drug delivery system design is a multivariate problem with 
interplay between the biomaterial, the drug, the processing conditions, and the in vivo 
conditions into which the drug is delivered. Optimizing these variables to administer the drug 
at a specific rate to a specific organ or tissue is a daunting challenge that could benefit by the 
36 
 
 
 
use of combinatorial methods. This methodology also plays a central role in the subsequent 
biological screening of cellular interactions with these biomaterials. The versatility of the 
combinatorial methodology makes it amenable to a number of applications and processes 
allowing for accelerated discovery, optimization, and reduced experiment-to-experiment 
variability. It must be borne in mind that the combinatorial method is a screening tool and 
enables the rapid identification of “hot spots” or areas of interest in a large search space and 
must be validated by conventional experimentation.  
 
The various steps in the combinatorial process are shown in Figure 2.4.1, beginning with 
experimental design. The primary goal of this step is to design a process which focuses on a 
limited parameter space by employing previous knowledge, thus resuting in the most 
efficient method for collecting useful data. The experimental design is then implemented to 
rationally design and synthesize either a discrete or continuous combinatorial library, in 
which properties are varied systematically in one or more directions. Next, high throughput 
characterization techniques are utilized to investigate the structure-property relationships 
within the parameter space of the library, which minimizes experimental variability. The 
large data sets obtained through these analyses are then validated by informatics and 
statistical methods, which provide insight into the design and development for further 
experiments. The key findings and results discovered through the combinatorial approach are 
then validated by conventional techniques, allowing for an accelerated approach to the design 
and optimization of biomaterials for drug delivery. Throughout the process, there is feedback 
built into the system to enable optimization at every step. 
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The keystone of this process for biomaterial design begins with the creation of a single, 
multi-dimensional library [229]. This has been made possible by major advancements in 
lithography and robotics, enabling highly expedited deposition and synthesis of these 
libraries [230]. The libraries are amenable to high throughput characterization employing 
methods such as Fourier transform infrared spectroscopy (FTIR), optical microscopy, and gel 
permeation chromatography (GPC). This parallel characterization results in the rapid 
evaluation of properties such as phase behavior, contact angle, and glass transition 
temperature, all of which play a critical role in the design of specific biomaterials as drug 
carriers.  
 
The main goal of the combinatorial approach in drug delivery is to explore a vast array of 
biomaterials in a single high throughput experiment which covers a large parameter space 
and allows for parallel screening. This reduces experiment to experiment inconsistency and 
provides a large database of information for employing informatics to identify hot spots [231]. 
This review provides a discussion of the various combinatorial methods that have been 
developed to synthesize and characterize biomaterials, the cell-based high throughput 
screening methods to characterize their interactions with cells, and combinatorial drug 
delivery [232-234]. The article concludes with the authors’ opinion on the challenges and 
opportunities provided by the combinatorial approach in the discovery and development of 
rapid and optimal drug delivery systems based on polymeric biomaterials. 
 
2.4.2 Combinatorial Biomaterial Library Fabrication and Characterization  
The combinatorial approach has been widely applied to synthesize libraries of polymeric 
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biomaterials as summarized in Table 2.4.1. Often, polymerization reaction conditions and 
duration cannot be varied, so making the process combinatorial involves synthesizing 
multiple polymers simultaneously while varying properties such as composition or molecular 
weight. Many polymeric biomaterials syntheses have been reported using a parallel approach 
[231]. Polymer libraries of poly(dimethylsiloxane) (PDMS) and poly(ε-caprolactone—block-
dimethylsiloxane-block-ε-caprolactone) triblock copolymers were synthesized by Ekin and 
Webster with the use of combinatorial experimentation in which novel PDMS oligomers 
were synthesized by reacting ethylene carbonate with 3-aminopropyl terminated PDMS 
oligomers [235]. A secondary reaction of these oligomers with ε-caprolactone resulted in the 
triblock copolymers. Polyanhydrides based on 1-6 bis(p-carboxyphenoxy)hexane (CPH) and 
sebacic acid (SA) have been synthesized using a rapid microwave polymerization technique 
described by Vogel et al [236]. A high throughput deposition and polymerization method of 
fabricating discrete polyanhydride libraries based on rapid prototyping and thiolene 
photopolymerization has been described by Vogel et al. [221]. In this method, thiolene-based 
multi-wells are used to robotically deposit anhydride monomers and the monomer library is 
then subjected to melt polycondensation under vacuum to result in a library of 
polyanhydrides. Langer and co-workers have developed a method for synthesizing a library 
of poly(β-aminoesters) via the addition of bifunctional amines to bisacrylamides [237, 238]. 
Brocchini and co-workers have synthesized polyester libraries derived from serinol, 
producing a 16-member library by polymerizing four N-substituted serinol-diol monomers 
with four commercially available diacids [239].  
 
The fabrication of both continuous and discrete polymer libraries has been reported by 
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Narasimhan with polyanhydrides [36, 139, 146, 147, 153, 154, 221, 240] and by Meredith with 
polystyrene (PS) and poly(vinyl methyl ether) (PVME) [241]. Figure 2.4.2 shows an example 
of a robotically deposited discrete polyanhydride library with a composition gradient. Such 
libraries have been used to study polymer blend phase behavior annealed over a temperature 
gradient stage by optical microscopy [221, 242]. The polyanhydride phase behavior from the 
combinatorial experiments exhibited upper critical solution temperature behavior [221], which 
is consistent with the conventionally obtained phase diagram by Kipper et al [243]. Meredith 
and co-workers reported a PS/PVME phase diagram with lower critical solution temperature 
behavior [241]. The polymer phase behavior plays a significant role in drug release as it 
controls the drug distribution within the system, which influences the rate of drug release [37, 
38]. Such rapid analysis of phase behavior will provide a basis for the rational optimization 
and design of porous three-dimensional polymer scaffolds for tissue engineering and drug 
delivery.  
 
Other polymer properties have been measured at high throughput by Kohn and co-workers 
[244]. Polyarylate libraries were characterized by GPC, differential scanning calorimetry 
(DSC) and contact angle measurements. The glass transition temperature (Tg) determined 
from DSC was found to decrease in correlation with the presence of oxygen moieties in the 
polymer backbone, while the water contact angle was found to decrease with increasing 
polymer chain length [244]. Knowledge of such properties and their trends within the polymer 
library are important for the fabrication of drug delivery devices such as tablets and micro- 
and nano-spheres. 
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High throughput characterization techniques such as FTIR, GPC, and optical microscopy 
allow for the rapid screening of polymer libraries. GPC and FTIR employ automated 
sampling which enables parallel and rapid validation of molecular weight and polydispersity 
(GPC), and chemical composition, drug interactions, and molecular weight (all with FTIR). 
FTIR microscopy has been used as a high throughput technique to characterize the linear 
variation of composition in polymer libraries as shown in Figure 2.4.3 [154, 240]. Optical 
microscopy has been utilized to observe phase behavior when such linearly varying libraries 
are annealed along a temperature gradient in a direction that is orthogonal to the composition 
gradient [242]. In addition to the methods described above, there are a number of studies in the 
literature on combinatorial synthesis and screening of biomaterials [245-250], including 3D 
gradients of polymer tissue scaffolds [251-255]. These accelerated methods are amenable to 
numerous other applications involving property determination and characterization of 
polymer systems. 
 
Understanding the relationship between important biomaterial properties (e.g., chemistry, Tg, 
Tm, phase behavior, and drug/polymer interactions) and drug release is paramount for the 
design and optimization of drug delivery vehicles. For example, Kipper et al. have shown 
that the phase behavior of biodegradable polymer blends, specifically the length scale of the 
microphase separation of polyanhydride copolymers, significantly affects the thermodynamic 
partitioning of drugs in these systems, thus affecting their release kinetics [256]. When the 
solubility of the drug or protein within a copolymer phase is exceeded, the drug or protein is 
forced to disperse into less favorable regions, thus resulting in a rapid initial release or burst 
of the protein [256]. This is also important for the design of multi-drug releasing polymer 
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systems and degradable polymer systems for protein stabilization [39, 142]. Properties such as 
the Tg and Tm are important because they dictate processibility of the materials. For example, 
the low Tg of certain polyanhydride copolymers controls the conditions under which 
microspheres of these copolymers are fabricated [136, 156]. Likewise the crystallinity of the 
biomaterial also affects the processibility and degradation kinetics and hence the release rates 
of drugs from these materials [256].  
 
2.4.3 High Throughput Cell-Based Screening 
Combinatorial approaches have led to the development of biological assays and high 
throughput plate readers allowing for rapid and parallel data acquisition and quantification 
[228]. When these high throughput methods are integrated with multi-dimensional polymer 
libraries, interactions of the polymeric carriers with drugs or cells can be assessed at high 
throughput. These include, but are not limited to, polymer chemistry effects on cell 
proliferation, adhesion, transfection, differentiation, cytotoxicity, and immune modulation. 
Understanding and optimizing these processes can enable the development and optimization 
of protein therapies, tissue engineering scaffolds, and vaccine delivery systems for localized 
treatments that target specific organs or tissues.  
 
Cytotoxicity is an important factor to consider when designing polymeric biomaterials for in 
vivo applications. The concentration and composition of polymeric biomaterials often 
regulate cellular functionality and viability. High throughput methods have been developed 
to ascertain the cytotoxic effect of biocompatible polyanhydrides based on CPH, SA, and 
1,8-bis(p-carboxyphenoxy)3,6-dioxaoctane (CPTEG) on different cells [139, 153, 154]. The initial 
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libraries studied were based on a gradient of 25 linearly varying polymer concentrations, 
which were fabricated using the multi-well system described before [154]. These libraries were 
screened at high throughput using an in vitro cytotoxicity assay (i.e., the MTT assay) and 
demonstrated that concentrations of the CPH:SA copolymer system less than 14 mg/mL and 
of the CPTEG:CPH system less than 16 mg/mL resulted in total viability in Sp2/O myeloma 
cells when compared to the control groups. The average in vivo concentration for human 
applications is 0.5 mg/mL [46], thus demonstrating the viability of these copolymers as drug 
carriers. Further, 25-member polyanhydride libraries with a compositional gradient were 
synthesized and screened for cytotoxicity. It was observed that there were no resulting 
compositions of either copolymer systems found to be toxic to any of the cell lines [154].  
 
Other role-specific biomaterials include transfection vectors, a group of specialized polymers 
studied by Langer and co-workers that collapse on DNA and transfect it into the cell [237, 238]. 
This is a key process for controlling many intracellular functions by targeting the cell nucleus 
and has potential for use in cancer therapies. The commercially available transfection vector, 
polyethylene amine, has been found to be problematic due to its inability to target and kill 
specific tumor cells. It was toxic to healthy cells resulting in tissue damage and wounding. 
Langer and colleagues used high throughput techniques based on a library of poly(β-
aminoesters) to address the cytotoxicity issue, which revealed a few specific cationic 
polymers that were not cytotoxic. These polymers were further studied in vivo and found to 
eliminate the toxic effect on healthy tissue while reducing the tumor size by 40% [257]. 
Combinatorial cell-based transfection screening has also been used for the design of polymer 
libraries by synthesizing diacrylates with primary or secondary amines. The findings of the 
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cell uptake studies emphasize the importance of the size of the polymer/DNA transfection 
complex and the polymer to DNA (N/P) ratio. Hydrophobicity was also shown to play a 
significant role in the transfection process. The histidine components of the polymer allowed 
for up to 4 to 8 times better transfection efficiencies than commercially available products. In 
further studies, this library synthesis process was automated, permitting the study of 1000 
reactions per day, creating a 2350 multi-component library [257, 258]. This library was used to 
show that transfection was controlled by polymer molecular mass and end groups [257-259]. 
 
Combinatorial methods provide an ideal platform to investigate cell-biomaterial surface 
interactions. This enables a rapid means for measuring and screening cell behavior including 
proliferation, migration, and cell attachment. Kohn and co-workers used a library of 
biodegradable carbonates to study the relationship between cell proliferation and polymer 
properties including hydrophobicity and molecular weight [244, 260]. It was demonstrated that 
the cells grew as a function of oxygen incorporation in the polymer backbone [244]. Further 
studies exploring the relationship between the hydrophobicity of polyarylates and cell 
proliferation found a significant trend relating the cell growth to decreasing hydrophobicity 
of the non-oxygen containing polymers [260]. Similar results were reported correlating cell 
proliferation with the oxygen content of the polymer [231].  
 
Combinatorial methods can also be used to explore alternate polymer systems for improved 
cell attachment. Brocchini et al. synthesized a library of polyesters in the presence of N-
substituted serinols which added another dimension to the library by allowing for the 
addition of functional groups to the side chains of the polymers [239]. It was shown that hexyl 
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side chains on the polyesters inhibited cell attachment. Similar studies with poly(ethylene 
glycol) (PEG) libraries were carried out by Langer and co-workers in which a polymer blend 
array of 3456 spots was screened for cell attachment and growth [261]. The screening results 
indicate that very little cell adhesion occurred until the blend approached 30 wt% poly(l-
lactide-co-glycolide) (PLGA). This is attributed to phase separation in the copolymers, 
preventing cellular adhesion in the PEG-rich sections, which have minimal attachment area 
[239]. 
 
Cell adhesion and proliferation are important aspects in the design of tissue engineered 
scaffolds. Meredith et al. have studied the relationships between cell behavior, adhesion and 
proliferation, and polymer library temperature and composition [127]. They created a 
continuous combinatorial library varying between different compositions of PLGA and 
poly(ε-caprolactone) (PCL) which was annealed over a temperature gradient to vary the 
microstructure and roughness. There were significant correlations between cell adhesion and 
the average surface roughness of the amorphous PLGA and the crystalline PCL under normal 
cell conditions at 37°C. The authors reported that the cell adhesion was at its highest at the 
high temperature annealed polymer regions and for the mid to high PCL regions on the 
polymer library. They also investigated the effect of protein adsorption on the polymer 
library [127]. Increasing hydrophobicity of the carbon-rich regions of the library was found to 
increase protein adsorption. Although protein adsorption was found to be independent of cell 
adhesion early on in the experiment, the prolonged studies demonstrated that the highest 
amount of protein adsorption correlated to the regions of high cell attachment (i.e., mid to 
high PCL regions) [127]. 
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Combinatorial techniques have been developed to identify the effect of stem cell 
differentiation on libraries containing di and triacrylates mixed with a photoinitiator on a 
poly(hydroxyethyl methacrylate)-based coating [259]. The authors report that nearly all 
compositions provided the necessary framework for cell adhesion and growth, but when 
retinoic acid was added to the cell growth medium, the monomer composition appeared to 
differentially regulate these cellular functions. This demonstrates the ability to control 
cellular behavior thus leading to better optimization of tissue scaffolds in an efficient high 
throughput approach.  
 
Polymer chemistry is hypothesized to play a significant role in immune modulation, which is 
a key factor for the design and optimization of polymers as adjuvants. A high throughput 
technique based on cytokine analysis has been developed to study the effect of polymer 
chemistry on the immune response [154]. Using a CPH:SA polyanhydride library and a 
macrophage cell line, a correlation was identified between adjuvant hydrophobicity (i.e., 
increasing CPH content) and TNF-α production (Figure 2.4.4) and between adjuvant 
hydrophilicity (i.e., increasing SA content) and IL-6 production. The production of TNF-α 
typically leads to inflammation and endothelial activation whereas IL-6 can induce fever, T 
and B cell growth and differentiation, and production of acute phase proteins [179]. Based 
upon the cytokines released from antigen presenting cells such as macrophages or dendritic 
cells the adaptive immune response can be modulated between a T helper 1 (TH1) cell-
mediated response and a T helper 2 (TH2) humoral response. The TH1 pathway activates 
macrophages and cytotoxic T cells which are directed to eliminate the invading foreign body 
and is effective at neutralizing intra-cellular pathogens; the TH2 pathway activates B cells 
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leading to antibody production and long term cellular memory and is effective at dealing with 
extra-cellular pathogens. Tuning the immune response is important for the optimal design of 
vaccine delivery systems and their ability to target and activate the necessary intracellular 
processes for successful prophylactic treatment. With the numerous applications for 
polymers as adjuvants in vaccine delivery devices, knowledge of how the polymer adjuvant 
modulates immune response pathways (i.e., cellular vs. humoral) is vital for the rational 
design and optimization of these devices. 
 
2.4.4 Combinatorial Drug Release 
Vogel et al. designed a high throughput method to study drug release from a linearly varying 
polyanhydride library based on CPH and SA [40]. The previously discussed rapid prototyping 
technique for multi-compositional library synthesis and rapid characterization of polymer 
properties was modified to study drug release. A non-reactive ultraviolet dye, ethidium 
bromide bisacrylamide, was encapsulated in the polymer libraries upon combinatorial 
polymer synthesis and released from the libraries as they were incubated in buffer. The 
results produced clear trends between the rate of dye released and the degradation 
characteristics of the polymer carriers. The higher the percent of the faster degrading 
component, SA, the more rapid was the dye release (Figure 2.4.5) [40]. These results were 
consistent with conventionally obtained dye release profiles from this polymer system [37]. 
 
2.4.5 Expert Opinion 
The above examples clearly demonstrate that combinatorial methods have been successfully 
applied to screen biomaterials for applications in drug delivery and tissue engineering. 
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However, many challenges and obstacles remain in the path to further the design of 
biomaterials for drug delivery and tissue engineering. The literature in this area mainly 
focuses on discrete and continuous polymer libraries, which are typically films and their 
correlations to cellular behavior which is applicable to areas such as tissue engineering. 
However, the majority of drug delivery systems employ injectable devices. This emphasizes 
the need for the development of new combinatorial techniques to fabricate micro- and nano-
particles for drug delivery. The development of such a technique would significantly 
accelerate discovery by fabricating particles of multiple chemistries simultaneously as well 
as decrease batch-to-batch variability commonly associated within the conventionally 
synthesized polymer particles, which employ techniques such as double emulsion and spray 
drying [144, 156, 262, 263]. 
 
The challenges in library fabrication lend to the difficulties encountered with screening of 
intra-cellular processes such as trafficking and transfection. The intracellular processes are 
often difficult to track due to lack of space and resolution in a typical combinatorial library, 
which only allows for a restricted population of cells. The behavior of cells can be affected 
by numerous external variables that can hinder the actual objective of the experiment itself. 
Screening of these processes can be expensive and difficult to apply to combinatorial 
libraries, hampering their ability to provide a large library of data. Thus, new methods are 
required in which large populations of cells can be screened at high throughput for intra-
cellular information and processes. Additionally, there are limitations on developing 
combinatorial methods for drug release since these methods rely upon following a tag (e.g., 
fluorescent) that needs to be incorporated into the drug of interest. 
48 
 
 
 
The implementation of high throughput techniques will lead to the generation of large 
libraries of data. Due to the major changes in information generation and composition, there 
is a need for highly developed statistical analysis techniques to address the multi-dimensional 
error analysis and refined informatics tools to process the enormous libraries of data. These 
statistical and informatics methods will become an invaluable resource to efficiently mine 
and analyze large data sets, better focusing the library parameter space on key areas of 
interest. The development of such methods will require close collaborations between 
researchers in the areas of computer science, biomaterials, and bioinformatics.  
 
In combining the multiple aspects of combinatorial discovery for biomaterials design, it is 
clear that there is a lack of formalized educational programs that meld analytical methods, 
molecular biology, biomaterials, chemistry, computer programming etc. The multi-faceted 
disciplines related to this field present many hurdles for newcomers to this area, requiring a 
significant amount of time and effort to master the cross-cutting ideas in combinatorial 
science. So there is an urgent need to develop novel educational programs that provide both a 
strong scientific grounding as well as a balanced exposure to the various techniques in this 
area. 
 
2.4.6 Conclusions 
Combinatorial and high throughput approaches to design and optimize biomaterials for drug 
delivery will become increasingly important as molecular structures become more complex, 
more variables are thrust into system design, and processes become more expensive [231]. In 
this brief review, we have discussed initial efforts which demonstrate the viability and 
49 
 
 
 
effectiveness of this approach and its ability to accelerate discovery, provide new insights, 
and reduce time and cost. We have discussed several applications covering the vast array of 
possibilities for this approach to the rapid discovery and design of biomaterials. High 
throughput techniques have been employed for processes ranging from biomaterials synthesis 
and characterization to the downstream development of parallel methods for drug release and 
cell screening. With the large array of parameters affecting many design problems in drug 
delivery and tissue engineering, this technique can be an invaluable resource for rapid design 
and optimization of biomaterials. However, this method is also fraught with numerous 
obstacles and eliminating these will have to be a primary goal in the next decade if 
combinatorial methods are to be used routinely for biomaterials discovery and design. 
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2.6 List of Figures 
 
 
      
 
Figure 2.2.1: Polyester chemical structures: a) PGA, b) PLA, c) PLGA, and d) PCL 
  
Figure 2.2.2: a) Bulk and b) surface erosion mechanisms. 
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c) d) 
a) 
b) 
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Figure 2.2.3: Acid-catalyzed polymer chemical structures: a) polyacetal, b) polyketal, and c) 
polyorthoester. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.4: Polyanhydride chemical structures: a) poly(CPH), b) poly(SA), and c) 
poly(CPTEG). 
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Figure 2.2.5: Polyether chemical structure: a) poly(ethylene glycol) and b) poly(propylene 
glycol). 
 
  
 
Figure 2.3.1: Induction of cellular vs. humoral immune response upon antigen presentation 
by a DC. 
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Figure 2.4.1: The combinatorial methodology.  
 
 
Figure 2.4.2: A discrete polyanhydride library polyanhydrides, increasing in SA composition 
from right to left and front to back (CPH is designated by blue and by SA yellow) [154]. 
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Figure 2.4.3: Mole percent of CPH varying along a discrete composition gradient library as 
determined in high throughput by FTIR microscopy [154]. 
 
 
 
 
 
 
 
        
 
 
 
Figure 2.4.4: Correlation between mole percent of CPH and TNF-α production [154]. 
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Figure 2.4.5: Fraction of dye released from a compositionally varying polyanhydride library 
of CPH:SA copolymers. The SA content increases incrementally from the bottom (50%) to 
top curve (100%) [40]. 
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2.7 List of Tables 
Table 2.4.1: Polymeric biomaterials and the various high throughput screening methods that 
have been developed to study these materials. 
 
 
Polymeric biomaterial High throughput screening Reference 
Polyanhydrides Cytotoxicity 
Blend phase behavior 
Immune activation 
Drug delivery 
[40, 154, 221, 236] 
PEG and polyesters Cell adhesion and growth [239, 261] 
Aminoesters Transfection [237, 238, 257-259] 
Poly(ethylene glycol)-4000 diacrylate 
(PEG4000DA) and acryloyl- 
poly(ethylene glycol)-RGDS (Acr-
PEG-RGDS) 
Cell adhesion [245] 
Polyarylates Cell proliferation [244, 257, 260] 
PLGA and poly(β-caprolactone) (PCL) 
PVME and PS 
Blend phase behavior 
Cytotoxicity 
Cell adhesion, growth, 
aggregation, and protein 
production 
Cell alkaline phosphatase 
expression 
[127, 241, 242, 
246] 
Plasma polymerized hexane (ppHex) 
and plasma polymerized allyl amine 
(ppAAm) 
Cell adhesion and growth 
3D polymer scaffold synthesis 
 
[247, 255] 
Poly(dimethylsiloxane) (PDMS) and 
poly(ε-caprolactone—block-
dimethylsiloxane-block-ε-
caprolactone) 
Synthesis 
Structural characterization 
(NMR, DSC, FTIR, and GPC) 
[229] 
Poly(dichlorodimethylsilane) Cell adhesion [248] 
Poly(2-hydroxyethyl methacrylate) Cell adhesion [249] 
Poly(L-lactic acid) (PLLA) 
poly(D,L-lactic acid) (PDLLA) 
Poly(lactic-co-glycolic acid) (PLGA) 
Cell proliferation 
3D polymer scaffold synthesis 
Bone growth 
[250, 251, 253, 
264] 
Polyglycolide and poly(hydroxyacetic 
acid) 
3D polymer scaffold synthesis [252] 
Collagen-glycosaminoglycan (CG) 3D polymer scaffold synthesis [254] 
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Chapter 3: Research Objectives 
The overall goal of this research is to develop and utilize high throughput approaches to 
expedite the design and optimization of degradable polymeric biomaterials for applications in 
drug and vaccine delivery. The combinatorial approach allows for multiple variables to be 
investigated in parallel to better understand protein/polymer, cell/polymer, and host/polymer 
interactions. Informatics analysis were applied to identify underlying trends associated with 
polymer chemistry and to identify material properties influencing these interactions.  
 
To carry out this research a host of multi-sample substrates (including wells, vials, and tubes) 
were fabricated and/or modified and used in conjunction with a robotic apparatus controlled 
by a third party software to enable the rapid synthesis of polymer libraries which were then 
translated to the fabrication of film and nanoparticle libraries. Upon construction of these 
libraries, they were characterized by 1H NMR, GPC, and FTIR and investigated for 
protein/polymer interactions, including protein release kinetics and protein stability. The 
release kinetics were rapidly investigated as a function of polymer chemistry, pH, and device 
geometry by utilizing a novel, fluorescent based high throughput assay. Protein stability was 
assessed upon fabrication, storage (time and temperature dependent), and release for all 
chemistries investigated. These methodologies were translated to study cell/polymer 
interactions. Several polymer chemistries in both film and nanoparticle geometries were 
examined for their effect on cellular toxicity (using both cell lines and primary cells), 
adhesion, differentiation, and immune activation. Additionally, informatics analysis enabled 
the identification of immune activation ‘hot spots’ which indicated that poly(SA) and 50:50 
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CPTEG:CPH nanoparticles best enhanced immune activation and that aliphatic carbons, 
hydroxyl end groups, and hydrophobicity were the properties responsible for this activation. 
These high throughput methodologies were further employed to investigate polymer/host 
interactions to study the dependence of chemistry and administration route on nanoparticle 
biodistribution, mucoadhesion, and depot effects in an in vivo mouse model. The 
combinatorial approach has helped identify the effect of polymer chemistry on protein 
release kinetics, protein stability, cellular toxicity, cellular adhesion, cellular differentiation, 
cellular immune activation, and in vivo biodistribution and mucoadhesion. These approaches 
will aid in more efficient and effective design of polyanhydrides for use as drug delivery 
devices and vaccine adjuvants. 
 
The specific goals (SGs) of this research are as follows: 
SG1: Combinatorial polymer synthesis and film and nanoparticle fabrication 
SG2: Combinatorial investigation of protein/polymer interactions 
SG3: In vitro combinatorial examination of cell/polymer interactions 
SG4: In vivo combinatorial examination of host/polymer interactions 
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4.1 Abstract 
Controlled delivery of therapeutic protein drugs using biodegradable polymer carriers is a 
desired characteristic that enables effective, application-specific therapy and treatment. 
Previous studies have focused on protein delivery from polymers using conventional “one-
sample-at-a-time” techniques, which are time-consuming and costly. In addition, many 
therapeutic proteins are in limited supply and are expensive, so it is desirable to reduce 
sample size for design and development of delivery devices. We have developed a rapid, 
high throughput technique based on a highly sensitive fluorescence-based assay to detect and 
quantify protein released from polyanhydrides while utilizing relatively small amounts of 
protein (~40 μg). These studies focused on the release of a model protein, Texas Red 
conjugated bovine serum albumin, from polyanhydride copolymers based on sebacic acid 
(SA) and 1,6-bis(p-carboxyphenoxy)hexane (CPH). The protein release profiles were 
assessed simultaneously to investigate the effect of polymer device geometry (nanospheres 
vs. films), polymer chemistry, and pH of the release medium. The results indicated that the 
nanosphere geometry, SA-rich chemistries, and neutral pH release medium led to a more 
rapid release of the protein compared to the film geometry, CPH-rich chemistries, and acidic 
pH release medium, respectively. This high throughput fluorescence-based method can be 
readily extended to study release kinetics for other proteins and polymer systems. 
 
4.2 Introduction 
The delivery of protein-based drugs (such as vaccine antigens, therapeutic proteins, and 
growth factors) using biodegradable polymeric devices has become an extensively explored 
area of innovation and research over the past decade [1-5]. Often, the dual tasks of providing 
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an environment capable of maintaining the functionality of the protein drug and releasing it 
in a sustained manner are challenging. In addition, the assays available for protein release 
kinetics are limited in that they lack sensitivity and are resource consuming. Many current 
protein release systems are carried out in a conventional ‘one-sample-at-a-time’ format and 
require several milligrams of protein for adequate detection and quantification.  
 
Several degradable polymeric biomaterials have shown much potential as protein carriers 
including polyesters, polyorthoesters, and polyanhydrides [3, 6-13]. Polyester-based systems 
undergo bulk erosion allowing significant water ingress and increased microenvironment 
acidity, which may affect both the stability of the protein and its release kinetics. 
Polyanhydrides, which are generally more hydrophobic, undergo surface erosion through 
hydrolytic degradation, which makes the erosion more controllable, allowing for tailored 
degradation ranging from days to months [14-16]. In all these systems, it is evident that the 
chemistry of the polymeric carrier plays a significant role in maintaining the function of the 
protein and in governing its release kinetics. This work is focused on polyanhydrides, which 
are biocompatible materials that have been studied extensively for use in drug and vaccine 
delivery [1, 3, 14, 17-28]. The polymers of interest are based on 1,6-bis(p-carboxyphenoxy)hexane 
(CPH) and sebacic acid (SA). In addition to their biocompatibility, the degradation of these 
materials is base-catalyzed [6, 29] and can be tuned allowing for drug delivery ranging from 
weeks (SA-rich chemistries) to months (CPH-rich chemistries) [2, 14, 15]. 
 
In this design of delivery vehicles, one can envision a large parameter space to investigate, 
based on the chemistry of the polymer, the type of protein drug to be encapsulated, the 
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desired release rate of the protein, the in vivo release environment of the protein, the required 
geometry of the protein encapsulation device (nanospheres for drug/vaccine delivery or films 
for drug-eluting implants), and the end-use application. High throughput approaches, 
employing combinatorial library synthesis, can be valuable to more rapidly develop and/or 
screen new biomaterials for controlled delivery of proteins. There are several examples in the 
literature of high throughput screening of biomaterials to study their interactions with 
proteins and cells [4, 17, 26, 30-40]. Vogel et al. developed the first high throughput approach to 
study combinatorial drug release kinetics from CPH:SA polyanhydride films [27]. In this 
study, the release profile of ethidium bromide bisacrylamide from polyanhydride films was 
investigated and it was shown that the more hydrophobic (CPH-rich) chemistries released the 
dye the slowest. The conditions used to study the release of dyes, which can withstand harsh 
processing (e.g., high temperature, solvent exposure, low vacuum, etc.), are not ideal for 
protein-based drugs. In addition, some of the colorimetric methods available to quantify dyes 
are not readily applicable to protein analysis.  
 
In this work, the development of a novel and multiplexed technique to concurrently study the 
release kinetics of proteins from polyanhydrides with multiple varying parameters (device 
geometry, polymer chemistry, and pH of release medium) by employing a highly sensitive 
fluorescence-based assay is described. To the best of the authors’ knowledge, no 
combinatorial methods are currently available to evaluate the delivery of protein-based drugs 
from polymers. The high throughput technique described herein allowed for the rapid 
detection and quantification of a model fluorescent protein (Texas Red bovine serum albumin 
(TRBSA)) released from five different chemistries of two different CPH:SA polymer device 
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geometries (nanospheres and films) in media of three different pHs. This highly sensitive, 
fluorescence-based approach reduced the amount of protein needed (total of ~40 μg) because 
very small amounts of the fluorochrome-conjugated protein are necessary to get sufficient 
excitation, emission, and quantification as compared to alternate assays, which require 
significantly larger amounts of protein to obtain similar data. In addition, this novel method 
eliminated the need for repeated sampling, which can often introduce experimental error, and 
allowed for combinatorial protein release and simultaneous, rapid protein detection and 
quantification. High throughput methods are an invaluable resource for studying release of 
protein-based drugs, which are often made recombinantly and are therefore expensive and 
available in limited supplies. The use of multiplexed methods to study protein release 
kinetics will help to more readily advance the rational design and optimization of protein-
based drug and vaccine delivery systems.  
 
4.3 Materials and Methods 
Materials 
The chemicals utilized in monomer synthesis, 1-methyl-2-pyrrolidinone, 4-p-hydroxybenzoic 
acid, and 1,6-dibromohexane were purchased from Sigma Aldrich (St. Louis, MO); and 
sulfuric acid, was obtained from Fisher Scientific (Fairlawn, NJ). The chemicals needed for 
the polymerization, nanosphere fabrication, and buffer preparation include acetic anhydride, 
chloroform, methylene chloride, petroleum ether, pentane, monobasic potassium phosphate, 
dibasic potassium phosphate, sodium acetate trihydrate and glacial acetic acid, all of which 
were purchased from Fisher Scientific. BSA was purchased from Sigma Aldrich. The micro-
bicinchoninic acid (BCA) protein assay kit was obtained from Pierce Biotechnology Inc. 
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(Rockford, IL). Texas Red® conjugated BSA was obtained from Invitrogen (Carlsbad, CA). 
Deep-welled 96-well polypropylene (0.5-2.0ml) plates and sealing mats were purchased from 
Corning (Corning, NY). 
 
Polymer film library synthesis & characterization 
The CPH monomer was synthesized as described previously [28]. The SA monomer was 
purchased from Sigma Aldrich. CPH:SA copolymer libraries were synthesized from the 
corresponding monomers via a melt polycondensation reaction in multi-well substrates 
utilizing a robotic deposition apparatus, as reported previously [4, 25]. Copolymer chemistry 
and molecular weight were determined for the polymer film libraries by proton nuclear 
magnetic resonance (1H NMR) spectroscopy using a Varian VXR 300 MHz spectrometer 
(Varian Inc., Palo Alto, CA). Each sample was dissolved in deuterated chloroform and the 
chemical shifts were calibrated with respect to the chloroform peak (δ= 7.26 ppm). Gel 
Permeation Chromatography (GPC) was also used to measure the molecular weight on the 
polymer film libraries. Samples were dissolved in HPLC-grade chloroform and separated on 
a Waters GPC chromatograph (Milford, MA) containing PL Gel columns (Polymer 
Laboratories, Amherst, MA). Elution times were compared to monodisperse polystyrene 
standards (Fluka, Milwaukee, WI). The surface chemistry of the combinatorially synthesized 
CPH:SA polymer film libraries (no protein) was evaluated at high throughput using Fourier 
transform infrared spectroscopy with a Nicolet 6700 FTIR spectrometer (Thermo Scientific) 
as described previously [4, 26].  
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Fabrication of protein encapsulated film and nanosphere libraries and nanosphere library 
characterization 
An automated polymer synthesis/nanosphere fabrication device was designed for the initial 
deposition of the monomer library into a multi-vial substrate. Following synthesis, the 
combinatorial nanosphere library was fabricated from the polymer film library as described 
before [4, 26]. Additional steps were incorporated into the process for protein encapsulation. 
The protein (TRBSA) was initially homogenized (Tissue-Tearor™, Biospec Products, 
Bartlesville, OK) in chloroform for 60 s at 10,000 rpm resulting in a final concentration of 1 
mg/mL. The protein/chloroform solution was robotically deposited via syringe pumps into 
each vial of the multi-vial film library, thus dissolving the polymer films with a resulting 
polymer concentration of approximately 25 mg/mL. Each solution was homogenized for 60 s 
at 10,000 rpm to uniformly disperse the polymer and the protein in the chloroform. They 
were either dried to create the protein encapsulated film library (in a deep welled, clear, 
polypropylene 96-well plate) or precipitated into petroleum ether and dried to create a 
protein-encapsulated nanosphere library. Smaller quantities of the protein-encapsulated 
nanospheres were weighed out and transferred to a deep-welled, clear, polypropylene 96-well 
plate for evaluating the release kinetics. This nano-precipitation process is a modification of a 
previously described method [4, 40]. Scanning electron microscopy (SEM) was performed 
using a JEOL JSM-840A SEM (JEOL USA Inc., Peabody, MA) to study the external 
morphology of the protein-loaded nanospheres by coating their surface with 200 Å of gold. 
 
TRBSA release kinetics and protein quantification 
Following fabrication of the protein-loaded film and nanosphere libraries, 1 mL of the 
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appropriate buffer (phosphate buffer pH 7.3, phosphate buffer pH 6.0, or acetate buffer pH 
4.3) was added to each well. The well plates were sealed to prevent evaporation and 
incubated in a horizontal shaker at 37°C and 100 rpm for the duration of the experiment. 
TRBSA detection and quantification was performed incrementally throughout the study, 
which was terminated after one month. The protein release data is presented as a cumulative 
fraction of protein released, in which the amount of protein released is normalized by the 
total amount of protein encapsulated into the nanospheres or films. The TRBSA release was 
quantified using two methods: a micro-BCA assay and a high throughput fluorescence-based 
assay. 
 
Micro-bicinchoninic acid (BCA) assay 
Three hundred μL samples were withdrawn at several time points from each release well and 
quantified with the micro-BCA assay. Samples were run in triplicate, as described by the 
manufacturer (Pierce). Fresh buffer was added to the sample well to maintain constant sink 
conditions.  
 
High throughput fluorescence-based assay 
In this automated technique (i.e., no sampling), each clear, deep-welled, polypropylene 96-
well plate was modified by joining each neighboring pair of wells between neighboring 
columns: 1 and 2, 3 and 4, 5 and 6, 7 and 8, 9 and 10, and 11 and 12 (i.e., wells A1 and A2, 
B1 and B2, A3 and A4, etc were joined together) (Figure 4.1). The first wells were home to 
the fluorescent protein-loaded film or nanospheres and the second, adjoining wells were 
empty. 500 μL of buffer was added to all the wells and the plate was centrifuged (100 rcf for 
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10 min) to localize the nanospheres to the bottom of the wells. The wells were slowly filled 
to the top with buffer and due to the modified well geometry, any released protein was 
uniformly dispersed between the two wells while keeping the films and nanospheres isolated 
to the first well. Each subsequent time prior to protein quantification, the polymer libraries 
were centrifuged (100 rcf for 10 min) to localize the nanospheres and film particulates to the 
bottom of the well. High throughput protein detection was performed with a Typhoon 9410 
imaging system (GE Healthcare, Piscataway, NJ). The 96-well plate was placed on a flatbed 
scanner and a laser was directed at the bottom of the plate to excite the fluorochrome-
conjugated protein. The light emission was collected through a series of filters, which was 
immediately output to a computer quantification program (Image Quant TL, GE Healthcare, 
Piscataway, NJ). A row of protein standard concentrations was included in the 96-well plate 
to account for the effect of subsequent scanning or light bleaching on the fluorescent protein.  
  
4.4 Results and Discussion 
In this work a novel, fluorescent, high throughput technique for studying protein release has 
been designed, enabling rapid data quantification in a multiplexed format, eliminating error 
associated with repeated sampling, and minimizing sample size requirements. This approach 
allowed for the simultaneous evaluation of several key parameters involved in protein release 
including polymer chemistry, device geometry, and pH of release medium, which were 
carried out using two modified 96-well release plates. 
 
Characterization 
The CPH:SA film libraries were characterized with high throughput FTIR to determine 
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surface chemistry and the overall accuracy of the deposition process. The results 
demonstrated excellent agreement between the intended molar compositions deposited and 
the actual molar compositions deposited into the multi-well substrate using the automated 
deposition apparatus (data not shown). These findings are consistent with previous work [4, 26] 
and confirm the accuracy of the depositions apparatus. In addition, molecular weight and 
copolymer composition were determined with 1H NMR and GPC, Table 4.1, and the results 
were in agreement with conventionally synthesized CPH:SA copolymers [2, 15, 41]. Following 
characterization of the polymer film libraries, the TRBSA loaded nanosphere libraries were 
characterized with SEM to determine shape and size. They were found to be very similar to 
previously published results with polyanhydride nanospheres [4, 40] with an average size of 
~300 nm. Representative images from two selected chemistries are shown in Figure 4.2.  
 
Combinatorial protein release from polyanhydrides nanospheres  
Knowledge of the protein release kinetics from these carrier systems is very important for the 
rational design and optimization of devices for in vivo applications. To investigate this, the 
effect of polyanhydride nanosphere chemistry on TRBSA release was evaluated at high 
throughput using the highly sensitive fluorescence-based assay. The combinatorially 
measured protein release kinetics was validated with a commonly used micro-BCA assay. 
The multiplexed method enabled five different nanosphere chemistries ranging from 100 
mole % SA to 100 mole % CPH to be simultaneously evaluated in replicates of four. The 
polymer chemistry played an integral role in controlling the release of TRBSA from the 
CPH:SA nanosphere library with the most hydrophobic chemistry (i.e., poly(CPH)) releasing 
the protein the slowest and the least hydrophobic chemistry (i.e., poly(SA)) releasing the 
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protein the most rapidly (Figure 4.3). It is well known that polymer hydrophobicity directly 
influences polymer erosion and protein release kinetics [14, 19, 41]. This high throughput 
method allowed for other observations to be made simultaneously, which were consistent 
with previous work, including complete release of TRBSA from poly(SA) nanospheres [19] 
and initial protein bursts of 5-20% (nanosphere chemistry dependent) [15]. As discussed 
previously, the TRBSA release profile obtained with the fluorescence-based assay was 
validated with the micro-BCA assay, which yielded consistent protein release profiles for all 
the CPH:SA nanosphere chemistries tested (Figure 4.4). This provides evidence supporting 
the accuracy and reliability of the high throughput fluorescence-based assay. In fact, in most 
cases the micro-BCA assay demonstrated more variability in the release curve data than the 
fluorescence-based assay, which is likely a result of error introduced with repeated sampling 
and the use of a less sensitive protein detection assay. The results indicate that this method 
would be amenable to study protein release kinetics in other biodegradable polymer systems 
intended for drug or vaccine delivery. This technique can also be used to study protein 
release under other simulated in vitro conditions that better mimic in vivo applications (e.g., 
in the presence of serum proteins).  
 
It is known that protein release from biodegradable polymers is affected by the pH of the 
polymer degradation environment [6, 29, 42-45]. Polyanhydride degradation is known to be base-
catalyzed [6, 29]. It is important to understand the release behavior of proteins from such 
polymers post injection, inside the host, because the intracellular pH tends to be more acidic 
(pH of 4.5-6) enabling the breakdown of phagocytosed particulates in endocytic 
compartments [46]. To this end, protein release kinetics were studied for five different 
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chemistries of TRBSA-encapsulated CPH:SA nanospheres with the fluorescence-based 
protein detection assay in release media with three different buffered pH values: 7.3 
(neutral), 6.0 (mildly acidic), and 4.3 (intracellular pH) [46]. Due to the small sample size (~1 
mg nanospheres) and the buffering capabilities of the release medium, it is highly unlikely 
that the polymer degradation will alter the pH of the release buffer. The high throughput 
technique allowed for concurrent, rapid protein quantification of a two-dimensional 
combinatorial library varying in nanosphere chemistry and pH of the release medium. The 
results are consistent with the base-catalyzed degradation mechanism of polyanhydrides, 
clearly demonstrating a reduced protein release as the pH of the release medium was 
lowered, as indicated in Figures 4.4-4.6. The pH level appears to more strongly affect the less 
hydrophobic (i.e., SA-rich) nanosphere chemistries, which is likely due to their more rapid 
degradation over the period of study. It is hypothesized that this effect would be evident for 
the more hydrophobic (CPH-rich) nanosphere chemistries if the study were carried out for a 
more extended period allowing for complete degradation of the polymer. While pH is not the 
only in vivo parameter that controls polymer degradation, this high throughput approach is 
amenable to simulate and study numerous other intracellular or extracellular phenomena 
(e.g., enzymatic degradation, serum protein adsorption). 
 
Combinatorial protein release from polyanhydride films 
The high throughput fluorescence method was also used to study the release of TRBSA from 
five linearly varying CPH:SA copolymer films in replicates of four, which was performed in 
parallel with the aforementioned nanosphere release. These studies were carried out for two 
reasons. First, there is interest in discerning in the effect of device geometry (films vs. 
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nanospheres) on protein release kinetics. As mentioned before [3, 41, 47, 48], polyanhydride 
devices of various geometries have been tested for in vivo applications and the high 
throughput method provides a rapid way to simultaneously study the effects of polymer 
chemistry and device geometry. Second, it is important to demonstrate that the fluorescence 
technique is amenable to various device geometries. As expected, the films displayed a 
polymer chemistry-dependent protein release profile with the most hydrophobic (i.e., CPH-
rich) chemistries releasing the protein the slowest (Figure 4.7). These results were in 
agreement with release profiles obtained with the micro-BCA assay (data not shown). The 
overall release of protein from the films was lower and resulted in a smaller initial protein 
burst when compared with the nanospheres, which is likely due to the reduced polymer 
surface area exposed to the release buffer. The variances observed with the TRBSA release 
profiles from the films were higher than those with the TRBSA release profiles from the 
nanospheres. This observation can be attributed to the tendency of films, in some cases, to 
delaminate and break off into non-uniform pieces, thus exposing different amounts of surface 
area. As stated before, this technique is amenable to investigate drug/protein release from 
alternate geometries such as three-dimensional scaffolds used for tissue engineering [49-51] or 
core-shell particles used for multi-drug therapies [52, 53]. 
 
4.5 Conclusions 
The development of a highly sensitive fluorescent technique for the simultaneous detection 
of protein release from biodegradable polyanhydride nanospheres and films has enabled 
rapid evaluation of the effects of device geometry, polymer chemistry, and pH of release 
medium on the protein release kinetics. The film geometry, CPH-rich chemistries, and acidic 
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release conditions all demonstrated the ability to significantly decrease protein release over 
their respective counterparts (nanosphere geometry, SA-rich chemistries, and neutral release 
conditions). Both the nanosphere and film systems released TRBSA protein in a sustained 
and polymer chemistry-dependent manner while the nanospheres also demonstrated a pH-
dependent protein release. The high throughput fluorescence-based technique is amenable to 
other polymer and protein systems as well as alternate release environments which will allow 
for rational and rapid design of delivery devices. Finally, these findings contribute to the 
large body of evidence supporting the use of polyanhydrides as highly tunable biomaterials 
for the controlled delivery of drugs and proteins. 
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4.8 List of Figures 
 
Figure 4.1: a) Schematic of modifications made to horizontal pair of wells in the 96-well 
polypropylene release plate, and b) actual fluorescence images of the 96-well plate while 
performing the TRBSA relase studies from CPH:SA films (only wells with TRBSA in them 
are visible in the image). 
 
Figure 4.2: SEM images of TRBSA-loaded polyanhydride nanospheres: A) poly(SA) and B) 
50:50 CPH:SA. 
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Figure 4.3: Cumulative mass fraction of BSA released from combinatorially fabricated 
CPH:SA nanospheres for one month at pH 7.3 as detected by the micro-BCA assay. Error 
bars represent standard deviation and n=4. 
 
Figure 4.4: Cumulative mass fraction of TRBSA released from combinatorially fabricated 
CPH:SA nanospheres for one month at pH 7.3 as detected by the high throughput 
fluorescence assay. Error bars represent standard deviation and n=4. 
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Figure 4.5: Cumulative mass fraction of TRBSA released from combinatorially fabricated 
CPH:SA nanospheres for one month at pH 6.0 as detected by the high throughput 
fluorescence assay. Error bars represent standard error and n=2. 
 
Figure 4.6: Cumulative mass fraction of TRBSA released from combinatorially fabricated 
CPH:SA nanospheres for one month at pH 4.3 as detected by the high throughput 
fluorescence assay. Error bars represent standard error and n=2. 
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Figure 4.7: Cumulative mass fraction of TRBSA released from combinatorially fabricated 
CPH:SA films for one month at pH 7.3 as detected by the high throughput fluorescence 
assay. Error bars represent standard deviation and n=4. 
 
4.9 List of Tables 
Table 4.1: Molecular weight analysis of CPH:SA copolymer film libraries using GPC and 1H 
NMR. 
CPH:SA Polymer 
 Library 
Mn (Da) from 
GPC 
Mn (Da) from 
1H NMR 
Poly(SA) 11154 12555 
25:75 CPH:SA 9692 10854 
50:50 CPH:SA 13264 12872 
75:25 CPH:SA 12674 13442 
Poly(CPH) 16477 15247 
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5.1 Abstract 
With the complexity and fragile nature of many protein molecules used in therapeutic 
treatments and vaccines, devices capable of protecting and preserving the functionality of 
these proteins are essential. In addition, the half-lives of many vaccine antigens and 
therapeutic proteins are often short, especially at elevated temperatures. In this work a high 
throughput methodology has been developed to rapidly assess the effects of polymer 
chemistry and the various steps during protein delivery (i.e., encapsulation, storage, and 
release) from biodegradable polyanhydride nanoparticles on the stability of a model protein, 
bovine serum albumin. Additional factors including microenvironment pH were also 
investigated in this multi-parametric approach to evaluate protein stabilization. The findings 
indicate that the microenvironment pH caused by the acidic polymer degradation products 
was the most detrimental factor affecting protein stability. Nanoparticles based on 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane and 1,6-bis(p-carboxyphenoxy)hexane maintained protein 
antigenicity over a range of temperatures for one month. These nanoparticles were also 
successful in preserving protein structure and emerged as viable candidates for use in future 
drug/protein stabilization and delivery applications. The combinatorial approach developed 
in this work allowed for a 25-fold decrease in time and a 10-fold decrease in the amount of 
materials needed for the investigation of protein stability when compared to conventional 
methods. 
  
5.2 Introduction 
The delivery of expensive and fragile protein-based drugs is challenging and poses many 
hurdles including limited availability and drug stabilization upon storage and administration. 
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Short shelf lives expedited by elevated storage temperatures limit protein functionality and 
use; this is especially pronounced in developing countries where resources are limited. The 
administration of proteins for vaccination, disease treatment, and anti-cancer therapy all 
require protein stabilization. It is known that small structural changes can be detrimental to 
protein function, leading to a decrease in the efficacy of the intended treatment [1-3]. In 
addition, repeated drug administration or surgical implantation might pose problems with 
patient compliance. Thus, there is a need for delivery devices that can stabilize fragile protein 
molecules as well as provide a sustained release to eliminate the need for repeated 
administration. With the large database of readily available biodegradable polymers intended 
for protein stabilization and delivery, new high throughput methodologies are needed for the 
discovery, testing, and design of these biomaterials [4]. These approaches are emerging in the 
field of biomaterials [4-13] to study large numbers of biomaterials in parallel for use as drug 
and vaccine delivery vehicles. 
 
Polyanhydrides are a versatile class of biodegradable materials with applications in drug and 
vaccine delivery [10, 14-17]. The polyanhydrides of interest in this work are based on 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 
sebacic acid (SA); the chemical structures of the monomers are shown in Figure 5.1. These 
polymers are composed of anhydride bonds, which undergo hydrolysis in the presence of 
water as shown in Figure 5.1d). Materials based on these monomers have shown promise for 
applications in drug delivery with their ability to stabilize and release proteins in a controlled 
manner ranging from days (CPTEG-rich) to weeks (SA-rich) to months (CPH-rich) [13, 17-21]. 
Additionally, the polyanhydrides of interest can be rapidly fabricated into micro or 
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nanoparticles allowing for non-invasive administration via inhalation or injection. These 
micro and nanoparticles are promising for applications in vaccine administration, as they 
possess adjuvant characteristics that may be necessary for efficacious vaccination with 
poorly immunogenic protein antigens. However, stabilization of the antigen is a primary 
concern, because without the ability to deliver a fully functional antigen, protection may not 
be viable. Polyanhydride microparticles have been previously shown to stabilize protein 
antigens, specifically tetanus toxoid (TT), which confirmed the ability of TT-loaded CPH:SA 
microparticles to deliver functional antigen and modulate the immune response [14]. Given 
that polyanhydrides are versatile and can be tailored for specific properties (e.g., protein 
stability, protein release, immune activation, adjuvant capabilities, etc.) [10, 13, 14, 17, 19, 20, 22, 23], 
the use of traditional, ‘one-sample-at-a-time’ approaches has and will continue to expend 
large amounts of time and resources for the necessary optimization of these materials for 
their intended applications.  
 
There is an urgent need to develop high throughput approaches to screen and design delivery 
systems to keep pace with the rapid increase in the number of expensive, fragile, protein 
drugs that are in development for disease therapy and treatment [17, 24]. The combinatorial 
approach for biomaterials design has emerged in the past decade as a viable method which 
allows for the use of reduced amounts of expensive proteins and accelerates the throughput 
and development of materials for numerous applications including but not limited to drug 
delivery, vaccine design, tissue engineering, gene therapy, etc [5-11, 13, 25-33]. More recently, 
combinatorial studies have been carried out for the investigation of polyanhydrides in the 
areas of phase behavior, drug/protein release kinetics, cytotoxicity, and immune activation 
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[10-12, 33]. However, to the best of the authors’ knowledge, this approach has not been applied 
to study protein stability in the polyanhydride (or any other biodegradable polymer) system.  
 
In this work, the stability of a model protein (bovine serum albumin, BSA) upon release from 
polyanhydride nanoparticles of various chemistries was investigated at high throughput with 
an antigenicity assay. Since it is well known that protein stability could be affected by the 
fabrication, storage, and release conditions, high throughput methods were developed to 
assess BSA stability upon nanoparticle fabrication/protein encapsulation (solvent exposure, 
sonication, and vacuum), storage (shelf life at different temperatures), and release (polymer 
chemistry and pH). The multi-parametric nature of this problem and the proposed high 
throughput methodology is illustrated in Figure 5.2. This combinatorial method allowed for a 
25-fold decrease in time and a 10-fold decrease in the materials used to fabricate libraries of 
polyanhydride nanoparticles and enabled the simultaneous investigation of the effect of 
polymer chemistry, shelf life, storage temperature, and microenvironment pH on protein 
stability. To better understand the mechanisms of instability caused by the chemistries that 
were detrimental to protein antigenicity, a high throughput multi-level structural analysis was 
carried out, utilizing previously described automated synthesis and fabrication techniques, to 
determine the source of protein degradation and improve the throughput of the experiments. 
The use of the combinatorial approach will lead to a more in-depth understanding of the 
relationship between protein stability and the multiple the steps in the delivery process, 
ranging from fabrication to administration. This will therefore help expedite the rational 
design and development of biomaterial carriers for protein stabilization and delivery. 
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5.3 Materials and Methods 
Materials 
The chemicals needed for the polymerization, nanoparticle fabrication, and buffer 
preparation include acetic anhydride, chloroform, methylene chloride, petroleum ether, 
pentane, monobasic potassium phosphate, and dibasic potassium phosphate; all were 
purchased from Fisher Scientific (Fairlawn, NJ). Monomer synthesis utilized the following 
chemicals: 1,6-dibromohexane, tri-ethylene glycol, 4-hydroxybenzoic acid, 1-methyl-2-
pyrrolidinone, 4-p- and 1,6-dibromohexane; these were purchased from Sigma Aldrich (St. 
Louis, MO); 4-p-fluorobenzonitrile was purchased from Apollo Scientific (Cheshire, UK); 
and sulfuric acid, acetonitrile, dimethyl formamide (DMF), toluene, and potassium carbonate 
were obtained from Fisher Scientific. Deuterated chemicals for NMR analysis (chloroform 
and dimethyl sulfoxide (DMSO)) were purchased from Cambridge Isotope Laboratories 
(Andover, MA). BSA was purchased from Sigma Aldrich. Precast 12% polyacrylamide gels 
(Tris-HCl), low molecular mass standards, and 2-mercaptoethanol were purchased from 
BioRad (Hercules, CA). Polypropylene black round bottom 96-well plates and polystyrene 
clear 96-well plates were obtained from Fisher Scientific. The ELISA kit for determining 
BSA antigenicity and the kits for making reagents and buffers were purchased from Bethyl 
Labs (Montgomery, TX). The primary (coating) antibody utilized in this kit was sheep anti-
bovine albumin-affinity purified and the secondary (detection) antibody was sheep anti-
bovine albumin-HRP conjugate.  
 
Polymer library synthesis 
The CPH and CPTEG monomers were synthesized as described previously [34]. The SA 
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monomer was purchased from Sigma Aldrich. The linearly varying library in molar 
composition of CPH:SA prepolymer was deposited at high throughput using an automated 
robotic apparatus as described previously [10, 11, 13, 15]. The prepolymer library was 
polymerized at 0.3 torr vacuum and the desired temperature (180 °C for CPH:SA and 140 °C 
for CPTEG:CPH) for 1.5 h resulting in a discrete library of CPH:SA (poly (SA), 25:75 
CPH:SA, 50:50 CPH:SA, 75:25 CPH:SA, and poly (CPH)) and CPTEG:CPH (60:40 
CPTEG:CPH, 50:50 CPTEG:CPH, 40:60 CPTEG:CPH, 30:70 CPTEG:CPH, 20:80 
CPTEG:CPH and 10:90 CPTEG:CPH) copolymer films in replicates of four. The resulting 
polymer library included a total of 44 samples (11 chemistries x 4 replicates).  
 
Protein encapsulation into nanoparticles  
The fabrication of protein-loaded nanoparticles utilized the automated robotic deposition 
apparatus to increase throughput. Following synthesis of the discrete polymer film libraries, 
lyophilized protein was dispersed in methylene chloride and added to each polymer well, 
thus dissolving the polymer film. The protein/polymer solution was first sonicated for 30 s at 
40 Hz to uniformly disperse the protein, then precipitated into a non-solvent (pentane) to 
create protein-loaded nanoparticles, and finally dried in a vacuum chamber (CPH:SA) or 
filtered via rapid vacuum filtration (CPTEG:CPH) as described previously [10, 13, 16]. This 
resulted in a 44-sample protein-loaded nanoparticle library (11 chemistries x 4 replicates). 
 
Polymer and nanoparticle characterization 
The discrete polymer libraries were characterized with 1H nuclear magnetic resonance 
(NMR) spectroscopy and high throughput Fourier transform infrared (FTIR) spectroscopy. 
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End group analysis of the NMR spectra was used to determine molecular weight, copolymer 
chemistry, and chemical structure with a Varian VXR 300 MHz spectrometer (Varian Inc., 
Palo Alto, CA). Deuterated chloroform was used to dissolve the samples and chemical shifts 
were calibrated with respect to the chloroform peak (δ= 7.26 ppm). The surface chemistry of 
the polymer libraries was characterized using high throughput FTIR spectroscopy (Nicolet 
6700 FTIR spectrometer, Thermo Fisher Scientific) as described previously [10, 13]. A polymer 
film library was synthesized on a 25-well silicon nitride (IR transmissive) substrate in an 
automated fashion with the use of a programmable mapping software package (Atlμs). This 
software enabled a specific sample and background map to be programmed into the FTIR 
sample detection, allowing for multiple FTIR spectra to be quantified without user operation. 
Scanning electron microscopy (SEM) was used to determine size of the polyanhydride 
nanoparticles. 
 
Enzyme-linked immunosorbent assay (ELISA): protein antigenicity  
A BSA-specific ELISA kit was used to analyze protein antigenicity, following the 
manufacturer’s protocol. Samples were centrifuged, and the supernatant diluted with the 
sample diluent (50mM Tris, 0.14 M NaCl, 0.05% Tween 20, pH 8.0) to a protein 
concentration in the range of 100 – 400 ng/mL. A horseradish peroxidase detection antibody 
was diluted to a concentration of 33.3 ng/mL. The enzyme substrate 3,3’,5,5’-
tetramethylbenzidine was applied, and after the reaction was stopped with 2 M sulfuric acid, 
the absorbance was measured at 450 nm for high throughput analysis in a 96 well plate 
format. The samples were analyzed in replicates of four. 
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Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE): primary structure 
SDS PAGE was used to assess changes (i.e., hydrolysis or aggregation) in the protein 
primary structure. Each protein sample was mixed (1:1/v:v) with a loading buffer (10% w/v 
SDS, 1M Tris-HCl (pH 6.8), 3 mM glycerol, 0.01% w/v bromophenol blue, and 0.05% v/v β-
mercaptoethanol) and heated for 5 min at 95°C. The samples were resolved through a 12% 
polyacrylamide precast gel (Tris-HCl; Bio-Rad) using a constant voltage of 140 V. The gels 
were removed, incubated in a fixative solution (40% ethanol and 10% acetic acid) for 3 h, 
stained with Coomassie Blue for 30 min, destained overnight, and scanned for image 
analysis. All experiments were performed in replicates of four. 
 
FTIR spectroscopy: secondary structure 
FTIR spectroscopy was performed to determine changes in the secondary structure of the 
BSA protein based on a method described previously [19, 35]. To quantify these structural 
changes, the protein samples were deposited in high throughput using an automated robotic 
deposition apparatus onto a 25-well silicon nitride substrate (IR transmissive) and dried at 50 
oC under vacuum. Using a Nicolet Nexus 470 Continuum infrared microscope (Thermo 
Fisher Scientific, Madison, WI) with a cooled MCT/A detector and an Ever-Glo source, a 
total of 200 scans per spectrum was collected at a resolution of 4 cm-1. Dry nitrogen was used 
to purge the optical bench to reduce the water absorbance. For data collection and analysis, 
Omnic software was used in conjunction with an automated mapping program, Atlμs, to 
enhance speed and repeatability. Protein structural quantification and analysis was modified 
from a previously described procedure for determining the amount of α-helices and ß-sheets 
of the protein [35]. The experiments were performed in replicates of four. Spectral data was 
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gathered from the amide I region of BSA and smoothed with an 11pt smoothing function. In 
all cases a linear baseline was fit to the spectral data and Gaussian curve fitting was used to 
determine the relative area under each peak in the amide I region. Table 5.1 provides a list of 
the IR peak positions and areas for the amide I region of BSA used in this structural analysis. 
The Atlμs software was employed to automate this process. 
 
Fluorescence spectroscopy: tertiary structure 
Fluorescence spectroscopy was used to study the changes in protein tertiary structure with a 
Cary Eclipse fluorescence spectrometer (Varian, Inc., Palo Alto, CA). The samples were 
arranged for high throughput analysis in a 96-well plate. They were excited at a wavelength 
of 280 nm and a voltage of 800 V, with a resulting emission spectrum that reflects the 
tryptophan and tyrosine residues of the protein. The emission spectrum from 300-500 nm 
was analyzed for shifts in peak intensity and wavelength, which are indicative of alterations 
in protein tertiary structure. The experiments were performed in replicates of four.  
 
Statistical and data analysis  
All data (except for Figure 5.5) was statistically analyzed by using a student’s t-test with the 
statistical software JMP® 7 (Cary, NC). Comparisons between treatments were made and p-
values of less than or equal to 0.05 were considered significant. Data in Figure 5.5 was 
statistically analyzed using a one-way model ANOVA with JMP® 7 to account for 
comparison-wise error since three treatments were studied in parallel. Comparisons between 
treatments were made with Tukey’s HSD to determine statistical significance and p-values of 
less than or equal to 0.05 were considered significant. Additionally, the data in Figures 5.4-
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5.6 are presented as ‘Relative Antigenicity’. This was calculated by quantifying the epitope 
availability/antigenicity of the sample (BSA-specific ELISA) by dividing by the amount of 
protein in the sample (Micro BCA Assay). In Figure 5.8, the data is presented as “Fold 
Change in Absorbance”, which was calculated by quantifying the α-helix and β-sheet content 
per sample by dividing by the α-helix and β-sheet content of the NP (no polymer, 
unencapsulated protein) control. 
 
5.4 Results and Discussion 
It is necessary to preserve the functionality and biological activity of proteins during their 
encapsulation into the delivery vehicle, storage, and upon release in vivo. Therefore, this 
work focused on utilizing a combinatorial approach to rapidly assess the capabilities of 
polyanhydride drug delivery vehicles based on CPH:SA and CPTEG:CPH copolymer 
nanoparticles to preserve protein antigenicity upon release. When loss or reduction of protein 
antigenicity was observed, further studies were carried out to identify the cause(s) of protein 
instability by examining the effects of nanoparticle fabrication conditions (solvent exposure, 
sonication, and vacuum) and the acidic release microenvironment caused by polymer 
degradation.  
 
The CPH:SA and CPTEG:CPH polymer nanoparticle libraries were synthesized in a 
combinatorial format, allowing for the synthesis of up to 25 different polymer chemistries in 
the same batch thus reducing the synthesis time by 25 fold. We add that by integrating a 
temperature gradient [33] or a pH gradient [13] with these libraries, further savings in time may 
be obtained. These polymer libraries were then rapidly precipitated with protein, forming 
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subsequent protein-loaded nanoparticle libraries of the desired polymer chemistries, which 
were also carried out at high throughput with a 25 fold reduction in time. In addition, this 
high throughput approach allowed for reduced sample size from the conventional 100 mg 
batch size [16, 17, 24] to a 10 mg batch size. This 10-fold reduction in material usage is critical 
when testing expensive, limited supply materials (antigens, peptides, growth factors, etc.) and 
also allows for analysis of the protein with different types of biomaterials. These polymer 
libraries were characterized by measurements of the polymer molecular weight, copolymer 
chemistry, and chemical structure. These properties were consistent with previous work on 
conventionally synthesized polymers [17, 19, 20, 34]. The 1H NMR characterization resulted in 
molecular weights ranging from 10-15 kg/mol which is consistent with previously published 
work with combinatorially and conventionally synthesized copolymers [17-20, 34]. Copolymer 
chemistries of both the CPTEG:CPH and CPH:SA libraries were characterized with 1H NMR 
and the CPH:SA library was further characterized with high throughput FTIR (CPTEG and 
CPH chemical species have indistinguishable IR spectra and could not be characterized in 
this manner). These methods revealed that the robotic apparatus was effective at depositing 
the intended molar ratios of the monomers into the discrete multi-well substrate (data not 
shown), which is in agreement with previously published data [10, 13]. Additionally, the high 
throughput FTIR method employed an automated mapping software package, which 
significantly reduced experimental time and user error. SEM was used to assess size and 
morphology of the nanoparticle libraries. SEM images, representative of the chemistries 
studied, are shown in Figure 5.3, and are consistent with previous work employing 
polyanhydride nanoparticles, with particle diameters in the 300-600 nm range across all the 
chemistries studied [10, 13, 16]. 
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Initial studies investigated the stability of BSA following encapsulation and release from 
CPTEG:CPH and CPH:SA nanoparticle libraries. These studies examined the effect of 
polymer chemistry on protein stability during encapsulation and after 48 h of release. Figure 
5.4 shows the effect of polymer chemistry on protein antigenicity, measured at high 
throughput by a protein-specific ELISA. In the CPH:SA system, it can be observed that the 
protein antigenicity decreased as the SA content in the copolymer increased whereas the 
protein released from CPTEG:CPH nanoparticles retained its antigenicity. This chemistry-
dependent trend may be controlled by the pH microenvironment resulting from the degraded 
polymer surrounding the protein. As the libraries shift from CPTEG-rich to CPH-rich to SA-
rich chemistry, there is a significant decrease in the pH of the polymer degradation products 
[20], exposing the protein to a much more acidic microenvironment. Acidic pH environments 
have previously been shown to be detrimental to protein structure, specifically to albumins 
like BSA [24, 35]. However, with the combined surface and bulk erosion mechanisms exhibited 
by polyanhydrides, water ingress into the bulk is controllable and in most cases not 
significant and therefore proteins would most likely only be exposed to these low pH 
microenvironments once they are released into surrounding solution. All nanoparticle 
chemistries of the CPTEG:CPH system were able to preserve the protein antigenicity 
presumably because of their ability to produce less acidic degradation products and to limit 
water ingress into the device, thus resulting in release of antigenic protein.  
 
Next, the combinatorial libraries were utilized to study the shelf life of protein encapsulated 
into nanoparticles over a period of 28 days at three temperatures (4, 25, and 40 °C). The 
throughput of this experiment was expedited by the combinatorial approach, which allowed 
108 
 
 
 
for this multi-parametric (polymer chemistry, temperature, and time) investigation of protein 
stability. The BSA-loaded nanoparticle libraries were stored under dry conditions at the 
desired temperature for the desired amount of time and then incubated for 2 days in buffer to 
allow for protein release and analysis of the effect of storage temperature and polymer 
chemistry on BSA stability. The results (Figure 5.5) indicate that the antigenicity of the 
protein released from the nanoparticles did not significantly change over the period of 28 
days for any of the chemistries tested. This suggests that the storage of the protein in 
polyanhydride nanoparticles is not detrimental to the protein antigenicity. When assessing the 
effect of temperature, there was no statistical difference in BSA antigenicity between 4 and 
25 °C, however; at 40 °C all the CPTEG:CPH nanoparticle chemistries and only 75:25 
CPH:SA and poly(CPH) nanoparticle chemistries were able to maintain, and in most cases 
exceed, preservation of the antigenic epitopes of BSA when compared to the non-
encapsulated protein (NP) stored at that specific temperature. This suggests that 
CPTEG:CPH and the CPH-rich chemistries of the CPH:SA polymer system may be able to 
protect proteins at elevated temperatures when they may otherwise lose structural stability 
when stored alone. It is also observed in Figure 5.5 that some CPTEG:CPH polymer 
chemistries resulted in a statistical increase in relative antigenicity greater than one. This 
suggests that more epitopes of the protein may have become available and thus exposed to 
antibody binding upon encapsulation into CPTEG:CPH chemistries.  
 
These findings prompted further examination of the effects of nanoparticle fabrication 
conditions and acidic release microenvironment on the stability of the protein. Again, parallel 
studies employing the combinatorial technique were carried out to rapidly investigate the 
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effect of the nanoparticle fabrication conditions on protein stabilization by measuring BSA 
antigenicity after exposure to the same conditions in the absence of polymer. This included 
prolonged contact with organic solvents (methylene chloride and pentane), sonication (at 40 
Hz), and extended exposure to a low vacuum (10-3 torr) chamber. These experiments 
revealed that the antigenicity of BSA was not affected by the processing conditions, as 
indicated in Figure 5.4 (bar marked “NFC”), which suggests that other factors, such as the 
microenvironmental pH, may play a more integral role in protein instability.  
 
To better understand the detrimental effect on the protein released from SA-rich chemistries, 
BSA was exposed to the acidic degradation products of CPH:SA copolymers for an extended 
period of time. Under saturated conditions, aqueous solutions of the SA monomer have been 
reported to have a pH of 4.2 whereas aqueous solutions of the CPH monomer have a pH of 
5.5 [20]. These studies were carried out by incubating BSA in a linearly varying gradient 
library of saturated CPH:SA monomers for seven days. Protein antigenicity was once again 
assessed with the BSA-specific ELISA and revealed a trend corresponding to a loss in 
antigenicity with increasing SA monomer content (decreasing pH) as shown in Figure 5.6. 
However, the relative decrease in antigenicity was less severe than that observed when the 
protein was released from the CPH:SA nanoparticles. Here, it is important to consider that 
the ratio of degradation products released from an eroding copolymer nanoparticle at any 
given time may be enriched in the more acidic/hydrophilic component, SA. This is likely due 
to variable backbone degradation rates of the copolymers and the increased solubility of SA 
[20], which may result in a more severe decrease in protein stability than observed in the 
corresponding monomer composition. While it is apparent that the microenvironmental pH is 
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playing an important role in the protein instability, other protein/polymer interactions could 
also be contributing to the loss in protein antigenicity. A detailed analysis of structural 
alterations of the protein was performed to provide a more complete explanation of how loss 
of protein structure is related to loss in protein antigenicity and to identify the structural 
levels at which the changes were occurring. The combinatorial approach provided a 
convenient platform for this investigation because the sample libraries were easily amendable 
to rapidly test many protein stability parameters (primary, secondary, and tertiary structures 
as well as antigenicity). 
 
The primary structure as indicated by molecular weight of the BSA protein incubated with 
the monomer library as determined with SDS PAGE, shown in Figure 5.7, revealed that the 
primary structure of the protein was preserved when incubated with all the monomer 
compositions. This indicates that the changes in antigenicity as determined by the BSA-
specific ELISA were not a result of structural alterations at the primary structure level upon 
incubation in the monomer library. While it has been reported previously [16], it is instructive 
to add that the hydrophobic nature of the CPH:SA chemistries likely did not induce non-
covalent aggregation. This is because even the most hydrophobic chemistries (CPH-rich) 
studied did not reveal any high molecular weight bands in the gels (Figure 5.7). 
 
The secondary structure of BSA was assessed by creating a combinatorial sample library of 
BSA from the incubation groups on a multi-well silicon nitride substrate and using 
transmission mode FTIR with an automated mapping program to enhance speed and 
repeatability. The amide I region of BSA (Table 5.1) was analyzed for α-helix and β-sheet 
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content, which are characteristic signatures of secondary structure [35]. As shown in Figure 
5.8, the α-helix content of BSA decreased with increasing SA content. This suggests that the 
acidic environment resulting from SA-rich monomer compositions is detrimental to the 
secondary structure of the protein, which is in agreement with previously published work on 
the deleterious effects of acidic environments on the secondary structure of BSA [35]. This is 
likely to be the critical factor that altered the antigenicity of BSA upon incubation with the 
CPH:SA monomer library (Figure 5.6). In addition, Figure 5.8 shows that the β-sheet content 
increased with an increase in CPH monomer content. As observed in Figures 5.4 and 5.5, this 
small increase in the β-sheet content with CPH-rich monomer compositions is not sufficient 
to cause non-covalent aggregation or alterations in the protein antigenicity.  
 
The tertiary structure of BSA incubated with the monomer library was investigated at high 
throughput using fluorescence spectroscopy. This assay was used to determine if the tyrosine 
and tryptophan residues of the BSA were folded in their native confirmation, which is 
usually indicative of biological activity [17]. The peak intensity and peak shift of the tyrosine 
and tryptophan residues were measured for each treatment and compared to that of the native 
protein. While there were no apparent peak shifts in wavelength over seven days of monomer 
incubation, there were changes in the peak intensity with increase in SA monomer content as 
shown in Table 5.2. This suggests that there was a decrease in tyrosine and tryptophan 
residue content, thus altering the overall three dimensional structure of the fully folded 
protein. This is in agreement with both the decrease in α-helix content as determined by 
FTIR and the protein antigenicity as determined by the BSA-specific ELISA. Such changes 
in the tertiary structure may also constitute alterations in the primary structure of the protein; 
112 
 
 
 
however, such subtle differences may not be detectable by the resolution of SDS PAGE. 
 
In this work a combinatorial approach was used for rapid examination of the effect of 
polyanhydride nanoparticle chemistry on protein stability and enabled an accelerated means 
of testing and designing delivery vehicles. Additionally, these studies helped paint an overall 
picture of the effect of encapsulation, storage, and release on protein stability and the causes 
leading to the instabilities and the structural level(s) at which these changes took place. It was 
demonstrated that the CPTEG:CPH nanoparticles are robust delivery vehicles capable of 
preserving the protein antigenicity upon encapsulation, storage (over one month at elevated 
temperatures), and release. This is in agreement with recently published work in which the 
CPTEG:CPH system showed promise in the preservation of protein function [17, 21, 24]. The 
ability of the CPTEG:CPH chemistries to preserve protein structure is a very significant 
feature because it allows for the exploitation of the entire range of protein release kinetics 
(CPTEG-rich: days to CPH-rich: months) to fit the desired application. In the case of the 
CPH:SA system, CPH-rich chemistries proved to be robust delivery devices, preserving 
protein functionality upon encapsulation, storage, and release; on the other hand, the SA-rich 
chemistries proved to be detrimental to protein antigenicity. The acidic microenvironmental 
pH, resulting from SA-rich polymer degradation, played an integral role in protein instability. 
These instabilities caused by pH resulted in a loss in protein antigenicity, which was reflected 
by losses in both secondary and tertiary structure. In addition to the pH, other phenomena 
such as protein adsorption/desorption may play a role in protein degradation. While protein 
adsorption can occur as a function of both surface hydrophobicity and electrostatic charge, 
further investigation of these protein/polymer interactions is necessary to enhance our 
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understanding of how the SA-rich polymer chemistries are influencing protein degradation.  
 
The combinatorial approach allowed for a 25-fold decrease in time (when compared to 
performing 25 “one-sample-at-a-time” experiments) and a 10-fold decrease in the amount of 
materials needed for the investigation of protein stability when compared to conventional 
methods. In addition, the use of a temperature or pH gradient as described previously [13, 33] 
could lead to further savings in time. In this work we were able to rapidly test numerous 
variables/aspects associated with both the nanoparticle delivery system (shelf life, 
temperature, polymer chemistry, processing conditions, and pH of degradation products) and 
the protein (antigenicity and primary, secondary, and tertiary structures) with a significant 
number of replicates. The trends identified in this work using the model protein, BSA, are 
applicable to other proteins when predicting their stability in these polymer systems. Many 
previous studies investigating stability of various proteins (e.g., TT, lysozyme, ovalbumin, 
F1-V antigen) in polyanhydrides utilized similar conventional particle fabrication techniques 
as those employed in this study [14, 17-21, 23, 24]. Therefore, the combinatorial methods described 
herein could easily be extended to study other proteins. Additionally, several ongoing studies 
with the polyanhydride system have reported trends in stability with other proteins very 
similar to those identified in this work [24]. This high throughput technique is easily amenable 
to investigate other materials for protein stabilization and to evaluate other factors that may 
contribute to protein instability. In addition, the work may also be extended to study other 
protein molecules (e.g., vaccines and anti-toxins) which when stored alone demonstrate 
structural instabilities and thus are in need of protective delivery vehicles. 
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5.5 Conclusions 
A high throughout method was developed to study the stability of a model protein (BSA) in 
polyanhydride nanoparticles. It was observed that all CPTEG:CPH chemistries and CPH-rich 
chemistries from the CPH:SA system were capable of providing stabilizing environments for 
BSA. These nanoparticles were also demonstrated to preserve the antigenicity of the protein 
during storage, even at elevated temperatures. The acidic microenvironment of the SA 
degradation products from the CPH:SA library proved to be a deleterious factor that affected 
the antigenicity of BSA. Further structural investigations revealed that the decrease in 
antigenicity caused by the acidic SA degradation products was due to perturbations of the 
secondary and tertiary structure of the protein. The combinatorial methodologies developed 
in this work are amenable to rapidly design and test other biomaterial systems and to study 
their protein stabilization capabilities. The use of BSA as a model protein has provided a 
general understanding of the trends associated with protein stability and polymer chemistry 
and the results obtained are applicable to other proteins of interest. The versatility of this 
combinatorial approach can also enable the study of multiple proteins simultaneously with 
biodegradable polymer systems. Utilization of this rapid, multiplexed approach can expedite 
research with limited availability of expensive proteins and lead to rapid and rational design 
of biomaterials for applications in drug delivery and vaccine administration. 
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5.8 List of Figures 
 
Figure 5.1: Chemical structures of: a) SA; b) CPH; and c) CPTEG; d) polyanhydride 
hydrolysis mechanism. 
 
Figure 5.2: Schematic describing the high throughput methodology for studying protein 
stability with polymer nanoparticle libraries from the initial synthesis/fabrication to storage 
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over time at variable temperatures to the release and subsequent level of stability as affected 
by pH, temperature, and polymer chemistry. This process allow for a 25 fold savings in time 
and 10 fold savings in materials compared with conventional techniques. 
 
Figure 5.3: SEM images of a) 50:50 CPTEG:CPH and b) 50:50 CPH:SA nanoparticles [13].  
 
Figure 5.4: Antigenicity of BSA following encapsulation and release from CPH:SA and 
CPTEG:CPH nanoparticles and after exposure to the nanoparticle fabrication conditions 
(NFC). Error bars represent standard deviation (n=4). NP = no polymer, unencapsulated 
protein control. See adjoining table for statistical analysis. Treatments with the same letter 
are not statistically significant from one another. Statistical significance (stat. sig.) 
corresponds to p < 0.05.  
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Figure 5.5: Shelf life study of BSA encapsulated into a library of nanoparticles poly(SA), 
25:75 CPH:SA, 50:50 CPH:SA, 75:35 CPH:SA, poly(CPH), 60:40 CPTEG:CPH, 50:50 
CPTEG:CPH, 40:60 CPTEG:CPH, 30;70 CPTEG:CPH, 20:80 CPTEG:CPH, and 10:90 
CPTEG:CPH) at three different temperatures 4, 25, and 40 °C (n=4). NP = no polymer, 
unencapsulated protein control. A) week 1, B) week 2, C) week 3, and D) week 4. See 
adjoining table for statistical analysis. Treatments with the same letter are not statistically 
significant from one another. Statistical significance (stat. sig.) corresponds to p < 0.05. 
A) 
B) 
C) 
D) 
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Figure 5.6: Antigenicity of BSA following a seven day incubation in a CPH:SA monomer 
library (n=4). Error bars represent standard deviation. NP = no polymer, unencapsulated 
protein control. See adjoining table for statistical analysis. Treatments with the same letter 
are not statistically significant from one another. Statistical significance (stat. sig.) 
corresponds to p < 0.05. 
 
Figure 5.7: Primary structure of BSA using SDS PAGE following a seven day incubation in a 
CPH:SA monomer library (n=4) (not all gel images are shown). NP = no polymer, 
unencapsulated protein control. 
121 
 
 
 
 
Figure 5.8: Secondary structure of BSA using FTIR following a seven day incubation in a 
CPH:SA monomer library to determine α-helix and β-sheet content (n=4). Error bars 
represent standard deviation. NP = no polymer, unencapsulated protein control. See adjoining 
table for statistical analysis. Treatments with the same letter are not statistically significant 
from one another. Statistical significance (stat. sig.) corresponds to p < 0.05. 
 
5.9 List of Tables 
Table 5.1: Amide I region of BSA peak assignment, position, and area. 
Peak Assignment Peak Position Peak Area 
β-sheet 1695±1 7±1 
α-helix 1657±1 31±1 
β-sheet 1639±1 15±4 
β-sheet 1628±2 8±3 
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Table 5.2: Tertiary structure of BSA with fluorescence spectroscopy, following a 7 day 
incubation in a CPH:SA monomer library, as determined by % change in peak intensity and 
shift in peak position from 340 nm. 
  SA 25:75 CPH:SA 
50:50 
CPH:SA 
75:25 
CPH:SA  CPH NP 
% Change in 
Peak Intensity 22 22 18 18 16 8 
Shift in Peak 
Position (nm) 4 1 1 0 2 1 
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6.1 Abstract 
Advancements towards an improved vaccine against Bacillus anthracis, the causative agent 
of anthrax, have focused on formulations composed of aluminum hydroxide adsorbed 
protective antigen for anthrax (PA). However, due to the fragile nature of this antigen, 
stability has become a primary concern for vaccine commercialization. Thus, there is a need 
for a delivery system capable of preserving the functionality of PA throughout all the steps of 
the vaccine fabrication process through storage and until administration. In this work, we 
present a class of biodegradable, polyanhydride nanoparticle-based vaccine delivery 
adjuvants, which have previously been shown to provide controlled antigen delivery, antigen 
stability, immune modulation, and protection in a single dose against a live pathogen 
challenge. These nanoparticle vaccine delivery adjuvants demonstrated hydrophobicity 
dependent PA release kinetics and preserved the functionality of PA upon encapsulation, 
storage (over extended time and elevated temperatures) and release. Specifically, amphiphilic 
polyanhydride nanoparticles revealed the ability to best preserve PA functionality over 
extended time periods and elevated temperatures. These studies provide new insights for the 
use of amphiphilic nanoparticles as delivery vehicles for long-term vaccine storage as well as 
single-dose protective immunization against B. anthracis infections. 
 
6.2 Introduction 
Anthrax is a significant public health concern due to its potential as a bioterrorism and 
biowarfare agent. Use of the currently licensed anthrax vaccine (AVA) poses many concerns 
due to its high reactogenicity, multi-dose (five) immunization schedule followed by yearly 
boosters, and painful side effects [16]. The key element of the AVA vaccine involved in 
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immunity to the anthrax infection is the recombinant protective antigen for anthrax (PA) 
which has been the focus for new vaccines [14]. PA is the receptor-binding subunit for both 
the lethal factor (LF) and the edema factor (EF), which upon binding to the factors is 
responsible for the formation of the lethal toxin (LT) and the edema toxin (ET) [31]. 
Unfortunately, the PA protein possesses a fragile recombinant structure and is extremely 
unstable, especially in low pH and high temperature environments [4, 11, 25, 26]. These stability 
concerns have led to manufacturing roadblocks during a phase 1 clinical trial for a new 
anthrax vaccine based on PA [36].  
 
It has been reported that any PA circulating in the blood stream is eliminated within six hours 
[17]; hence the need for multiple immunizations with the AVA vaccine [31]. Methods to 
increase its availability to the immune system and improve the immunogenicity of PA 
include engineering recombinant PA, including other antigens or adjuvants in the vaccine, 
vaccination through alternate delivery routes, as well as the use of controlled delivery 
systems [31]. Currently, the AVA vaccine is administered intramuscularly and many murine in 
vivo studies have focused on subcutaneous delivery of PA. However, intranasal vaccination, 
targeting the lungs, has been reported as the ‘seemingly best route for stimulation’ [9, 31]. 
However, the best known mucosal adjuvants (cholera, pertussis, and edema toxin bacterial 
proteins and CpG) have significant limitations due to their potential toxicity in humans [8, 31]. 
This work focuses on a controlled delivery system for PA based on biodegradable 
polyanhydride nanoparticles, which provide safe intranasal delivery [10], non-specific 
adjuvant effect to the cells of the immune system [22, 23, 33], sustained release of encapsulated 
antigens [2, 5-7, 18, 21, 28], and a stabilizing environment for antigens during fabrication, storage, 
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and delivery [2, 5-7, 15, 18, 20, 28].  
 
Polyanhydrides are a class of biomaterials with excellent biocompatibility and have been 
studied as vaccine delivery vehicles and adjuvants [3, 13, 22, 23, 30, 32]. Specifically, copolymers 
based upon sebacic anhydride (SA), 1,6-bis(p-carboxyphenoxy) hexane (CPH), and 1,8-
bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) have been of particular interest as 
adjuvants. Micro- and nanoparticles of these materials, which are suitable for inhalation or 
injection, have tunable antigen release kinetics [2, 5-7, 15, 18, 21, 28], which would provide an 
antigen depot in vivo, allowing for long-term antigen exposure and eliminating the need for 
multiple administrations. Polyanhydride nanoparticles have demonstrated sustained release 
of encapsulated molecules for extended periods of time (in excess of 30 days) in vivo [10, 19]. 
Furthermore, these materials have excellent protein stabilization capabilities, and have been 
shown to protect and structurally preserve a wide range of proteins upon encapsulation, 
storage, and delivery [2, 5-7, 15, 18, 20, 28]. These surface eroding polymers slowly release 
encapsulated antigen, minimizing exposure to unfavorable aqueous environments. Additional 
studies have shown that polyanhydride nanoparticles are capable of non-specific stimulation 
of immune cells [3, 22, 23, 30, 33]. They enhance cell surface marker expression and cytokine 
production similar to many other adjuvants (e.g. LPS) without any toxic side effects.  
 
The goal of this work is to design a nanoparticle-based vaccine formulation capable of 
encapsulating and releasing PA in a biologically functional form during fabrication, storage 
and release, to provide a delivery system capable of promoting a robust, high avidity, 
neutralizing antibody response. Nanoparticles based on 50:50 CPTEG:CPH, 20:80 
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CPTEG:CPH, 50:50 CPH:SA, and 20:80 CPH:SA were investigated for their ability to 
stabilize and release PA. The amphiphilic CPTEG:CPH nanoparticle chemistries 
demonstrated the ability to preserve the functionality of PA throughout all the stages of 
nanoparticle fabrication, storage, and controlled delivery, proving the opportunity for long-
term antigen presentation to the immune system. This strategy of using amphiphilic 
nanoparticles as delivery vehicles presents a possible solution for long-term vaccine storage 
as well as single-dose protective immunization against B. anthracis infections. 
 
6.3 Materials and Methods 
Materials 
The chemicals needed for polymerization, nanoparticle fabrication, and buffer preparation 
include acetic anhydride, chloroform, methylene chloride, petroleum ether, pentane, 
monobasic potassium phosphate, and dibasic potassium phosphate; all were purchased from 
Fisher Scientific (Fairlawn, NJ). Monomer synthesis utilized the following chemicals: 1,6-
dibromohexane, tri-ethylene glycol, 4-hydroxybenzoic acid, 1-methyl-2-pyrrolidinone, 4-p- 
and 1,6-dibromohexane; these were purchased from Sigma Aldrich (St. Louis, MO); 4-p-
fluorobenzonitrile was purchased from Apollo Scientific (Cheshire, UK); and sulfuric acid, 
acetonitrile, dimethyl formamide (DMF), toluene, and potassium carbonate were obtained 
from Fisher Scientific. Deuterated chemicals for NMR analysis (chloroform and dimethyl 
sulfoxide (DMSO)) were purchased from Cambridge Isotope Laboratories (Andover, MA). 
Precast 12% polyacrylamide gels (Tris-HCl), low molecular mass standards, and 2-
mercaptoethanol were purchased from BioRad (Hercules, CA). PA and LF were obtained 
from BEI Resources (Manassas, VA). 
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Polymer synthesis, nanoparticle fabrication, protein encapsulation, and characterization 
The CPH and CPTEG monomers were synthesized as described previously [29, 35]. The SA 
monomer was purchased from Sigma Aldrich (St. Louis, MO). Pre-polymer and polymers 
were synthesized as described before [12, 28]. The CPTEG:CPH and CPH:SA copolymers were 
formed into nanoparticles as described previously [20, 21, 23]. A 2% (w/w) PA loading into the 
nanoparticles was used in the experiments of Figures 6.1-6.4 and a 0.8% PA loading was 
used in the experiments of Figures 6.5-6.6. These loading percentages were chosen due to 
protein detection limitations of the assays and techniques required by each experiment. 
Polymer molecular weight, chemical structure, and chemical composition were determined 
with 1H NMR spectroscopy using a Varian VXR 300 MHz spectrometer (Varian Inc., Palo 
Alto, CA). Nanoparticle size and morphology were characterized with scanning electron 
microscopy (SEM) (JEOL 840 A, JEOL Peabody, MA).  
 
In vitro protein release kinetics 
PA-loaded nanoparticles were placed in microcentrifuge tubes with 0.1 mM PBS buffer (pH 
7.6). Samples were sonicated for uniform nanoparticle distribution and placed in a 
shaker/incubator at 37 °C. Sample supernatants were removed incrementally over time to 
measure the amount of released PA with the micro bicinchoninic acid (BCA) assay. 
Equivalent volumes of PBS buffer were added following supernatant removal to maintain 
perfect sink conditions. Data is presented as percent fraction released, which was determined 
by dividing the amount released at each time point by the total amount encapsulated into the 
nanoparticles [2, 5-7, 15, 18, 21, 28].  
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In vitro pH study 
Blank nanoparticles were placed in centrifuge tubes with 0.1 mM PBS buffer (pH 7.6). 
Samples were sonicated for uniform nanoparticle distribution and placed in a 
shaker/incubator at 37 °C. The pH measurements were carried out incrementally to monitor 
the buildup of acidic degradation products.  
 
Protein release and in vivo administration of released protein 
PA-loaded nanoparticle samples were incubated in PBS buffer for 14 days at 4 °C in dialysis 
cassettes to accumulate enough PA for immunization and to prevent temperature induced 
instability. Protein concentration was determined with the micro-BCA assay and adjusted for 
all samples. Equal amounts of PA (10 μg) released from the different nanoparticles studied 
(20:80 CPTEG:CPH, 50:50 CPTEG:CPH, and 20:80 CPH:SA) and PA alone were adsorbed 
to imject alum (Fisher Scientific) for 30 min. A/J mice (Jackson Laboratories, Bar Harbor, 
Maine) were immunized subcutaneously in the nape of the neck with 10 μg of PA absorbed 
to alum from each of the above formulations (3 mice per group), boosted on day 15 with 10 
μg of PA, euthanized on day 21, and serum collected from a cardiac puncture. All mice were 
housed under specific pathogen-free conditions where all bedding, caging, and feed were 
sterilized prior to use. All animal procedures were conducted with the approval of the Iowa 
State University Institutional Animal Care and Use Committee.   
 
Enzyme-linked immunosorbent assay (ELISA): PA-specific serum antibody response 
PA-specific serum antibody response (total IgG [H+L]) was analyzed by ELISA, modified 
from a method described previously [32]. High binding 96 well plates were coated with 0.5 
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μg/mL PA overnight at 4 °C. Following antigen incubation, the plates were blocked for 2 h 
(PBS containing 0.5% Tween 20 (PBS-T) and 2% gelatin) at room temperature, washed three 
times in PBS-T, and then incubated with mouse serum for 24 h at dilutions from 1:1,000 to 
1:1,000,000. The following day the plates were washed three times in PBS-T, incubated with 
the alkaline phosphatase-conjugated secondary IgG [H+L] antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA) for 2 h at room temperature, washed again, 
and incubated with alkaline phosphatase substrate buffer (Sigma Aldrich) for plate 
development for 2 h at room temperature. The absorbance was measured as an optical 
density (OD) at 405 nm using a Spectramax 190 Plate Reader (Molecular Devices, 
Sunnyvale, CA). The samples were analyzed in triplicate. 
 
Enzyme-linked immunosorbent assay (ELISA): serum antibody avidity  
Serum antibody avidity was determined by modifying a method described previously [32]. 
They avidity assay was carried out similar to the ELISA serum antibody response protocol 
described above. Following serum incubation for 24 h at a dilution of 1:1,000,000, sodium 
thiocyanate was incubated with increasing dilutions ranging from 0 to 5 M for 20 min at 
room temperature. Plates were washed four times in PBS-T and detection of bound serum 
antibody followed as described above. Relative avidity index is defined as the concentration 
of sodium thiocyanate required to decrease the optical density of each sample with 0 M 
sodium thiocyanate by 50%. 
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Lethal toxin biological assay 
The lethal toxin assay was modified from a previously described method [11]. The murine 
macrophage-like cell line RAW 264.7 obtained from ATCC (Manassas, VA) were 
maintained in culture at 37°C in a 5% CO2 humidity using high glucose DMEM medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated FBS (Valley 
Biomedical, Winchester, VA), 100 IU/ml penicillin and 10 μg/ml streptomycin (Mediatech, 
Herndon, VA).  For the lethal toxin assay, RAW cells were transferred to a 96 well plate 
(100,000 cells per well) grown to approximately 90% confluency in 100 μL medium over 
two days. Treatments (released PA, PA-loaded nanoparticles, medium only control, PA 
control, LF control, cell lysis buffer control) were added to the cells with 0.3 μg/mL LF for 6 
h unless otherwise stated. The amount of released protein was calculated from the release 
curve in Figure 6.1. This assay was also utilized to investigate antibody neutralization as well 
as shelf life of the nanoparticle vaccines. For antibody neutralization assessment, sera from 
the different immunized mouse groups was added to the RAWs along with PA (0.8 μg/mL) 
and LF (0.3 μg/mL). The samples were then allowed to incubate for 6 h after which the MTT 
assay was used to determine cell viability. Optical density (OD) was measured at 570 and 
690 nm. Antibody neutralization was considered significant when OD values measured 3X 
higher than the saline only control. Data is presented as % residual activity, as determined by 
Equation 1: 
 
Ψݎ݁ݏ݅݀ݑ݈ܽܽܿݐ݅ݒ݅ݐݕ ൌ
୓ୈ౩౗ౣ౦ౢ౛ି୓ୈ౤౛ౝౙ౥౤౪౨౥ౢ
୓ୈ౦౥౩ౙ౥౤౪౨౥ౢି୓ୈ౤౛ౝౙ౥౤౪౨౥ౢ
                              Eq. 1 
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In vitro release of PA for analysis of activity, antigenicity and structure 
Groups tested for their effect on PA stability were nanoparticles of 20:80 CPTEG:CPH, 
50:50 CPTEG:CPH, 20:80 CPH:SA, and 50:50 CPH:SA, PA (positive control stored at -20 
°C), and nanoparticle fabrication conditions (NFC) which included sonication, solvent 
exposure (methylene chloride and pentane), and vacuum drying. All groups were sonicated 
and placed in microcentrifuge tubes with 0.1 mM PBS buffer (pH 7.6) in a shaker/incubator 
at 37 °C. PA was released from the nanoparticles for two days to accumulate enough protein 
for characterization. Following the release, sample supernatants were removed, PA 
concentration quantified with the micro-BCA assay, concentrations adjusted uniformly to 60 
μg/mL and analyzed for PA antigenicity, activity, and structure alterations.  
 
Enzyme-linked immunosorbent assay (ELISA): PA antigenicity 
High binding 96 well plates were coated with 0.5 μg/mL of released PA overnight at 4 °C 
and incubated with serum collected from mice immunized with released PA from 50:50 
CPTEG:CPH nanoparticles at a dilution of 1:1,000. The detection of antigenic PA antibody 
was carried out using an ELISA as described above.  
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE): primary structure 
SDS PAGE was used to assess changes in the protein primary structure. Each protein sample 
was mixed 1:1 (v/v) with a loading buffer (10% w/v SDS, 1M Tris-HCl (pH 6.8), 3 mM 
glycerol, 0.01% w/v bromophenol blue, and 0.05% v/v β-mercaptoethanol) and heated for 5 
min at 95 °C. The samples were resolved through a 12% polyacrylamide precast gel (Tris-
HCl; Bio-Rad, Richmond CA) using a constant voltage of 140 V. The gels were removed, 
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incubated in a fixative solution (40% ethanol and 10% acetic acid) for 3 h, stained with 
flamingo fluorescent gel stain overnight, and then scanned for image analysis (Typhoon™ 
Variable Mode Imager 9400, GE Healthcare, Piscataway, NJ). All experiments were 
performed in replicates of four. 
 
Circular dichroism: secondary structure 
Far UV circular dichroism (CD) (190–250 nm) was used to study the changes in protein 
secondary structure. All CD spectra were collected for samples on a Jasco J-170 
Spectropolarimeter (Easton, MD). The emission spectrum from 200-260 nm was analyzed 
for shifts in molar ellipticity and wavelength, which are indicative of alterations in protein 
secondary structure. The experiments were performed in replicates of four.  
 
Fluorescence spectroscopy: tertiary structure 
Fluorescence spectroscopy was used to study the changes in protein tertiary structure with a 
Cary Eclipse fluorescence spectrometer (Varian, Inc., Palo Alto, CA). The samples were 
excited at a wavelength of 280 nm and a voltage of 800 V, with a resulting emission 
spectrum that corresponds to the tryptophan and tyrosine residues of the protein. The 
emission spectrum from 300-500 nm was analyzed for shifts in peak intensity and 
wavelength, which are indicative of alterations in protein tertiary structure. The experiments 
were performed in replicates of four.  
 
Shelf life stability 
The storage of PA was studied while loaded into the nanoparticles (dry) (labeled by polymer 
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chemistry), dissolved in PBS buffer (labeled “PBS”), and adsorbed to alum (labeled 
“Alum”). All groups were stored under desiccant at four different temperatures, 40, 25, 4, 
and -20 ºC, for two months and tested for their activity at incremental time points. Following 
the storage time the groups were tested for their ability to preserve PA activity using the LT 
assay as described before [11]. In these studies, 125 μg/mL of PA-loaded nanoparticles was 
utilized because a 6 h release (assay incubation time) resulted in ~0.1 μg/mL PA (equivalent 
to the PA control concentration). 
 
Statistical analysis  
Statistical analysis was carried out using a one-way model ANOVA with JMP® 7 (Cary, NC) 
to account for comparison-wise error since three treatments were studied in parallel. 
Comparisons between treatments were made with Tukey’s HSD to determine statistical 
significance (data from Figures 6.3 and 6.5 was log transformed for statistical analysis). 
 
6.4 Results 
Polymer and nanoparticle characterization 
Polymer characterization by 1H NMR and GPC indicates that the polymer molecular weights 
were within the desired ranges of 9,000-15,000 Da, which agrees with previous work [1, 12, 29]. 
The structure and composition of the polymers was also confirmed using NMR and the 
results were as expected. SEM images (data not shown) indicated that protein-loaded and 
blank nanoparticles resulted in similar size (~212 ± 43 nm) and morphology, consistent with 
other work [20-22, 32, 34]. Particle yield was 80%. 
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In vitro PA release and pH of nanoparticle degradation are dictated by chemistry 
Release of PA and change in pH due to nanoparticle degradation was studied for two months 
and one month, respectively.  We observed chemistry-dependent degradation kinetics, which 
controlled the release of the encapsulated protein as well as the buffer acidification. 
Increasing the content of SA or CPTEG resulted in a more rapid release of encapsulated PA. 
In contrast, the CPH-rich chemistries provided a more long-term PA release profile as shown 
in Figure 6.1A. This is in agreement with release kinetics of several other proteins from 
polyanhydride nanoparticles, which demonstrate chemistry-dependent release profiles [2, 5-7, 
15, 21, 28, 38]. The effect of the polymer chemistry is also evident in the pH profile of the 
degrading nanoparticles, as shown in 6.1B. The acidic monomers produced from the 
degradation of CPH:SA nanoparticles have been shown to be water soluble [7] and result in a 
greater decrease in pH (∆pH = 2.5) as compared with that of the CPTEG:CPH monomers 
(∆pH = 0.6). Our results are consistent with previous findings [7, 28].  
 
In vivo immunization with PA released from amphiphilic CPTEG:CPH nanoparticles results 
in high titer, high avidity, neutralizing antibody 
In order to determine the immunogenicity of the released protein, mice were immunized with 
PA released from the nanoparticles, adsorbed to alum. Antibody response to the released 
protein was characterized in terms of titer, avidity, and neutralizing ability. The antibody 
titers (Figure 6.2A), relative avidity (Figure 6.2B), and neutralizing antibody titers (Figure 
6.2C) indicate that PA released from CPH:SA nanoparticles produced a weak humoral 
response, while that released from the CPTEG:CPH nanoparticles resulted in the induction of 
high titer antibody. This indicates that the amphiphilic CPTEG:CPH nanoparticles preserved 
136 
 
 
 
the immunogenicity of the released PA. While the overall and neutralizing antibody titers for 
PA released from CPTEG:CPH nanoparticles remained indistinguishable from the positive 
control (i.e., PA), the antibody avidity was notably less.  
 
Protein activity and structural stability was preserved by amphiphilic CPTEG:CPH 
nanoparticles 
The stability of PA released from the nanoparticles was evaluated and is summarized in 
Figure 6.3. Specifically, Figure 6.3A and Figure 6.3B depict PA antigenicity and activity, 
respectively.  Our analysis revealed that PA released from amphiphilic 50:50 CPTEG:CPH 
nanoparticles retained almost 80% of its functional activity and antigenicity. PA released 
from 20:80 CPTEG:CPH nanoparticles retained only 52% of its activity and antigenicity 
while CPH:SA-containing nanoparticles preserved very little PA activity and antigenicity. 
Nanoparticle fabrication conditions had little to no effect on the antigenicity or activity of PA 
(Figure 6.3). 
 
To better understand the loss in antigenicity and activity, a detailed structural evaluation of 
PA was carried out as shown in Figure 6.4. The primary structure of PA from SDS-PAGE 
studies (Figure 6.4A) appears to be altered for all conditions except for the positive control 
(PA) and NFC. The primary band for PA appears at 83 kDa, which can be clearly identified 
in the PA control lane (Figure 6.4A). While this main band at 83 kDa was observed for PA 
released from both CPTEG:CPH chemistries, the band was significantly weaker in intensity. 
In contrast, no bands were observed for PA released from the CPH:SA nanoparticles. Since 
no high molecular weight bands were observed in the gel image, it is hypothesized that the 
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PA underwent degradation rather than aggregation.  
 
The CD spectra for PA showed a minimum at approximately 208-210 nm and a shoulder at 
215-217 nm (Figure 6.4B). This is consistent with PA secondary structure from CD spectra 
reported previously and indicates that PA consists mainly of a mixture of α-helices and β-
sheets [11, 24]. Figure 6.4B reveals that only the NFC and 50:50 CPTEG:CPH nanoparticles 
were able to preserve the secondary structure. All other conditions (20:80 CPTEG:CPH, 
20:80 CPH:SA, and 50:50 CPH:SA) resulted in a significant increase in molar ellipticity 
(Δε), signifying a loss in secondary structure.  
 
Tertiary structure analysis, performed with intrinsic fluorescence spectroscopy, displayed a 
red shift in peak position for the PA released from all nanoparticle formulations (Figure 
6.4C). This peak shift indicates exposure to a more polar environment indicative of protein 
unfolding [11]. However, PA peak intensity was best preserved by the amphiphilic 50:50 
CPTEG:CPH nanoparticles and to a lesser extent by 20:80 CPTEG:CPH nanoparticles. The 
nanoparticle fabrication conditions appeared to have no detrimental effects on the tertiary 
structure of PA.  
 
PA functionality upon release from nanoparticles is maintained in all chemistries in a dose 
and time dependent manner 
An in vitro cytotoxicity assay was employed to assess the ability of PA-loaded nanoparticles 
to preserve the biological function of PA directly after its release. Moreover, this functional 
assay eliminated the effects of any structural changes that may have occurred to the PA 
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during the two-day release experiment. Six h of co-culture with the RAW264.7 cells and 125 
μg/mL of PA-loaded nanoparticles was determined to provide a concentration of released PA 
equivalent to that of the positive control (i.e., only PA). Because there was no statistical 
difference in the amount of PA released between the different nanoparticle chemistries in the 
first 6 h (as shown in Figure 6.1), direct comparisons between the various groups can be 
made. Nanoparticles released PA in a time- and nanoparticle concentration-dependent 
manner (Figure 6.5). More importantly, nanoparticle chemistry clearly influenced the 
biological activity of PA. Specifically, amphiphilic 50:50 CPTEG:CPH nanoparticles 
released fully functional PA after only 4 h of incubation at 62.5 μg/mL. Although 50:50 
CPTEG:CPH nanoparticles appeared to have a superior ability to preserve PA activity 
(Figure 6.5), all other nanoparticle chemistries released PA that possessed a similar level of 
activity as the positive control when incubated for 6 h at a concentration of 125 μg/mL 
(Figure 6.5C).  
 
Shelf life stability of PA encapsulated into 50:50 CPTEG:CPH, 20:80 CPTEG:CPH and 
20:80 CPH:SA is superior to that of PA adsorbed to alum 
The ability of a PA-containing vaccine to retain full activity upon storage remains a primary 
concern. Therefore, we investigated the shelf life storage capabilities of PA loaded into 
polyanhydride nanoparticles (dry), PA dissolved in PBS buffer (pH 7.6), and PA adsorbed to 
alum and then stored at 40, 25, 4, and -20 °C. It is known that adjuvant solutions containing 
alum are acidic (pH = 5.6) [37], so the PBS buffer group was included to investigate the effect 
of storage temperature at a neutral pH on the stability of PA. After one week of storage at 40 
°C, the biological activity of PA adsorbed to alum and PA stored in PBS buffer was 
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completely lost (Supplementary Figure 6.1). Following two weeks of storage at 25 °C, PA 
adsorbed to alum lost half of its activity, and after one month, it lost all of its activity 
(Supplementary Figure 6.1). After two months of storage at 25 and 40 °C, only PA released 
from 50:50 CPTEG:CPH and 20:80 CPH:SA nanoparticles was capable of maintaining 
almost 100% of its biological activity (Figure 6.6). PA adsorbed to alum lost all its 
functionality when tested after two months of storage (Supplementary Figure 6.1). 
Nanoparticles made of 20:80 CPTEG:CPH nanoparticles were capable of preserving 100% 
of PA activity under cold storage and partial activity at the two elevated temperatures.  In 
contrast, nanoparticles made of 50:50 CPH:SA were ineffective at stabilizing PA under any 
storage temperatures above freezing. 
 
6.5 Discussion 
Next-generation anthrax vaccines need to possess several attributes, including storage 
stability and reduced immunization frequency. In this work, we have demonstrated that 
polyanhydride nanoparticle-based controlled delivery systems can provide these attributes. In 
particular, our studies have shown that amphiphilic polyanhydride nanoparticles provide 
controlled antigen release over several weeks, high titer total and neutralizing antibody 
production, and extended shelf lives at tropical temperatures. 
 
Long term, repeated antigen exposure (depot effect) is essential for the development of 
immunological memory, which is why the AVA vaccine regimen consists of five 
immunizations with yearly boosters [31]. In the event of a bioterrorism attack, this long-term 
vaccination strategy is not a viable option; thus there is a need for a vaccine capable of 
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mimicking the current immunization regimen in a single dose. Such a single dose vaccine 
will also improve patient compliance. The nanoparticle-based delivery system demonstrated 
long term release kinetics for over two months, dictated by polymer chemistry, as shown in 
Figure 6.1A. These long-term release kinetics have also been demonstrated in vivo [19].  
 
While controlled release kinetics enable long-term antigen exposure, it is essential that the 
antigen remain intact during fabrication, long-term storage, and release, in order to generate a 
protective immune response. The current vaccine adjuvant approved for human use in the 
U.S., alum, is known to produce an unstable acidic micro-environment for pH sensitive 
proteins [37]. While the adsorbed antigen can be better protected by the less acidic 
microenvironment pH on the surface of alum [37], any antigen in the bulk could be rendered 
inactive (i.e., pH sensitive antigens such as PA) due to the increased acidic environment (pH 
~5.6). In addition to pH sensitivity, PA has also demonstrated sensitivity to increased 
temperature; an effect that is exacerbated as the conditions become more acidic [11]. In this 
work, we demonstrated the superior PA stabilization capabilities of a nanoparticle-based 
delivery system that preserved the biological activity of PA during fabrication, delivery, and 
storage, overcoming several of the problems associated with current vaccine strategies. 
 
Nanoparticle fabrication conditions (solvent exposure, sonication, and vacuum drying) had 
no effect on the structure, antigenicity, or activity of PA. This renders the nanoparticle 
fabrication process safe for PA and is in agreement with similar results for other proteins 
exposed to these conditions [20]. The pH and temperature, however, has been reported to be a 
more influential factor on the stability of PA [4, 11, 24, 26, 27]. As shown in Figure 6.1B, the pH 
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of CPTEG:CPH nanoparticles only drops to approximately 7.0 and is maintained at that 
value for over 30 days; on the other hand, the pH of CPH:SA nanoparticles decreases to 5.25, 
which is similar to alum, within the first few days of PA release. This acidic micro-
environment caused by the CPH:SA nanoparticle degradation products can be correlated with 
the losses in antigenicity and activity (Figure 6.3) and structure (Figure 6.4) of PA after 
release from these nanoparticles. This is also reflected in the low levels of total and 
neutralizing antibody titers and low antibody avidity observed in Figure 6.2. Detailed 
structural analysis studies demonstrated that significant alterations in the primary, secondary 
and tertiary structure of PA are important determinants of the loss in antigenicity, activity 
and antibody production (Figure 6.5). Consistent with these results, it has been reported that 
thermally-induced ellipticity changes in PA occurred in acidic environments [4, 11, 26, 27] and 
PA under low pH and high temperature conditions is structurally modified to a molten 
globular state [11]. As observed in this work, this modified state is rendered inactive and non-
immunogenic.  
 
Amphiphilic CPTEG:CPH nanoparticles, specifically 50:50 CPTEG:CPH, provided an 
effective stabilizing environment for PA. Nearly 80% of PA antigenicity and activity was 
preserved upon release from 50:50 CPTEG:CPH (Figure 6.3). The total and neutralizing 
antibody titers for PA released from 50:50 CPTEG:CPH nanoparticles were indistinguishable 
from the positive control (Figure 6.2). From the detailed structural analysis, it is likely that 
the alterations in the tertiary structure of PA released from 50:50 CPTEG:CPH nanoparticles 
(Figure 6.4C) may be responsible for the slight loss in antibody avidity (Figure 6.2) and 
antigenicity and activity (Figure 6.3). These alterations are likely a result of the slight 
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decrease in pH at 37 °C as reported by Jiang et al.[11] When administered in vivo (i.e. 
intranasally), this acidic microenvironment would be readily eliminated, thereby reducing 
pH-dependent alterations of PA. Based upon these results and previous in vivo protection 
reports [32], we hypothesize that when PA-loaded nanoparticles are injected in vivo they will 
adjuvant the immune response by providing an antigen depot to enable the development of 
high avidity antibody and long term immune memory.  
 
Successful vaccine formulations provide a sustained release of functional protein over time, 
while limiting the number of doses needed. All nanoparticle chemistries revealed dose- and 
time-dependent release of functional PA (Figure 6.5), suggesting that they are viable 
candidates for releasing functional PA in a vaccine formulation. However, the amphiphilic 
50:50 CPTEG:CPH once again outperformed the other formulations, demonstrating the 
ability to best preserve the function of PA. 
 
One of the most difficult challenges to overcome in vaccine design and development is long-
term storage capabilities. This is an immediate concern in developing countries with limited 
cold storage. In this work, we tested storage of dry PA-loaded nanoparticles over two months 
at elevated temperatures. All nanoparticle chemistries, except for 50:50 CPH:SA, 
outperformed alum in preserving the stability of PA at 40, 25, and 4 °C (Figure 6.6). Since 
the build-up of acidic degradation products leading to a decrease in pH was largely 
eliminated from these studies, it is hypothesized that the hydrophobic 50:50 CPH:SA 
nanoparticle chemistry induced hydrophobic interactions with PA, leading to non-covalent 
aggregation. These same formulations also proved to be superior to PA stored in PBS buffer 
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at 40 °C (Figure 6.6). The changes observed with PA stored with alum are hypothesized to be 
a result of the low pH environment combined with the storage temperature. In contrast, PA 
stored in PBS buffer at a neutral pH is only likely to be affected by the elevated temperature. 
The 50:50 CPTEG:CPH and 20:80 CPH:SA nanoparticles revealed surprising similar 
capabilities to preserve PA at 40 and 25 °C for the entirety of our study, demonstrating 
enhanced protein stabilization as compared to lyophilized PA stored with stabilizers after 
only one month [11]. The ability of 20:80 CPH:SA nanoparticles to stabilize PA was 
surprising based upon the lack of a robust antibody response following immunization with 
PA released from this formulation.  However, it is to be noted that the time course of this 
study was short, thereby reducing the buildup of acidic degradation products that could 
negatively affect stability. 
 
6.6 Conclusions 
Together, the studies reported herein demonstrate the potential use of the polyanhydride 
nanoparticle platform in next-generation anthrax vaccines. These nanoparticles provide the 
ability to control protein release kinetics, which would provide an in vivo antigen depot 
capable of long-term antigen presentation. Additionally, the particles are capable of 
preserving PA activity upon fabrication, storage at elevated temperatures, and after release. 
Of all the formulations tested, amphiphilic 50:50 CPTEG:CPH nanoparticles demonstrated 
the best combination of characteristics compatible for PA preservation and release, making it 
an ideal candidate for a future, single-dose anthrax vaccine. We are currently investigating 
formulations based on these particles for protective capability upon a lethal challenge. 
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6.9 List of Figures 
 
 
Figure 6.1: PA is released from polyanhydride nanoparticles in a chemistry dependent 
manner with 20:80 CPH:SA and 50:50 CPTEG:CPH releasing the fastest. A) Release of PA 
from polyanhydride nanoparticles over 60 days and B) the change in pH of PBS buffer (pH 
7.6, 0.1 mM) from nanoparticle degradation over 30 days. Error bars represent standard 
deviation of 3 independent experiments. 
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Figure 6.2: Mice immunized with PA released from 50:50 and 20:80 CPTEG:CPH, 
adjuvanted with alum, developed the highest antibody titers, the most avid antibody 
response, and highest neutralizing antibody titers. A) Antibody titers, B) antibody avidity, 
and C) antibody neutralization titers from immunized mice. Data is representative of pooled 
samples of 3 replicates for each treatment. 
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Figure 6.3: CPTEG:CPH nanoparticle chemistries release actively and antigenically intact 
PA. A) Residual antigenicity and B) residual activity of PA after a 2 day release from 
polyanhydride nanoparticles. The direct ELISA was performed with 0.5 μg/mL PA released 
from the nanoparticles. The biological assay was performed by incubating 6.4 μg/mL PA 
released from polyanhydride nanoparticles with 0.3 μg/mL LF with RAW cells for 6 h. Error 
bars represent standard deviation of 3 replicates performed in A) 3 independent and B) 1 
independent experiment(s). Treatments with different letters are significantly different from 
one another at p < 0.0003. 
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Figure 6.4: 50:50 CPTEG:CPH best preserves the structural integrity of PA while CPH:SA 
nanoparticle chemistries cause a loss in primary, secondary and tertiary structural integrity. 
A) SDS-PAGE analysis of released PA, B) secondary structure as measured by circular 
dichroism (CD), and C) tertiary structure as measured by fluorescence spectroscopy after a 2 
day release from polyanhydride nanoparticles. Data is representative of 4 independent 
experiments. 
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Figure 6.5: PA-loaded polyanhydride nanoparticles are capable of releasing fully functional 
PA in a dose and time dependent manner dictated by polymer release kinetics and stability of 
PA. A) 31.25, B) 62.5, C)125, and D) 250 μg/mL polyanhydride nanoparticles incubated for 
2, 4, or 6 h with LF (0.3 μg/mL) for the biological toxicity assay. Error bars represent 
standard deviation and of 4 replicates performed in 2 independent experiments. Treatments 
within each time point with different letters are significantly different from one another at p < 
0.048. 
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Figure 6.6: PA-loaded polyanhydride nanoparticles are capable of preserving the activity of 
PA for 2 months when stored at 40, 25, 4, and -20 °C. Nanoparticle made of 50:50 
CPTEG:CPH and 20:80 CPH:SA preserved full functionality of PA under all conditions 
tested. The biological assay was performed by incubating 125 μg/mL nanoparticles with 0.3 
μg/mL LF with RAW cells for 6 h. Error bars represent standard deviation of 3 replicates 
performed in 1 independent experiment. Treatments with different letters are significantly 
different from one another at p < 0.039. 
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6.10 Supporting Information 
 
 
Supplementary Figure 6.1: PA activity is sensitive to high temperature when stored adsorbed 
to alum A) or in PBS buffer B) over incremental time points (7, 14, 28, and 58 days). The 
biological assay was performed by incubating the storage groups (at a concentration of 0.1 
μg/mL PA) with 0.3 μg/mL LF and RAW cells for 6 h. Error bars represent standard 
deviation of 3 replicates performed in 1 independent experiment. Treatments with different 
letters are significantly different from one another at p < 0.048. 
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7.1 Abstract 
A parallel screening method has been developed to rapidly evaluate discrete library 
substrates of biomaterials using cell-based assays. The biomaterials used in these studies 
were surface-erodible polyanhydrides based on sebacic acid (SA), 1,6-bis(p-
carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
that have been previously studied as carriers for drugs, proteins, and vaccines. Linearly 
varying compositional libraries of 25 different polyanhydride random copolymers (based on 
CPH:SA and CPTEG:CPH) were designed, fabricated, and synthesized using discrete 
(organic solvent-resistant) multi-sample substrates created using a novel rapid prototyping 
method. The combinatorial libraries were characterized at high throughput using infrared 
microscopy and validated using 1H NMR and size exclusion chromatography. The discrete 
libraries were rapidly screened for biocompatibility using standard SP2/0 myeloma, CHO 
and L929 fibroblasts, and J774 macrophage cell lines. At a concentration of 2.8 mg/mL, there 
was no appreciable cytotoxic effect on any of the four cell lines evaluated by any of the 
CPH:SA or CPTEG:CPH compositions. Further, the activation of J774 macrophages was 
evaluated by incubating the cells with the polyanhydride libraries and quantifying the 
secreted cytokines (IL-6, IL-10, IL-12, and TNF-α). The results indicated that copolymer 
compositions containing at least 50% CPH induced elevated amounts of TNF-α. In summary, 
the results indicated that the methodologies described herein are amenable to the high 
throughput analysis of synthesized biomaterials and will facilitate the rapid and rational 
design of materials for use in biomedical applications. 
 
 
156 
 
 
 
7.2 Introduction 
Biodegradable polymers have been used in biomedical applications ranging from drug 
delivery [1], to sutures, to bio-absorbable prostheses [2], to tissue culture scaffolding [3], and 
stents. Their use in a broad range of applications stems largely from their uniquely versatile 
and tunable degradation behavior. In particular polyanhydrides have been widely used as 
carriers for drugs, proteins, and antigens. The Gliadel® wafer, a U.S. FDA approved 
polyanhydride based drug delivery system, has been used in the treatment of brain tumors. 
Their history of positive impact for human use [4] along with their chemical diversity makes 
them ideal candidates for protein and vaccine delivery. Today, many candidate drugs are 
proteins, which are more susceptible to various forms of deactivation due to their chemical 
and physical environment [5-7]. To ensure protein stability and functionality, it is highly 
desirable to provide stable microenvironments for these protein-based drugs during storage 
and in vivo delivery. Due to their versatile chemistries and degradation rates, polyanhydrides 
are excellent candidates for protein stabilization and delivery. 
 
Previous reports from this laboratory [5, 8, 9] have indicated that multiple proteins and antigens 
can be stably encapsulated into and released from micro/nanospheres composed of random 
copolymers of sebacic acid (SA) (Figure 7.1 a), 1,6-bis-(p-carboxyphenoxy)hexane (CPH) 
(Figure 7.1 b), and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) (Figure 7.1 c). 
Specifically, encapsulation of model proteins into these polyanhydrides preserves the 
primary and secondary structure of proteins [5] and maintains immunogenicity of biologically 
active antigens [8, 10]. CPH:SA devices degrade by surface erosion, rather than the bulk 
erosion seen in polyesters. Surface-eroding devices are able to exclude water from the 
157 
 
 
 
interior during degradation, offering more protection for sensitive payloads [11, 12]. This 
unique feature has also been observed in vivo, favoring the use of polyanhydrides in human 
medicine [5, 13, 14]. Additionally, CPTEG:CPH copolymers can be tailored to degrade from 
bulk-eroding to surface-eroding mechanisms, thereby enabling highly tunable release kinetics 
for controlled drug delivery [15]. Compared to polyesters, the degradation products of 
polyanhydrides are less soluble di-carboxylic acids, resulting in a less acidic micro-
environment, which enhances the long-term stability of encapsulated proteins [11]. 
 
Polyanhydrides have also been used as adjuvants in vaccine delivery devices [8, 16]. A 
persistent, near zero-order drug release can be obtained, and the polyanhydride chemistry can 
be used to control the immune response to an antigen. Prolonged presentation of an active 
antigen, as afforded by the polyanhydrides’ protection and controllable degradation, results 
in greater balance between the humoral and cell-mediated responses compared to bolus 
delivery of the antigen [8, 17]. Humoral or Th2 response is accompanied by antibody 
production, while cell-mediated, or Th1 response, is characterized by macrophage and 
cytotoxic T cell maturation and activity [18]. Such a balanced response is known to play an 
important role in the achievement of protective immunity against many intra-cellular 
pathogens. 
 
Modulation of the release of encapsulated substances is a critically important function of 
these polymeric devices, and is credited to the unique chemistry and kinetics of 
polyanhydride degradation in aqueous environment. These polymers have been shown to 
degrade via hydrolysis to their acidic monomers [13, 19] over a period of years for poly(CPH), 
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weeks for poly(SA) [20, 21], and days for poly(CPTEG) [15]. These degradation times can be 
modulated by synthesizing copolymers with various combinations of monomers as dictated 
by application. Less hydrophobic systems (CPTEG and SA rich) tend to degrade more 
quickly than more hydrophobic systems (CPH rich) [1, 15, 22-24]. Initial burst release from 
microspheres can also be achieved for certain CPH:SA compositions, and release kinetics 
can be additionally modified with altered microsphere size [10]. Simple changes such as the 
number of glycolic oxygens in the polymer’s backbone result in similar differences [15, 24]. 
Thus, choosing the right polymer chemistry for an application requires navigation of a large 
parameter space (composition, concentration, synthesis conditions, etc.), which if approached 
with classical macroscale, single-synthesis methods would require unacceptable amounts of 
time and cost. Thus, there is a significant need to develop high throughput combinatorial 
methods aimed to satisfy the demand for rapid discovery without needlessly sacrificing 
accuracy, time, or cost. 
 
Combinatorial discovery was thrust into the limelight with application in the pharmaceutical 
industry [2, 25]. Since then, there has been much interest in the development of combinatorial 
methods for materials science [2]. Recently, the hurdles of expense [26, 27], characterization [25], 
and availability [28] are being overcome; wide accessibility greatly increases combinatorial 
methods’ efficacy in allowing more work to be done in parallel. Past combinatorial work in 
biodegradable polymers has focused largely on characterization of physical properties, such 
as glass transition temperature [29] and elastic modulus [30], and drug delivery [28]. Cell-based 
combinatorial methods have also been used to study phenomena such as cell adhesion [31] and 
protein adsorption [32]. However to our knowledge, none of the past studies present a rapid 
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prototyping, parallel method for combinatorial synthesis and in vitro investigation of cellular 
interactions. When cells come into contact with biodegradable polymers in vivo, initial 
interactions and activation can be triggered by surface chemistry and there is a need for the 
design of in vitro tests that will allow for both combinatorial synthesis of biomaterials and 
robust cell based assays to assess the initial cell-biomaterial interaction. 
 
The present work describes the development of a new photolithographic method to design 
biomaterial libraries for rapid screening by cell-based assays. The speed, low cost, ease of 
use, and reproducibility of this method allowed for efficient cytotoxic screening and 
assessment of immune cell activation by discrete libraries of compositionally and 
concentrationally variant CPH:SA or CPTEG:CPH copolymers. Utilization of this method 
will allow for flexible and rapid characterization of cell-biomaterial interactions prior to the 
in vivo studies required for human or animal use [32]. 
 
7.3 Materials and Methods 
Materials 
HPLC Grade Chloroform, 100 mm plastic Petri dishes, and 500 x 750 x 1mm pre-cleaned 
glass microscope slides were acquired from Fisher Scientific (Fairlawn, NJ). 200 proof 
ethanol was purchased from Chemistry Stores (Ames, IA). Norland Optical Adhesive 81 
(NOA 81) was purchased from Norland Products (Cranbury, NJ). Sebacic acid and 1,6-bis-
(p-carboxyphenoxy)hexane prepolymers were prepared with slight modification to well 
known syntheses [1]. CPTEG diacid was prepared as described previously [15]. Deuterated 
NMR solvents (DMSO and chloroform) were purchased from Cambridge Isotope 
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Laboratories (Andover, MA). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assays for cytotoxicity screening were obtained from Sigma Aldrich (St. Louis, 
MO). Sp2/0 mouse myeloma cells were obtained from stock cultures maintained by Iowa 
State University’s Hybridoma Facility, J774A (J774) mouse macrophage cell line was a gift 
from Dr. Jesse Hostetter of the Department of Veterinary Pathology at ISU and Chinese 
Hamster Ovary (CHO) cells were a gift from Michael Kimbler (Department of Biomedical 
Sciences at Iowa State University). L929 cells were purchased from American Type Culture 
Collection (Manassas, VA). 
 
Multi-well library fabrication 
Rapid prototyping was used to fabricate discrete solvent-resistant multi-well substrates 
capable of containing large enough fluidic volumes to support cell proliferation (Figure 7.2). 
This procedure is an adaptation of existing photolithographic techniques utilizing frontal-
polymerizing optical resists [33] described elsewhere [28, 33-36]. Major modifications were made 
to enable ease of use, speed, durability, reproducibility and cost. The method uses a thiolene-
based, UV curing optical adhesive (NOA 81). Mechanistically, this involves the addition of a 
thiyl radical to a vinyl functional group, followed by radical transfer from the ensuing carbon 
radical to a thiol functional group [37]. The extremely fast curing in the presence of oxygen 
using UV light, without the need for traditionally required photoinitiators [38] means that 
fairly complex structures can be prototyped very easily and rapidly using a simple mask. In 
this work, the desired 5x5 array of discrete wells was created using a photomask designed 
with a readily available drawing program and printed on a commercially available laser 
printer. The mask was then copied as many times as desired onto transparencies with a 
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photocopier. Four of the transparencies were overlaid (to ensure complete opacity) and 
affixed to a standard glass microscope slide with tape. Wells were given lateral dimensions 
of 5 x 5 mm, which when combined with a wall height of 2 mm produced space for liquid 
volumes of 200 μL. To our knowledge, this represents a much greater well capacity than in 
any previous work. 
 
Spacers were taped to regions of a second glass slide which fall outside the desired area of 
structure formation and served as an upper limit to feature height. The corners of the glass 
slides were removed with a glass cutter to allow them to fit within standard Petri dishes. 
Aluminum foil was cut into circles, flattened and laid into standard disposable Petri dish lids. 
The layer of aluminum served as a surface which could be easily removed from the 
polymerized NOA 81. Previous work utilized a polydimethylsiloxane release layer (PDMS 
Sylgard 184 Base and PDMS Sylgard 184 Cure (Dow Corning, Midland, MI)) [28, 33, 34, 36] that 
requires 12 h to cure, is more expensive, and produced irregular and rounded features due to 
its uneven surface. NOA 81 was then poured slowly onto the flat aluminum foil to a depth 
slightly less than the height of the spacers. The slide with spacers was then slowly laid down 
onto the NOA 81 layer, allowing capillary action to wet only the lower glass surface 
smoothly and with minimal bubble formation. The stack was then exposed to a collimated 
long-wave UV source at an intensity of 10 mW/cm2 for 7 min. In order to provide increased 
resistance to the chlorinated solvents [39], high temperature, and high vacuum the substrate 
must endure during polyanhydride synthesis, it was necessary to polymerize a thin layer of 
NOA 81 in the bottom of each well. This was achieved by removing the photomask and 
exposing the naked substrate to 10 mW/cm2 intensity UV light for 5 seconds. After precure, 
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the aluminum foil layer was carefully peeled away from the structure and any unreacted 
NOA 81 remaining in the wells was removed with a blast of compressed air. Liberal amounts 
of ethanol from a spray bottle helped to more sharply define the features. After the ethanol 
evaporated, the substrates were postcured under UV light for 17 min at 10 mW/cm2. Finally, 
the substrates were thermally cured at 80°C for 12 h. 
 
Prepolymer solution deposition 
Libraries of varying concentration or mole fraction of CPH:SA and CPTEG:CPH copolymers 
were rapidly deposited using robotics. Two programmable syringe pumps (New Era Pump 
Systems, Farmingdale, NY) in conjunction with three programmable motorized stages 
arranged orthogonally (Zaber Technologies, Richmond, British Columbia, Canada) served to 
fully automate depositions. The pumps and syringes were controlled by third-party macro 
software operating on the actuators’ respective consoles. Complete 5 x 5 depositions were 
routinely completed in approximately 5 minutes. 
 
Combinatorial synthesis of polyanhydrides  
CPH:SA and CPTEG:CPH copolymer films were synthesized in the discrete well substrate 
from their corresponding prepolymers. CPH and SA prepolymers were dissolved in 
chloroform and deposited into the wells in various molar ratios. CPTEG:CPH prepolymers 
were dissolved in acetic anhydride and deposited in the same manner. With both systems the 
libraries were placed in a vacuum oven preheated to the necessary temperature (180°C for 
CPH:SA and 140°C for CPTEG:CPH) and 0.3 torr vacuum for the polycondensation reaction 
to occur. After synthesis, the polymer libraries were stored in desiccators. 
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Characterization 
Copolymer structures were characterized by 1H NMR in deuterated chloroform on a Varian 
VXR 300 MHz spectrometer (Palo Alto, CA). Molecular weights were measured by gel 
permeation chromatography (GPC). GPC samples were dissolved in HPLC-grade chloroform 
and separated using PL Gel columns from Polymer Laboratories (Amherst, MA) on a Waters 
GPC system (Milford, MA). 50 μL samples were eluted at 1 mL/min. Elution times were 
compared to monodisperse polystyrene standards (Fluka, Milwaukee, WI) and used to 
determine number averaged molecular weights (Mn), and polydispersity indices. Fourier 
Transform Infrared (FTIR) spectroscopy was conducted on a Nicolet Continuum infrared 
microscope (Thermo Scientific, Madison, WI) in order to verify the ability of the robotics to 
accurately deposit linearly varying composition gradients. Two hundred scans were collected 
for each data point at a resolution of 4 cm-1 and nitrogen purge flowrate of 30 SCFH.  
 
High throughput cytotoxicity screening 
Cell viability in the presence of CPH:SA and CPTEG:CPH films was assessed using MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells were grown to 
near confluency in either cRPMI (RPMI 1640 containing L-glutamine (Mediatech, Herndon, 
VA) supplemented with 1% non-essential amino acids (Mediatech), 1% sodium pyruvate 
(Mediatech), 2% essential amino acids (Mediatech), 25 mM HEPES buffer (Mediatech), 100 
units/mL penicillin, 0.1 mg/mL streptomycin (Mediatech), 0.05 mg/mL gentamycin (Gibco), 
1% L-glutamine (Mediatech), 5 x 10-5 M 2-mercaptoethanol (Sigma), and 10% heat-
inactivated fetal bovine serum for Sp2/0 cells or in Dulbecco’s Modified Eagle Medium or 
Ham’s F12 with 4.5 g/L glucose (Gibco, Invitrogen, Carlsbad, CA) supplemented with 1% 
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non-essential amino acids (Mediatech), 1% sodium pyruvate (Mediatech), 25 mM HEPES 
buffer (Mediatech), 100 units/mL penicillin, 0.1 mg/mL streptomycin (Mediatech), 1% L-
glutamine (Mediatech), and 10% heat-inactivated fetal bovine serum for J774 and CHO cells. 
L929 cells were grown to confluency in Dulbecco’s Modified Eagle Medium with 4.5 g/L 
glucose (Gibco, Invitrogen, Carlsbad, CA) supplemented with 1% non-essential amino acids 
(Mediatech), 1% sodium pyruvate (Mediatech), 2% Sodium Bicarbonate (10% solution) 
(Mediatech), 100 units/mL penicillin, 0.1 mg/mL streptomycin (Mediatech), 1% L-glutamine 
(Mediatech), and 10% heat-inactivated horse serum. Cells were maintained in a humidified 
incubator set at 37°C, 5 % CO2. J774 cells were removed from culture flasks with gentle 
scraping using sterile cell scrapers (Fisher). CHO and L929 cells were removed from culture 
flasks by treatment with Trypsin-EDTA solution (Gibco). To generate control wells 
displaying 100% cytotoxicity, cells were lysed with a cell lysis buffer (Qiagen) containing 
HCl (1 N), 2% sodium di-lauryl sulfate and 5% Triton 100x (LKB Instruments, Gaithersburg, 
MD). 
 
The multi-well substrates were incubated in 100 mm Petri dishes atop sterilized gauze pads 
cut to fit the Petri dish and saturated with sterile phosphate buffered saline (PBS, pH 7.4) in 
order to create a humid microenvironment and minimize evaporation. 80μL aliquots of 5.0 x 
105 cells/mL were incubated for 18 to 24 h with the desired polyanhydride films in each well 
of the multi-well substrates. 10 μL of MTT salt solution was added to each well. Plates were 
returned to the incubator for 2-3 h. The solution was then transferred to a 96 well polystyrene 
assay plate, and each NOA 81 well was washed with 80 μL acidic alcohol solution, which 
was then added to the corresponding well within the assay plates. Optical density (OD) at 
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570 nm minus the background OD at 690 nm was measured using a Spectramax 190 Plate 
Reader (Molecular Devices, Sunnyvale, CA). Assays were performed on duplicate plates on 
three separate occasions for each cell type and polymer composition (CPH:SA or 
CPTEG:CPH), so in total there were twenty-four assays performed with each composition, 
six for each cell line. The polyanhydride films were also incubated with the MTT solution 
alone in the absence of cells. The OD measurements were similar to that of the background 
OD suggesting that the presence of the polyanhydride copolymer films in the library wells 
did not interfere with the OD measurements. 
 
Cytokine secretion from J774 cells 
In order to assess immune activation, cytokine production from J774 macrophages was 
measured following incubation of the cells in the presence of the discrete polyanhydride 
libraries in the multi-well substrates. Dissolved polymer was deposited to create 4 replicate 
wells within the 25-well grid. Three wells were left blank (i.e., no polymer deposited) and 
two wells were treated with 2 μg/mL of lipopolysaccharide (Phenol water extract from E. 
coli, Sigma) (LPS), which served as a positive control. J774 cells were grown in media as 
described above to near confluency and removed from the tissue culture flasks using sterile 
cell scrapers. Cells were washed once by centrifugation and diluted to 1.25 x 106 cells/mL. 
100 μL of diluted cells added to each well, as described above. At 48 h, cell free supernatants 
were collected and stored at -20oC until assayed. Secretion of IL-6, IL-10, IL-12 and TNF-D 
was analyzed using a multiplexed fluorescence-based assay (FlowMetric System, Luminex, 
Austin, TX). Assays were performed on duplicate plates with the J774 cell line on at least 
three separate occasions for each polymer composition. The results for the background (no 
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polymer) and LPS wells were compared to cells grown in conventional 48 well tissue culture 
plates. 
 
Statistical analysis  
Analysis was performed with the aid of SAS statistical software (SAS Institute, Cary, NC). 
In the linear mixed models, the Kenwood-Rodgers method was used for calculating degrees 
of freedom. The cytotoxicity study consisting of varying concentrations (mg/mL) of 50:50 
copolymer was fit with a linear model using concentration (mg/mL) as the fixed term. 
Alternatively, assessment of cytotoxicity based upon changes in polymer composition (% 
CPH) was performed using a linear mixed model. The fixed term in the composition analyses 
was mol % CPH and the plate was assigned as the random term in the mixed model. In the 
analysis of cytokine secretion, a linear mixed model was used in which the mol % CPH was 
set as the fixed term and plate and day as random terms in the mixed model.  
 
7.4 Results 
Nuclear magnetic resonance (1H NMR) 
NMR analysis was performed to ensure that the substrate did not interfere in the parallel 
synthesis of the copolymer libraries. Polyanhydride libraries with concentrations three times 
higher than that used in the cytotoxicity assays were used in characterization to produce 
signals large enough to interpret. Representative spectra and lettered chemical shifts denoted 
in Figure 7.3 for CPH:SA and Figure 7.4 for CPTEG:CPH are marked as such by comparison 
to previous work [1, 22]. NMR spectra showed no difference between conventional syntheses 
methods of similar volumes performed in glass vials and the new combinatorial method 
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performed in the multi-well substrates. Mole fraction gradients in the CPH:SA and 
CPTEG:CPH systems produced the expected changes in 1H NMR peak area. That is, peaks 
corresponding to the CPH portion of the copolymer (Peaks a-e in Figure 7.3) became less 
intense when compared to SA peaks (Peaks f-I in Figure 7.3) as the CPH content was 
reduced. Similar results were obtained with the CPTEG:CPH system (Figure 7.4). This 
suggests that the multi-well substrate did in fact isolate discrete copolymer compounds with 
minimal cross-contamination, and that the deposition robot created a smooth compositional 
gradient. It is also important to note that the end group peaks in these spectra are relatively 
small, suggesting that the syntheses did in fact drive off much of the prepolymeric acid 
groups, producing long chain polymers. 
 
Molecular weights by gel permeation chromatography (GPC) and 1H NMR 
GPC was performed on various CPH:SA copolymers following synthesis in the wells and 
their molecular weights were compared to that of conventionally synthesized copolymers. As 
shown in Table 7.1, the copolymers had number-average molecular weights suitable for their 
processing into delivery devices such as tablets and microspheres, and the average 
polydispersity index was 2.2. Similar results were obtained with the CPTEG:CPH system. In 
this case, the molecular weights were determined by end-group analysis using 1H NMR 
spectra (Table 7.2, for example). These values are consistent with previous work on 
polyanhydrides synthesized by conventional polycondensation, and add further support to the 
success of the high throughput synthesis of polymers in the discrete wells [10, 28, 40, 41]. 
168 
 
 
 
Fourier transform infrared (FTIR) spectroscopy 
A typical IR spectrum of a CPH:SA copolymer is shown in Figure 7.5. The characteristic 
peak chosen for CPH is sharply defined at 1605 cm-1 and represents the aromatic ring 
stretching of the CPH moiety. The feature chosen for poly(SA) is at 1810 cm-1 and represents 
the carboxyl anti-symmetric stretching of the aliphatic-aliphatic anhydride bond [42].  
 
Each of the characteristic peaks was mathematically fitted with a standard normal 
distribution in order to calculate the area occupied by each band. The calculated peak areas 
for CPH (1605cm-1) and SA (1810cm-1) were divided by one another and further divided by 
their respective monomer molecular weights in order to account for the effect that differing 
values of Mr have on the area of the characteristic peak. The peak areas were also divided by 
their respective number of occurrences of characteristic peak functionality per monomer. 
Since the characteristic functionality for CPH (aromatic ring) and SA (aliphatic-aliphatic 
anhydride bond) both occur twice per monomer unit, the effect can be factored out. The 
measured area ratios were compared to a previously prepared calibration to elucidate the 
actual CPH mole fraction. Figure 7.6 shows the resulting CPH:SA composition gradient as a 
function of position in the 5x4 array. The CPTEG:CPH libraries were characterized using 
NMR. The linearity of the profile spanning the library demonstrates not only the accuracy of 
the deposition apparatus but also the viability of the thiolene/silicon substrate as a platform 
for high  throughput transmission FTIR characterization and parallel synthesis of 
polyanhydrides. 
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MTT cytotoxicity screening 
The MTT assay was chosen for screening of the polyanhydrides’ cytotoxicity due to its 
prevalent use in biocompatibility studies, with a decrease in cell viability being correlated to 
a decrease in optical density (OD) [43-46]. As the number of metabolically active cells 
decrease, the amount of tetrazolium rings cleaved and converted to a precipitating product 
(purple formazan crystals) is reduced, resulting in a relatively lower OD. Conversely, under 
favorable conditions, cells divide rapidly, thus more cells actively cleave tetrazolium rings 
resulting in a relatively higher OD. Preliminary tests were run to ensure that there was no 
interference of the MTT assay with the multi-well substrates. In order to estimate the 
polyanhydride concentrations at which cytotoxicity is observed, a concentration gradient 
from 0 to 28 mg/mL 50:50 CPH:SA and 50:50 CPTEG:CPH was combinatorially 
synthesized and assayed at high throughput by incubating Sp2/0 mouse myeloma cells in the 
wells for 18 h. The data points in Figure 7.7 represent the mean relative OD across four 
plates for a given concentration whereas the solid line depicts the estimate from the fit of the 
linear model to the data. The results presented in Figure 7.7 (top) display the linear fit of a 
quadratic model to the CPH:SA concentrations. The linear term has a slope of 0.029 with a 
standard error of 0.007 (p-value = 0.0002) and the quadratic term is -0.002 with a standard 
error of 0.0003 (p-value < 0.0001). Ninety one observations were used in the model resulting 
in 88 degrees of freedom for the error term. The results of fitting a linear model to the 
CPTEG:CPH compositions (Figure 7.7 (bottom)) has a slope of -0.019 with a standard error 
of 0.003 (p-value < 0.0001). Eighty eight observations were used for the CPTEG:CPH model 
resulting in 86 degrees of freedom in the error term. 
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Low concentrations of CPH:SA appear to be stimulatory to the cells as indicated by a mean 
OD greater than that obtained for cells cultured in wells containing no polymer (Figure 7.7 
(top)). However, at higher concentrations (i.e, above 20 mg/mL, which is well above that 
which would be used physiologically [8]), CPH:SA copolymers were shown to be cytotoxic to 
Sp2/0 cells. By altering the hydrophobic/hydrophilic properties of the copolymer (i.e., 
inclusion of CPTEG instead of SA) the overall cytotoxicity was reduced. Taken together, 
these results indicated that the biocompatibility of polyanhydride copolymers was relatively 
high. The studies of CPH:SA cytotoxicity determined that a concentration of 2.8 mg/mL was 
the maximal concentration at which no cytotoxicity was observed. The concentration at 
which cytotoxicity does not occur was estimated as two standard errors below the mean OD 
for Sp2/0 cells incubated in the absence of any polymer. The results depicted in Figure 7.7 
suggest that the concentration at which little or no cytotoxicity is observed may be much 
higher. To this end, all subsequent studies to evaluate the biological effect of a discrete 
copolymer library were performed using wells containing 2.8 mg/mL. 
 
In order to evaluate the effect of varying the fraction of CPH:SA or CPTEG:CPH, multi-well 
substrates were made in a 5 x 5 format and 2.8 mg/mL copolymer was combinatorially 
synthesized and deposited in a linear gradient ranging from 100 mol % CPH to 100 mol % 
SA or CPTEG. A few wells in each plate were left blank to control for the effect of 
incubating the cells in the NOA 81 substrate wells. Four separate cell lines were used to 
evaluate the cytotoxicity of the discrete polyanhydride libraries. After incubating the cells in 
the wells for 18 to 24 h, cytotoxicity was evaluated with MTT. The results in Figures 7.8 and 
7.9 show that there was no discernable effect of copolymer composed of either CPH:SA or 
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CPTEG:CPH on Sp2/0 myeloma cells. Similarly, these copolymer formulations did not 
induce cytotoxicity for CHO and L929 fibroblast cell lines or J774 macrophages (data not 
shown). Table 7.3 summarizes the findings of the linear mixed model fit for both CPH:SA 
and CPTEG:CPH copolymers for all the cell lines tested. With the CPH:SA compositional 
gradients, for Sp2/0 and CHO cells, though the estimated slope obtained using a linear model 
was significant for some formulations (p < 0.05), the magnitude of the slope was essentially 
zero (0.0006 and 0.0016, respectively), indicating that there was no biologically significant 
effect.  
 
High throughput cytokine screening 
In order to evaluate the effect of differing copolymer compositions on the activation of 
antigen presenting cells, J774 macrophage cells were incubated in the multi-well substrates 
with discrete compositions of CPH:SA copolymers. After 48 h, cell culture supernatants were 
collected and analyzed for the secretion of the following cytokines: IL-6, IL-10, IL-12, and 
TNF-α by capture immunoassay. For data analysis, a linear mixed model was fit in order to 
predict the effect of increasing % of CPH in the CPH:SA copolymer on the cytokine 
secretion.  
 
Following stimulation with 2 μg/mL LPS, results indicated that the incubation of J774 cells 
in the multi-well substrate did not affect the secretion of the measured cytokines when 
compared to that secreted by LPS-stimulated J774 cells incubated in 48 well tissue culture 
plates (data not shown). While the composition of the copolymer in the wells did not affect 
the secretion of IL-10 (Figure 7.10, panel B) or IL-12 (data not shown), copolymer 
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compositions containing greater than 50% CPH reduced the amount of IL-6 secreted from 
background levels (Figure 7.10, panel A). Correspondingly, the linear mixed model (Figure 
7.10, panel D) does predict a modest linearly decreasing rate (-0.8269) of IL-6 production 
with increasing percentages of CPH but essentially no change in IL-10 or IL-12 production 
(predicted slopes of -0.2382 and -0.0093, respectively). In contrast, the copolymer 
compositions rich in CPH enhanced the secretion of TNF-α (Figure 7.10, panel C), which 
was corroborated with the prediction of the fit linear mixed model with a slope of 11.7084 
(Figure 7.10, panel D). Collectively, these data suggest that the varying chemical 
compositions differentially regulate/affect the secretion of IL-6, IL-10, and TNF-α.  
 
7.5 Discussion 
Polyanhydrides, as stated earlier, are generally accepted as being highly biocompatible 
materials. The goal of these experiments was not to simply confirm the biocompatible nature 
of CPH:SA and CPTEG:CPH copolymers, but to illustrate a high throughput method for 
screening of degradable biomaterials using a novel multi-well substrate and combinatorial 
polymer synthesis. Taken together, these results are consistent with numerous conventional 
(one-sample-at-a-time) in vitro and in vivo studies that attest to the biocompatibility of 
polyanhydride systems [14, 47-49]. The highly generalized method developed here will be 
invaluable in the rapid testing and discovery of optimally tuned biomaterial compositions for 
drug delivery. Discrete libraries of virtually any geometry can be rapidly produced to screen 
polymers at any desired resolution. Similarly, the thermally cured multi-well substrate has 
been newly demonstrated to be highly robust during synthesis at high temperature in the 
presence of chloroform and acetic anhydride. Thus, many different types of polymer libraries 
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can be created via melt polycondensation in many solvents. 
 
Such a robust, rapid, and generalized method has great potential in various applications. A 
simple modification of the study could allow for time-dependent parallel monitoring of 
polyanhydride degradation and cytotoxicity. The study of drug and protein release kinetics 
would particularly benefit from a combinatorial methodology, as unique release mechanisms 
have been demonstrated at various copolymer compositions [1, 5, 11]. The discrete multi-well 
substrate may also find use in high throughput screening of biodegradable tissue scaffolding 
materials [50] and integration with microfluidics [35], thus providing a unique combination of 
generalized high throughput testing, rational design, and discovery of new biomaterials. 
 
7.6 Conclusions 
A rapid method has been outlined for prototyping discrete library substrates for high 
throughput cytotoxicity and cell activation screening of polyanhydride libraries. This 
methodology has been validated with NMR and GPC characterization of rapidly synthesized 
and deposited libraries of polyanhydride chemistries based on CPH:SA and CPTEG:CPH 
copolymers. The libraries were characterized by high throughput techniques using FTIR 
spectroscopy and biological responses of various cell lines. There was no observed cytotoxic 
effect for any CPH:SA or CPTEG:CPH composition at a concentration higher than that 
expected to be used for a variety of in vivo applications [8]. While the biocompatibility of 
polyanhydrides has long been established, the methods described herein show the 
compatibility of the polymers synthesized combinatorially and of the cell based assays. The 
results from the cytokine secretion studies confirmed the importance of polymer chemistry 
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on the activation of antigen presenting cells. Many of the promiscuous innate immune 
receptor ligands share the common feature of hydrophobic domains [51]. While it is known 
that microspheres of various chemistries (i.e. PLGA, PLA and poly-amino acid derivatives) 
are efficient at delivering protein antigens to antigen presenting cells [52] and that PLGA 
microspheres can increase activation markers on the surface of antigen presenting cells [53], 
these previous studies have not systematically evaluated the effect of varying polymer 
chemistry on immune cell activation. In contrast, the present studies demonstrated that 
copolymers containing higher hydrophobic (CPH) content induced greater TNFD or pro-
inflammatory responses than that observed with less hydrophobic polymers. The level of 
activation and the behavior of antigen presenting cells such as macrophages and dendritic 
cells are key factors in the induction and maintenance of a Th1 (cellular) or Th2 (humoral) 
immune responses [18] and thus underscores the potential of polyanhydrides as effective 
adjuvants to modulate immune responses [8]. The methods described herein lay a foundation 
for establishing rapid screening protocols of biomaterials and for quantifying the role of 
biomaterial chemistry not only in cellular toxicity but also immune activation. These results 
also add to the large body of evidence supporting the use of polyanhydrides as biocompatible 
materials for use in drug delivery devices.  
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7.9 List of Figures 
 
Figure 7.1: Chemical structures of a) poly(SA); b) poly(CPH); and c) poly(CPTEG).
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Figure 7.2: Schematic of photolithographic design of discrete thiolene-based multi-well 
substrates. 
 
Figure 7.3: Proton NMR spectrum for combinatorially synthesized 50:50 CPH:SA copolymer 
showing chemical shifts. 
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Figure 7.4: Proton NMR spectrum for combinatorially synthesized 50:50 CPTEG:CPH 
copolymer showing chemical shifts. 
 
Figure 7.5: Representative FTIR spectrum of a 60:40 CPH:SA copolymer with characteristic 
absorbances of 1605 cm-1 for the CPH aromatic peak and 1810 cm-1 for the SA aliphatic 
peak. 
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Figure 7.6: Comparison of predicted and experimentally measured composition in a 5x4 
discrete library (95% confidence intervals). 
 
Figure 7.7: Cell (Sp2/0 mouse myeloma) viability as a function of 50:50 CPH:SA (left) and 
CPTEG:CPH (right) concentration. The solid line depicts the fitted quadratic (for CPH:SA, n 
= 91) or linear (for CPTEG:CPH, n = 88) model respectively. The data points are the means 
for each concentration tested. 
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Figure 7.8: Effect of CPH:SA copolymer composition on cytotoxicity of Sp2/0 myeloma 
cells. 5 x 105 cells were incubated for 18 h on 25 multi-well substrate plates with a 
compositional library of CPH:SA and cytotoxicity was evaluated with MTT assay. Data is 
represented as mean OD r SEM for replicate plates. The filled bar indicates cells incubated 
on multi-well substrate plates without any copolymer. SEM = Standard Error of the Mean. 
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Figure 7.9: Effect of CPTEG:CPH copolymer composition on cytotoxicity of Sp2/0 myeloma 
cells. 5 x 105 cells were incubated for 18 h on 25 multi-well substrate plates with a 
compositional library of CPTEG:CPH and cytotoxicity was evaluated with MTT assay. Data 
is represented as mean OD r SEM for replicate plates. The filled bar indicates cells incubated 
on multi-well substrate plate without any copolymer. 
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Figure 7.10: Cytokine secretion from J774 macrophages incubated in multi-well substrates 
containing 2.8 mg/mL of discrete compositions of CPH:SA was measured by capture 
immunoassay. Data depicted is the mean r SEM. A) IL-6, B) IL-10, C) TNF-D, and D) 
statistical summary of linear mixed model fit to the experimental data. Data is representative 
of two replicate plates on two separate experiments. D.F. = degrees of freedom. 
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7.10 List of Tables 
Table 7.1 Number average molecular weight and polydispersity index of combinatorially 
synthesized CPH:SA copolymers obtained by GPC. 
 
 
 
 
 
 
 
 
Table 7.2 Number average molecular weight of combinatorially synthesized 50:50 
CPTEG:CPH copolymers obtained by 1H NMR. 
 
 
 
 
CPH:SA 
Copolymer 
Mn 
(Da) 
Polydispersity 
index 
0:100 11200 2.2 
10:90 12700 2.5 
20:80 9700 2.1 
50:50 10800 2.4 
80:20 13300 2.0 
90:10 16500 2.0 
50:50 CPTEG:CPH Trial Mn (Da) 
1 10900 
2 13500 
3 10500 
4 13500 
5 14200 
6 13800 
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Table 7.3 Summary of linear fit model to data from compositional cytotoxicity experiments. 
Estimated slope is the slope of the linear mixed model fit to each cell type for each 
copolymer composition tested. D.F. = degrees of freedom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copolymer 
Type 
Cell 
Type 
Estimated Slope 
of Linear Model 
Standard Error 
of Linear Model D.F. p-value 
CPH:SA Sp2/0 0.0006 0.0003 62 0.0326 
CPH:SA J774 0.0002 0.0002 186 0.2494 
CPH:SA L929 0.0005 0.0003 136 0.1503 
CPH:SA CHO 0.0016 0.0006 125 0.0051 
CPTEG:CPH Sp2/0 0.0009 0.0006 62 0.1258 
CPTEG:CPH J774 0.0005 0.0003 62 0.0967 
CPTEG:CPH L929 0.0010 0.0012 62 0.3961 
CPTEG:CPH CHO 0.0006 0.0005 83 0.2471 
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8.1 Abstract 
Polyanhydrides are a promising class of biomaterials for use as vaccine adjuvants and as 
multi-component implants. Their properties can be tailored for such applications as 
controlled drug release, drug stability, and/or immune regulation (adjuvant effect). 
Understanding the induction of immunomodulatory mechanisms of this polymer system is 
important for the design and development of efficacious vaccines and tissue compatible 
multi-component implantable devices using this polymer system. This study describes the 
development of a rapid multiplexed method for the investigation of the adjuvanticity of 
polyanhydride nanospheres and films using murine dendritic cells (DCs). To assess the 
immune response, cell surface markers including MHC II, CD86, CD40, and CD209 and 
cytokines including IL-6, IL-12p40, and IL-10 were measured. The DCs incubated with 
nanospheres displayed enhanced expression of all the surface markers and the production of 
IL-12p40 compared to DCs incubated with polymer films in a chemistry-dependent manner. 
This suggests that polyanhydrides of various chemistries and device geometries can be 
tailored to achieve desired levels of immune cell activation for specific applications. The 
observed biocompatibility and activation of DCs by polyanhydride devices supports their 
inclusion in vaccine delivery devices as well as in multi-component medical implants. 
 
8.2 Introduction 
Current advancements in the design and development of implantable/injectable biomaterial 
devices have focused on the need for a better understanding of their adjuvant effect on the 
host’s innate and adaptive immune responses. An adjuvant is an agent that, while having no 
intrinsic antigenicity, is able to simulate the immune system. Activation of the immune 
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system may or may not be desirable based on the intended application; injectable vaccine 
delivery devices will benefit by an enhanced immune response whereas implantable tissue 
engineering constructs will ideally avoid immune activation [1-3].  
 
The cells of the immune system principally responsible for inducing a primary immune 
response and enhancing a secondary immune response are dendritic cells (DCs) [2, 3]. The 
DCs play a major role in antigen presentation, which is a necessary step for induction of long 
term memory and protective immunity. Antigen processing and presentation is activated by 
cellular engagement of pathogen-associated molecular patterns (PAMPs) with Toll-like and 
other pattern recognition receptors on the host cell [1, 2, 4]. Many cell surface molecules such 
as MHC II, MHC I, and co-stimulatory molecules such as CD80, CD86, and CD40 are 
essential for antigen presentation by the DCs in order to activate T cells and to induce clonal 
expansion. It is also thought that adhesion molecule such as CD209 may play an important 
role in T cell activation and DC adhesion [5]. Activated DCs may also produce cytokines such 
as IL-4, IL-5, IL-10, IL-12, IL-6, TNF-α, TNF-β, and/or IFN-γ, which are chemical 
messengers capable of mediating several facets of the immune response [2]. Since very few 
DCs are necessary for the induction of a robust immune response [6], understanding these 
mechanisms of immune activation is critical for the rational design of vaccines and 
development of multi-component implants.  
 
Previous studies by Babensee and co-workers have investigated the adjuvant effect of the 
PLGA polymer system [7-10]. Specifically, work by Yoshida et al. focused on the adjuvant 
activity of PLGA films and microparticles [11]. The investigators found that the PLGA 
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microparticles did not enhance the expression of either CD80 or CD86; however, films were 
capable of significantly enhancing the expression of CD80. They also demonstrated that 
PLGA microparticles and films significantly enhanced the production of IL-6 and TNF-α 
over the non-stimulated DCs. More recently, Torres et al. assessed the adjuvant properties of 
polyanhydride microparticles and reported that the activated DCs were characterized by the 
enhanced expression of MHC II, CD86, CD40 and CD209 and by increased production of 
IL-12p40 and IL-6 [12].  
 
Biodegradable polymeric particles are a promising class of adjuvants because of their ability 
to preserve the activity of the protein antigen, release the antigen in a controlled manner, and 
modulate the immune response (adjuvant effect). This makes them promising candidates for 
vaccine delivery with the potential to reduce the number of doses necessary to induce 
protective immunity [13, 14]. In particular, polyanhydrides are a class of surface-eroding, 
biocompatible materials which have shown much promise for these applications with their 
ability to provide a controlled drug release that is mediated by the chemistry of the polymer, 
and, unlike polyesters, correlates closely with the polymer degradation profile [15-23]. The 
FDA has approved the use of a specific polyanhydride (called the Gliadel® wafer) to locally 
deliver anti-cancer drugs to the brain [17]. The polyanhydride chemistries of interest in this 
work, which are closely related to the FDA-approved polymer, are based on sebacic acid 
(SA) and 1,6-bis(p-carboxyphenoxy)hexane (CPH). Biocompatibility tests of these polymers 
have shown that they produce degradation products that are both non-mutagenic and non-
cytotoxic, which makes a strong case for their use in vivo [24, 25]. When copolymerized, the 
specific chemistry of the CPH:SA copolymer plays an integral role in modulating many 
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aspects related to drug and protein release and immune response. The copolymer 
composition controls the hydrophobicity of the polymer, allowing for tunable release kinetics 
(CPH degradation is much slower than SA degradation), protein stabilization, and immune 
modulation [12, 18, 19, 26]. Microspheres based on CPH:SA polyanhydrides have been 
previously shown to be promising vaccine carriers because of their adjuvant capabilities and 
immunomodulatory behavior both in vitro and in vivo, which are dependent on the chemistry 
of the polymer [12, 26]. Work by Kipper et al. demonstrated that a single dose of tetanus toxoid 
(TT)-loaded 20:80 CPH:SA microspheres induced a dominant IgG1 immune response while 
TT-loaded 50:50 CPH:SA microspheres induced a more balanced IgG2a:IgG1 anti-TT 
immune response [26].  
 
Many previous studies in the design and development of polyanhydrides and other 
biomaterials have been carried out in a conventional, one sample at a time format. This 
inefficient and laborious process consumes a large amount of time and resources, which is 
often not a viable option in the rapidly advancing world of nanomedicine. Viruses evolve 
with speeds far superior to the rate of medical technological advancements and new forms of 
cancer and disease are discovered every day. These rapidly advancing problems demand 
combinatorial approaches and advanced data mining techniques to accelerate the design and 
discovery of new materials for biomedical applications [27-34]. Initial studies employing this 
combinatorial methodology to study polyanhydrides have focused on the rapid synthesis, 
assessment of phase behavior, drug dissolution, and cytotoxicity of polymer films with cell 
lines [35-38]. The cytotoxicity study demonstrated that the polymer films were non-cytotoxic 
up to a total mass of 0.28 mg covering a 0.32 cm2 surface area in a volume of 100 μL, 
192 
 
 
 
resulting in a polymer concentration (~2.8 mg/mL) that exceeds the typical dosage for many 
in vivo applications [26]. The primary focus of this work was to assess and compare the 
adjuvant effect of CPH:SA nanosphere and film systems, using a rapid, multiplexed approach 
with the use of advance informatics techniques for the rational design and optimization of 
vaccine adjuvants and tissue engineering platforms. 
 
8.3 Materials and Methods  
Materials 
The chemicals utilized in monomer synthesis include potassium carbonate, dimethyl 
formamide, toluene, sulfuric acid, acetic acid, and acetonitrile, which were purchased from 
Fisher Scientific (Fairlawn, NJ); 1-methyl-2-pyrrolidinone, 4-p-hydroxybenzoic acid, 1,6-
dibromohexane, and tri-ethylene glycol were purchased from Sigma Aldrich (St. Louis, MO); 
and 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK). The 
chemicals needed for the polymerization, nanosphere fabrication, and buffer preparation 
include acetic anhydride, chloroform, methylene chloride, petroleum ether, monobasic 
potassium phosphate, dibasic potassium phosphate, sodium acetate trihydrate and glacial 
acetic acid, which were purchased from Fisher Scientific. Sebacic acid (99%), E. coli 
lipopolysaccharide (LPS), β-mercaptoethanol, and rat immunoglobulin (rat IgG) were 
purchased from Sigma Aldrich. The materials required for the DC culture medium include: 
RPMI 1640, penicillin-streptomycin, HEPES buffer, and L-glutamine, purchased from 
Mediatech (Herndon, VA); granulocyte macrophage colony stimulating factor (GMCSF), 
purchased from PeproTech (Rocky Hill, NJ); and heat inactivated fetal calf serum, purchased 
from Valley Biomedical (Winchester, VA). The materials needed for flow cytometry were: 
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unlabeled mouse IgG, purchased from Pharmingen, Becton Dickinson (Franklin Lakes, NJ); 
mouse serum and unlabeled CD36/16 FcγR, purchased from Southern Biotech (Birmingham, 
AL); unlabeled hamster IgG, phycoerythrin-Cy5 (PE/Cy5) conjugated anti-mouse CD11c 
(clone N418), Alexa Fluor® 700 anti-mouse CD11c (clone N418), fluorescein isothiocyanate 
(FITC) conjugated anti mouse/rat MHC Class II (I-Eᵏ) (clone 14-4-4S), allophycocyanin 
(APC) anti-mouse CD40 (clone 1C10), biotin conjugated anti-mouse CIRE (DC-SIGN or 
CD209) (clone 5H10), and phycoerythrin-Cy7 (PE/Cy7) anti-mouse CD86 (clone GL-1); and 
corresponding isotypes: PE/Cy5 rat IgG2a N (clone eBR2a), Alexa Fluor® 700 conjugated 
Armenian hamster IgG (clone eBio299Arm), FITC IgG2a N (clone eBM2a), APC rat IgG2a 
N (clone eBR2a), biotin conjugated rat IgG2a (clone eBR2a), and PE/Cy7 conjugated rat 
IgG2b (clone KLH/G2b-1-2); and APC-Cy7-conjugated streptavidin. All of these reagents 
were purchased from e-Bioscience (San Diego, CA).  
Polymer film synthesis 
1,6-bis(p-carboxyphenoxy)hexane (CPH) monomer was synthesized as described previously 
[39]. Sebacic acid (SA) monomer was purchased from Sigma Aldrich. The linearly varying, 
discrete library of CPH:SA polyanhydride films were synthesized in replicates of five from 
the corresponding monomers via a melt polycondensation reaction in thiolene based multi-
well substrates utilizing a multiplexed robotic deposition apparatus, reported previously by 
Adler et al [35]. A modification was made to the original size of the multi-well substrate 
previously reported. The size was increased to that of a 24 well-plate and included 24 wells 
which allowed for larger films and more cell growth area.  
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Film characterization 
All film characterization studies evaluated polymer synthesized in the full range of possible 
copolymers chemistries varying from 100 % SA to 100 % CPH. Five chemistries, poly(SA), 
25:75 CPH:SA, 50:50 CPH:SA, 75:25 CPH:SA, and poly(CPH), were investigated in these 
studies. Polymer functionality and molecular weight was determined by proton nuclear 
magnetic resonance spectroscopy (1H NMR) using a Varian VXR 300 MHz spectrometer 
(Varian Inc., Palo Alto, CA). Number average molecular weights, weight average molecular 
weights, and polydispersity indices were determined using gel permeation chromatography 
(GPC). Samples were first dissolved in HPLC-grade chloroform and then separated through a 
Waters GPC chromatograph (Milford, MA) containing PL Gel columns (Polymer 
Laboratories, Amherst, MA). Retention times were compared to polystyrene standards 
(Fluka, Milwaukee, WI). The surface chemistry of the synthesized polymer film libraries was 
rapidly evaluated at using Fourier transform infrared spectroscopy (FTIR) with a Nicolet 
6700 FTIR spectrometer (Thermo Fisher Scientific). The profile of the composition in each 
well was obtained using transmission mode FITR on a silicon nitride wafer substrate 
(University Wafer, South Boston, MA). By identifying the characteristic peaks from each 
sample (CPH aromatic peak at 1605cm-1 and SA aliphatic peak at 1850cm-1) the relative 
ratios between the monomer species were used to identify the corresponding compositions 
[37]. This was calculated by using Gaussian curve fitting and integration with the OMNIC 
software. The areas under each curve were used to determine the molar ratio between the two 
monomers. 
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Nanosphere fabrication 
An automated nanosphere fabrication apparatus was designed to create a multiplexed library 
of CPH:SA nanospheres from the synthesized polymer film library. This process requires a 
modification to the film library deposition described previously [35]. In the modified process, 
the thiolene based multi-well substrate was replaced by a multi-vial substrate to allow for 
larger holding volumes. The apparatus controlling the automated nanosphere fabrication 
process consisted of a series of 4 linear actuators (Zaber Technologies, Richmond, British 
Columbia, Canada) and 3 programmable syringe pumps (New Era Pump Systems, 
Farmingdale, NY) controlled by a third-party macro software operating on the actuators’ 
respective consoles. This fully automated process was initiated by chloroform solution 
deposition into each vial of the multi-vial substrate, thus dissolving the polymer films with a 
resulting polymer concentration of approximately 25mg/mL. Each solution was then 
homogenized for 60 s at 10,000 rpm to completely dissolve the polymer in the chloroform. 
After that petroleum ether was dispensed into 15 mL tubes, each tube corresponding to a 
separate copolymer vial. Next, the polymer solution was withdrawn from a vial and 
dispensed into its corresponding tube of petroleum ether. During this time a 
nanoprecipitation process occurs in which the dissolved polymer is rapidly precipitated out in 
the presence of the non-solvent (petroleum ether) and the nanospheres are formed. The 
optimal ratio of solvent to non-solvent was identified to be 1:40 for the fabrication of an 
average size of 300 nm polyanhydride particles. The nanospheres were characterized with 
scanning electron microscopy (SEM) to analyze size and surface morphology using a JEOL 
480A SEM (JEOL USA Inc., Peabody, MA). 
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Culture and stimulation of DCs 
Bone marrow derived dendritic cells (BMDCs) were prepared from bone marrow cells 
isolated from the femurs, tibias, humerus’ and iliums of C57BL/6 mice (obtained from 
Harlan Sprague Dawley and housed within the ISU Laboratory Animal Resource Facility, 
Ames, IA) as previously described [40]. Following mouse euthanization and bone excision, 
attached tissue and muscle were dissected away. The ends of the bone were cut and the 
marrow was flushed out using a syringe fitted with a 30 gauge needle. Each bone as flushed 
with 5 mL of RPMI medium containing 1% pen/strep. Large particulates were allowed to 
settle and then removed. After centrifugation, the cells were resuspended in DC medium 
(RPMI containing 1% L-glutamine, 1% penicillin-streptomycin solution, 2% HEPES, 0.5% 
gentamicin, 0.1% β-mercaptoethanol, and 10% heat inactivated fetal bovine serum (FBS) 
supplemented with GM-CSF (10 ng/mL). The cells were then placed in T75 cell culture 
flasks in 10 mL of DC medium containing 10 ng/mL GMCSF and incubated at 37 ºC under 
5% CO2 atmosphere. On day 3, 10 mL of fresh DC medium with 10 ng/mL GMCSF was 
added. On day 6, 10 mL of the culture medium was harvested and placed in a 15 mL 
centrifuge tube. After centrifugation, the supernatant was decanted and the cells were 
resuspended into 10 mL of fresh DC medium containing 10 ng/mL GMCSF and re-
inoculated into the original flask. On day 8, DCs were removed from the flasks, counted, 
resuspended in fresh DC medium, and transferred to 24-well plates (1 x 106 cells/well). On 
day 9, a portion of the cells were stained for CD11c to determine the percentage of DCs. On 
the same day the remaining DCs were incubated with the different stimulation treatments 
(films or nanospheres). The DCs were treated with CPH:SA copolymer films and 
nanospheres of the following chemistries: poly(SA), 13:87 CPH:SA, 25:75 CPH:SA, 37:63 
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CPH:SA, 50:50 CPH:SA, and 63:37 CPH:SA. Polyanhydride nanospheres were incubated at 
a concentration of 0.125 mg/mL (2 cm2 cell growth area). Non-stimulated (NS) DCs and LPS 
(200 ng/mL) treated DCs were used as negative and positive controls, respectively. After the 
addition of the stimulants, the DC cultures were incubated for an additional 48 h (37°C, 5% 
CO2) at which time the supernatants and DCs were harvested for cytokine production and 
cell surface marker expression, respectively. Cell viability was assessed by measuring trypan 
blue exclusion using a hemocytometer and light microscope.  
 
Cell surface markers 
The expression of cell surface markers including CD11c, CD86, CD40, MHC II, and CD209 
were assessed after the 48 h incubation period of the DCs with the stimulation treatments. 
The adherent DCs were harvested from the culture dishes with vigorous pipetting, placed in 
polystyrene tubes (BD FALCONTM, Franklin Lakes, NJ), centrifuged (250 rcf, 10 min, 4°C), 
and resuspended in Fc blocking solution consisting of PBS buffer with 0.1% anti-
CD16/CD32, 0.1% unlabeled hamster IgG, 1% rat IgG, 1% mouse serum, 0.1% sodium 
azide, and 1% FBS. After blocking, the DCs were stained and fixed for evaluation of cell 
surface markers using monoclonal antibodies against CD11c, MHCII, CD86, CD40, and 
CD209. The samples were analyzed using a Becton-Dickinson FACSCanto flow cytometer 
(San Jose, CA) and FlowJo (TreeStar Inc, Ashland, OR). 
 
Cytokine release 
Following incubation of the DCs with the stimulation treatments for 48 h, 200 μL of the 
supernatants were collected and assayed for the presence of IL-6, IL-10, and IL-12p40 using 
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the Luminex® Multiplex assay system (Austin, TX).  
 
Statistical analysis 
All data was statistically analyzed by using a one-way model ANOVA with the statistical 
software JMP® 7 (Cary, NC). Comparisons between treatments were made with Tukey’s 
HSD to determine statistical significance, and p-values of less than or equal to 0.05 were 
considered significant. All data was log transformed for use of the one-way model ANOVA. 
 
Principal component analysis (PCA) 
Principal Component Analysis (PCA), which is a dimension reduction technique, is typically 
used to represent directions with maximum variability and provide a simpler and more 
parsimonious description of the covariance structure [41-43]. In this work PCA was used in a 
blinded fashion to uncover the latent features of the stimulation data and explain the 
relationships between polymer chemistry and cell marker expression and cytokine 
production. PCA accomplished data reduction and facilitated interpretation by reducing the 
six original variables (CD209, CD40, CD86, MHC II, IL-6, and IL-12p40) to two principal 
components. The principal components are linear combinations of the original six variables, 
and make up new axes that represent the directions with maximum variability. The projection 
of the original six-dimensional data to the two-dimensional space constructed by the first 
principal component (PC1) and the second principal component (PC2) helps to visualize and 
interpret data and often reveals relationships that are not previously suspected, thereby 
allowing for interpretations that would not ordinarily result [41, 42]. Before PCA is applied on 
the data, the data was preprocessed by normalization, detection and elimination of outliers, 
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and missing values.  
 
The replicate experiments were conducted on several different days and to eliminate the 
effect of the day of experiment, the flow cytometry data for surface maker expression and the 
Luminex data for cytokine production were normalized according to Equation 1:  
                Xnorm = ௑ିேௌ௑௠௔௫ିேௌ                                                          Eq. 1 
Here, Xnorm is the normalized value of the sample being analyzed (either normalized mean 
fluorescence intensity (MFI) of surface marker or normalized concentration of cytokine), NS 
is the MFI or concentration value of the non-stimulated group, X is the MFI or concentration 
value of the sample being analyzed, and Xmax was derived from either the MFI value induced 
by poly(SA) nanospheres for cell surface marker expression or from the cytokine 
concentration produced by 63:37 CPH:SA nanospheres. This normalization method has been 
reported in the literature [44].  
 
The elimination of outliers is very important since outliers can dramatically change the data 
variance. In this study, the outliers were detected using boxplots. A boxplot is a convenient 
way of graphically depicting groups of numerical data through their smallest observation, 
lower quartile, median, upper quartile and largest observation. The IQR (interquartile range) 
is the range between the lower quartile and the upper quartile. Conventionally, any 
observation that lies out of 1.5 IQR from the lower quartile or the upper quartile is regarded 
as an outlier. Outliers were replaced using mean values of the stimulation data with the same 
polymer chemistry. 
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Each observation is a six-dimensional data point with two dimensions of cytokines and four 
dimensions of cell markers. Conventionally, the observations with more than 30% missing 
values are deleted. For example, if an observation for a specific CPH:SA nanosphere 
treatment has only values for IL-6 and IL-12p40 and no measured values for CD209, CD40, 
CD86 and MHC II, this observation was deleted. 
 
8.4 Results 
Discrete, combinatorial film libraries, linearly varying in copolymer composition of the 
CPH:SA system, were characterized with FITR using an automated method to verify that the 
deposition apparatus was depositing the intended molar volumes of monomer into each well. 
The observed results, shown in Figure 8.1, are in good agreement with the intended 
deposition of the molar composition of the copolymer chemistries. The copolymers were also 
characterized with GPC to determine molecular weight and 1H NMR to verify copolymer 
structure, chemistry, and molecular weight. These findings, shown in Table 8.1, are in good 
agreement with the properties of conventionally synthesized polymers [17]. Following 
synthesis of the polymer films, nanospheres of six copolymer compositions were rapidly 
fabricated using a nanoprecipitation technique. The multiplexed method enabled the 
simultaneous fabrication of nanospheres ~100 times faster than conventional “one sample at 
a time” nanoprecipitation methods [45]. Scanning electron photomicrographs of nanospheres 
of six copolymer compositions are shown in Figure 8.2. It can be observed that the size, 
between 200 nm and 500 nm, and relative roughness are similar across polymer chemistries. 
These sizes and morphologies are in good agreement with those of conventionally 
synthesized nanospheres [45]. 
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To assess activation of CD11c+ DCs by the CPH:SA film and nanosphere libraries, flow 
cytometry was used to measure levels of cell surface expression of co-stimulatory molecules 
CD86 and CD40, integrin CD209, and major histocompatibility complex molecule MHC II. 
Supernatants were also collected and analyzed for cytokine production, including IL-10, IL-
12p40p40, and IL-6. LPS was used as a positive control and a non-stimulated group with 
medium only acted as a negative control. Prior to use in cell stimulation assays, the BMDC 
cultures were shown to be >90% positive for CD11c (data not shown). 
 
The results from the analysis of cell surface marker expression following the 48 h stimulation 
period suggest differential regulation of the selected markers depending on the polymer 
chemistry and the relative hydrophobicity of each formulation. This effect was observed with 
both films and nanospheres, as shown in Figures 8.3-8.6 (statistical analysis of the data in 
these figures is shown in Table 8.2). In these figures, histograms depicting a representative 
profile of expression for the given cell surface marker are shown together with a normalized 
graphical compilation of all the replicates tested for each treatment. The SA-rich (least 
hydrophobic) chemistries demonstrated the ability to best promote the expression of MHC II, 
CD86, CD40, and CD209. The chemistry-dependent up-regulation of the cell surface 
markers in comparison to the non-stimulated control is clearly observed with SA-rich 
nanosphere and film compositions. Enhanced expression of these markers clearly correlates 
with the amount of SA in the films or nanospheres, exhibiting a maximum for the poly(SA) 
films and nanospheres. In addition to the MFI measurements, measurements of cells as 
percent positive for each of the specific markers was performed, and the results were 
consistent with the observed MFI for each specific cell surface marker (data not shown). 
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Although the trends observed between the film and nanosphere systems with respect to the 
copolymer chemistry were consistent, it is apparent that there are differential levels of cell 
surface marker up-regulation between the two geometries. More specifically, nanospheres 
more effectively up-regulated expression of all cell surface markers in comparison to films. 
The level of up-regulation of the cell surface markers induced by the nanospheres is 
markedly higher for MHC II (Figure 8.3) and CD86 (Figure8. 5) and even more pronounced 
for CD40 (Figure 8.4) and CD209 (Figure 8.6) relative to the changes in cell surface marker 
expression induced by the films. This is also noted in the histograms by the increased shift 
from the isotype control between nanosphere and film geometries. In comparison with LPS, 
poly(SA) nanospheres induced greater up-regulation of CD209 and lower up-regulation of 
CD40. LPS is not known to up-regulate CD209, so the low level of expression was not 
unexpected [4, 6, 46]. 
 
Supernatants were collected and assessed for cytokine concentrations. The results suggest 
differential cytokine production (enhancement of IL-6 and regulation of IL-12p40) in 
response to the composition of CPH:SA nanospheres and films. However, the trend for 
cytokine production is counter to the trend observed with the cell surface marker expression. 
The more hydrophobic or CPH-rich nanosphere chemistries appear to better promote 
production of IL-6 and IL-12p40 as shown in Figure 8.7. Consistent with the nanosphere 
data, a chemistry-dependent trend is observed in cytokine production with the film 
chemistries with the highest concentrations of IL-6 corresponding to cells stimulated with 
CPH-rich chemistries as shown in Figure 8.7 (statistical analysis is shown in Table 8.2). In 
the case of IL-12p40, the CPH-rich chemistries inhibited the background production to a 
203 
 
 
 
lesser extent than the SA-rich chemistries (Figure 8.7). The CPH:SA films considerably 
promoted IL-6 production over that of the corresponding CPH:SA nanospheres. Interestingly, 
IL-6 production was increased by DCs stimulated by the film library, while IL-12p40 
secretion was down-regulated by the film library in comparison to the non-stimulated group. 
IL-10 was not produced by any of the treatment groups, so the data is not included in the 
figures or histograms. 
 
PCA was used to analyze the cytokine production and the cell surface marker expression data 
and to draw inferences about the complexities of the immune activation. The use of refined 
data mining techniques is necessary to analyze the large data sets from flow cytometry and 
Luminex assays in parallel, and will be the subject of future studies. PCA enables the 
simultaneous investigation of the relationship between the multiple variables of this complex 
system, including polymer chemistry, device geometry (nanosphere and film), cytokine 
production, and cell surface marker expression. Figure 8.8 depicts the nanosphere system 
analyzed with PCA and shows that the nanospheres enhance the expression of all cell surface 
markers and production of all cytokines (except IL-10), which is seen by the strong 
chemistry-dependent (polymer chemistry is depicted by % CPH in the PCA biplots) 
correlation with the plot vectors. This analysis revealed that the polyanhydride nanospheres 
enhanced the expression of the co-stimulatory molecules and the IL-12p40 cytokine, which is 
important for induction of an immune response, more effectively than the films did as shown 
in Figure 8.9. This can be observed by the indicated nanosphere chemistries clustered in 
parallel to the cell surface marker and IL-12p40 vectors. This suggests that the cell surface 
interaction with a polymer film is not sufficient to promote DC activation. The film library 
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was also assessed with PCA and the biplot in Figure 8.10 illustrates the low level of cell 
surface marker expression which is achieved by DC interactions with films. This is indicated 
by the clustering of the cell surface maker vectors around the central axis while the cytokine 
production vectors (IL-6 and IL-12p40) are more outstretched demonstrating a better 
correlation to the ability of the film chemistry (i.e., % CPH) to affect cytokine production. 
This suggests that the film device geometry is poor at enhancing cell surface marker 
expression but is more effective at regulating cytokine production (i.e., activating IL-6 
production but inhibiting IL-12p40 production).  
 
8.5 Discussion 
The ability of a polymer system to both modulate its effect on the immune response and 
deliver a drug or antigen in a controlled fashion provides an ideal platform for both vaccine 
adjuvants and multi-component implants. Many factors influence the innate and adaptive 
immune responses, including the activation of DCs. This study was designed to utilize the 
known measures of DC activation as a means to more rationally design biodegradable 
adjuvants for vaccine development. Adjuvant properties such as enhancing immunogenicity 
have been investigated for many individual polyanhydride polymer formulations [11, 12]; 
however, to our knowledge this study represents the first time these analyses have been 
performed to assess a multiplexed polyanhydride library. Likewise, we are not aware of any 
reported methods that have multiplexed the fabrication of polymer nanospheres. The rapid 
technique for nanosphere fabrication described in this work may be applicable to fabricate 
nanospheres of other degradable or non-degradable polymers. It can also be easily extended 
to synthesize hundreds of nanospheres of various chemistries by either increasing the number 
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of wells in the substrate or by fabricating a large number of multi-well substrates. The 
concomitant use of this multiplexed technique and the informatics analysis will allow us to 
rapidly optimize the CPH:SA polyanhydride system for use in tissue engineering (where 
biocompatibility is desirable) or vaccine delivery (where enhanced innate immune responses 
are desirable). 
 
The multiplexed method described herein was able to clearly demonstrate that the chemistry 
of the polymer played a major role in up-regulating cell surface marker expression and 
cytokine production when films or nanospheres were used to stimulate DCs. The least 
hydrophobic (i.e., SA-rich) nanosphere chemistries were most effective at enhancing the 
expression of cell surface markers, while the most hydrophobic (i.e., CPH-rich) chemistries 
were most successful at enhancing cytokine production. With MHC II, CD86, and CD40 all 
playing critical roles in the induction of adaptive immunity through activation of CD4+ T 
cells, it would be preferable for an effective vaccine to enhance their expression [2]. CD209 is 
a marker with possible implications associated with activation of the immune system because 
it functions as a cell adhesion receptor that mediates DC migration and T cell activation [5]. In 
addition, IL-12 and IL-10 play important roles in adaptive immunity through enhancing or 
inhibiting events leading to the differential effector functions of CD4+ T cells [2]. The 
cytokine IL-6 is important to the innate immune response, contributing to systemic 
inflammation [5]. The multi-faceted immune responses associated with these various cell 
surface markers and cytokines are all directly correlated with the adjuvanticity of the 
CPH:SA polymer system. The PCA biplot (Figure 8.8) suggests that DC activation would be 
most optimal at intermediate CPH:SA nanosphere compositions (such as 37:63 CPH:SA) 
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which would simultaneously enable adequate production of the cytokines IL-12p40 and IL-6 
and cell surface expression of MHC II, CD86, CD209 and CD40. These findings are 
consistent with previous observations in as much as IL-10 is primarily responsible for 
inhibiting activated DCs through the inhibition of IL-12 production and MHC II expression 
[5]. The ability of the relatively hydrophobic polyanhydrides used in this study to activate 
DCs is in agreement with Matzinger’s “danger signal” hypothesis in which hydrophobic 
molecules are internalized and induce activation of innate immune cells [47].  
 
While significantly different cellular mechanisms are engaged by cells encountering 
nanospheres (internalization and intracellular interaction) versus those interacting with films 
(extracellular interaction), it is still important to understand the immune activation in the two 
geometries because their end-use applications may activate vastly different immune 
mechanisms. It appears that both the hydrophobic nature and the device geometry (film or 
particle) of this polymer system play important roles in DC activation processes. The 
hydrophobicity of the polymer alone was not enough to activate the DCs as demonstrated by 
the low levels of cell surface marker expression induced by the polyanhydride films. Particle 
internalization or phagocytosis, possibly mediated by hydrophobicity, appears to be 
necessary to achieve an enhanced DC activation as seen in Figure 8.9. Using confocal 
microscopy, it has been demonstrated that CPH:SA nanospheres are internalized by 
phagocytic cells [45]. However, internalization may not be necessary for production of IL-6, 
as an increased production of this cytokine is observed when the DCs are incubated with 
polyanhydride films. This is in agreement with previous studies with PLGA microparticles 
and films in which the inhibition of DC phagocytosis did not affect IL-6 production [11]. 
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Surface interactions between the DCs and the CPH-rich polymer film treatments may play an 
important role in the production of this cytokine. Overall, the results suggest that the specific 
chemistry of the polyanhydride nanospheres and films dictate the differential level of DC 
activation. These conclusions are broadly supported by previous work [45], which indicates 
that polyanhydride nanospheres are differentially engulfed by phagocytic cells based on 
polymer chemistry.  
 
In some cases, the cellular activation may not be a desirable feature for a biomaterial. For the 
body to accept an implant and resume tissue regeneration it is integral for such a device to 
avoid activating the immune system. The CPH:SA film system is a promising candidate for 
tissue engineering applications as the PCA biplot depicted its low level of immune activation 
both with cytokine production (except IL-6) and cell surface maker expression. In addition, 
as mentioned previously these films have shown outstanding cellular biocompatibility at 
concentrations of 2.8 mg/mL [35]. Despite the ability of CPH-rich film chemistries to enhance 
production of IL-6, the PCA analysis has shown that an intermediate or slightly SA-rich film 
chemistry (i.e., 25:75 CPH:SA) would have the least likelihood of producing an adjuvant 
effect or inducing a potent immune response (Figure 8.10). It should be emphasized that the 
interpretation of the PCA plots were made following blind data analyses. The fact that the 
clustering of data is consistent with expected observations simply confirms the robustness of 
the data analysis techniques. In this work the data dimensionality reduction techniques were 
used for classification purposes. With the availability of more experimental data, statistical 
learning tools can be introduced that will provide predictive information. 
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In the future, it will be necessary to study antigen presentation of DCs in vivo following 
stimulation by antigen-loaded polyanhydride nanospheres. Further, it will be critical to 
elucidate the mechanisms of DC activation as related to other immune effector cells and 
induction of protective immunity.  
 
8.6 Conclusions 
The CPH:SA polyanhydride system is a promising candidate for applications in drug/vaccine 
delivery and tissue engineering. It has been shown that the CPH:SA polymer film system 
provides a gentle, biocompatible environment necessary for multi-component implants; in 
contrast, the CPH:SA nanosphere system provides an adjuvant effect by enhancing DC 
activation. The informatics analysis employed in this study defined the clear differences 
between these two effects (chemistry and device geometry) and showed that the CPH:SA 
system has immunomodulatory capabilities to regulate both cellular expression of surface 
markers and production of cytokines. This rapid and multiplexed investigation of the 
adjuvant effect (five different polymer film chemistries and six different nanosphere 
chemistries with multiple replicates) was made possible by the use of a novel multiplexed 
approach to fabricate nanospheres and films and screen their interactions with immune cells. 
This generality of the technique paves the path for rational design and development of 
biomaterials for specific applications in drug/vaccine delivery and tissue engineering. 
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8.9 List of Figures 
 
 
 
Figure 8.1: High throughput FTIR analysis of the polymer chemistry (% CPH) varying across 
the CPH:SA film library. The line shows the intended copolymer compositions, which are 0, 
25, 50, 75, and 100% CPH for wells 1-5 respectively. 
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Figure 8.2: SEM images of the discrete library of combinatorially fabricated nanospheres 
starting with A) Poly(SA) B) 13:87 CPH:SA C) 25:75 CPH:SA D) 37:63 CPH:SA E) 50:50 
CPH:SA and F) 63:37 CPH:SA. Scale bar: 5 μm. 
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Figure 8.3: Analysis of MHC II expression by C57BL/6 DCs with histograms comparing 
between treatments in light grey             and the isotype non-specific control in dark  
grey              . Treatments represented in the histograms include a) LPS, b) NS, c) poly(SA) 
nanospheres, d) 25:75 CPH:SA nanospheres, e) 63:37 CPH:SA nanospheres, f) poly(SA 
film), g) 50:50 CPH:SA(film), and h) poly(CPH) film. Below the histograms is the complete 
set of results for MFI expression of C57BL/6 DC cell surface marker MHC II by multiplexed 
CPH:SA libraries. Data is representative of a minimum of 3 replicates per stimulation group. 
Errors bars indicate standard error. See Table 8.2 for statistical analysis. 
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Figure 8.4: Analysis of CD40 expression by C57BL/6 DCs with histograms comparing 
between treatments in light grey    and the isotype non-specific control in dark  
grey              . Treatments represented in the histograms include a) LPS, b) NS, c) poly(SA) 
nanospheres, d) 25:75 CPH:SA nanospheres, e) 63:37 CPH:SA nanospheres, f) poly(SA) 
film, g) 50:50 CPH:SA film, and h) poly(CPH) film. Below the histograms is the complete 
set of results for MFI expression of C57BL/6 DC cell surface marker CD40 by multiplexed 
CPH:SA libraries. Data is representative of a minimum of 3 replicates per stimulation group.  
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Figure 8.5: Analysis of CD86 expression by C57BL/6 DCs with histograms comparing 
between treatments in light grey     and the isotype non-specific control in dark  
grey               . Treatments represented in the histograms include a) LPS, b) NS, c) poly(SA) 
nanospheres, d) 25:75 CPH:SA nanospheres, e) 63:37 CPH:SA nanospheres, f) poly(SA) 
film, g) 50:50 CPH:SA film, and h) poly(CPH) film. Below the histograms is the complete 
set of results for MFI expression of C57BL/6 DC cell surface marker CD86 by multiplexed 
CPH:SA libraries. Data is representative of a minimum of 3 replicates per stimulation group. 
Errors bars indicate standard error. LPS (positive control) normalized value is 3.6. See Table 
8.2 for statistical analysis. 
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Figure 8.6: Analysis of CD209 expression by C57BL/6 DCs with histograms comparing 
between treatments in light grey     and the isotype non-specific control in dark  
grey               . Treatments represented in the histograms include a) LPS, b) NS, c) poly(SA) 
nanospheres, d) 25:75 CPH:SA nanospheres, e) 63:37 CPH:SA nanospheres, f) poly(SA) 
film, g) 50:50 CPH:SA film, and h) poly(CPH) film. Below the histograms is the complete 
set of results for MFI expression of C57BL/6 DC cell surface marker CD209 by multiplexed 
CPH:SA libraries. Data is representative of a minimum of 3 replicates per stimulation group. 
Errors bars indicate standard error. See Table 8.2 for statistical analysis. 
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Figure 8.7: Production of IL-6 and IL-12p40 by C57BL/6 DCs upon stimulation with 
multiplexed CPH:SA libraries. Data is representative of a minimum of 3 replicates per 
stimulation group. LPS (positive control) normalized value is 108 for IL-6 and 75 for IL-
12p40. The 63:37 CPH:SA nanosphere and non stimulated average concentrations before 
normalization for IL-6 were 406 pg/mL and 30 pg/mL respectively and for IL-12p40 
were1130 pg/mL and 335 pg/mL respectively. Errors bars indicate standard error. See Table 
8.2 for statistical analysis. 
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Figure 8.8: PCA biplot of CPH:SA nanosphere stimulation of all the cell surface markers, 
CD209, CD40, CD86 and MHC II and both cytokines IL-6 and IL-12p40. The plot maps out 
high dimensional correlations permitting one to track the relative influences of varying the 
polymer chemistry. For example, the cluster marked “cell surface markers” indicates its 
inverse correlation with increasing CPH concentration. On the other hand cytokine 
production is moderately correlated with CPH concentration. The choice of the principal 
components is based on standard statistical procedures. The first principal component (PC1) 
explains 19.54% data variance, and the second principal component (PC1) explains 55.99% 
data variance which together account for 75.39% of the data variance, meaning that PC1 and 
PC2 could replace the original six variables (CD209, CD40, CD86, MHC II, IL-6, and IL-
12p40) with little loss of information. 
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Figure 8.9: PCA biplot comparing the polyanhydride nanosphere and film systems showing 
inverse correlations with clusters in opposite quadrants. The IL-12p40 production is strongly 
associated with the nanospheres while the IL-6 production is more associated with the film 
geometry. The first principal component (PC1) explains 55.14% data variance, and the 
second principal component (PC1) explains 30.82% data variance which together accounts 
for 85.89% of the data variance, meaning that PC1 and PC2 could replace the original six 
variables (CD209, CD40, CD86, MHC II, IL-6, and IL-12p40) with little loss of information. 
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Figure 8.10: PCA biplot of CPH:SA film stimulation of all cell surface markers, CD209, 
CD40, CD86 and MHC II and both cytokines IL-6 and IL-12p40. This PCA projection shows 
the strong influence of cytokine production with polymer chemistry (as noted by their large 
PCA vectors) compared to the cell surface vectors of nearly zero or very small magnitudes. 
The first principal component (PC1) explains 88.41% data variance, and the second principal 
component (PC1) explains 9.52% data variance which together account for 97.93% of the 
data variance, meaning that PC1 and PC2 could replace the original six variables (CD209, 
CD40, CD86, MHC II, IL-6, and IL-12p40) with little loss of information. As depicted in the 
figure, most of the data variance is attributed to the two cytokines, IL-6 and IL-12p40. 
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8.10 List of Tables 
Table 8.1: Molecular weight analysis of the CPH:SA polymer film library using GPC and 1H 
NMR. 
CPH:SA Polymer 
Film Library 
Mn (Da) from 
GPC 
Mn (Da) from 1H 
NMR 
Poly(SA) 11154 12555 
25:75 CPH:SA 9692 10854 
50:50 CPH:SA 13264 12872 
75:25 CPH:SA 12674 13442 
Poly(CPH) 16477 15247 
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Table 8.2: Statistical analysis of cell surface marker expression and cytokine production 
corresponding to Figures 8.3-8.7. Treatments with the same letter are not statistically 
significant from one another. Statistical significance corresponds to p ≤ 0.05. 
 
  
MHC II 
Figure 
8.3 
CD40 
Figure 
8.4 
CD86 
Figure 
8.5 
CD209 
Figure 
8.6 
IL-6 
Figure 
8.7 
IL-12p40 
Figure 
8.7 
LPS    BCD ABC A      CDE A A 
NS            E              F           E           E               F      C 
Poly(SA) 
Nano A A AB A           E      C 
13:87 
CPH:SA 
Nano AB AB AB AB      CDE    BC 
25:75 
CPH:SA 
Nano    BC ABCD AB ABC           E    BC 
37:63 
CPH:SA 
Nano    BCD ABCD ABC ABCD      CDE    BC 
50:50 
CPH:SA 
Nano       CDE      CDEF    BCD    BCDE      CDE    BC 
63:37 
CPH:SA 
Nano          DE      CDEF      CDE         DE      CD    B 
Poly(SA) 
Film    BC ABCDE ABC    BCDE         DE           D 
25:75 
CPH:SA 
Film    BCDE    BCDEF    BCDE         DE    BCDE           D 
50:50 
CPH:SA 
Film      CDE         DEF    BCDE         DE    BCD        CD 
75:25 
CPH:SA 
Film      CDE            EF         DE         DE    BC        CD 
Poly(CPH) 
Film         DE            EF         DE            E    B        C 
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9.1 Abstract 
Several challenges currently exist for rational design of functional tissue engineering 
constructs within the host, which include appropriate cellular integration, avoidance of 
bacterial infections, and low inflammatory stimulation. This work describes a novel class of 
biodegradable, amphiphilic polyanhydrides with many desirable protein-material and cell-
material attributes capable of confronting these challenges. The biocompatible amphiphilic 
polymer films were shown to release laminin in a stable and controlled manner, promote 
neural cell adhesion and differentiation, and evade inflammatory responses of the immune 
system. Using high throughput approaches, it was shown that polymer chemistry plays an 
integral role in controlling cell-film interactions, which suggests that these polyanhydrides 
can be tailored to achieve the desired cell adhesion and differentiation while minimizing 
immune recognition. These findings have important implications for development of 
engineered constructs to regulate differentiation and target the growth of transplanted cells in 
stem cell-based therapies to treat nervous system disorders. 
 
9.2 Introduction 
Biodegradable polymeric scaffolds and implant coatings have been used widely to facilitate 
implant tissue integration while defending against bacterial burdens [1, 2]. Polymers provide 
the ability to mechanically and chemically control cellular integration through structure and 
surface functionalization with or without controlled release of biological cues (growth 
factors, adhesion molecules, etc.) [1, 2]. Functionalization or controlled release properties can 
also be used to inhibit bacterial growth and adhesion [1, 3]. Proper cellular integration, limiting 
fibrosis (adhesion of fibroblasts which results in poor implant binding), and low 
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inflammatory stimulation are essential for polymer implant or scaffold viability within the 
host [1, 2]. 
 
Many current polymer systems lack the ability to provide controlled release of biologically 
active molecules and some fragile proteins may lose their function when encapsulated in 
biodegradable polymers such as poly(lactide-co-glycolide) (PLGA) [4-6]. In addition, with 
bulk eroding polymers such as PLGA, the structural integrity of the device may be 
compromised because once the molar mass is low enough, there is a rapid loss of mechanical 
properties [2, 7, 8]. In contrast, surface eroding polymers are characterized by a slow loss of 
mechanical stability over time, which would reduce the possibility of scaffold collapse before 
new tissue formation and integration with the host [2]. In addition to mechanical integrity, it is 
important for the polymer construct to evade clearance by the immune system and avoid an 
inflammatory response. Inflammation and immune activation can lead to the buildup of 
fibroblasts which inhibit tissue integration and implant acceptance by the host [1, 2]. Thus, it 
would be desirable to design surface eroding polymeric constructs for tissue engineering that 
are capable of modulating the inflammatory response of the immune system to provide a 
controlled environment conducive to cellular growth and regeneration.  
 
Polyanhydrides have been studied extensively as vehicles for protein and vaccine delivery 
over the past decade [9-27]; however, little work to date has investigated their use in tissue 
engineering applications. These surface eroding polymers are biologically inert, non-toxic, 
and non-mutagenic and are capable of providing sustained release kinetics of encapsulated 
proteins [11-13, 16, 18, 19, 23]. Additionally, polyanhydrides have been shown to stabilize a wide 
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range of biologically active molecules, such as F1-V (vaccine antigen for pneumonic plague), 
PA (vaccine antigen for anthrax), lipocalin-2, ovalbumin, lysozyme, and tetanus toxoid 
(vaccine antigen for tetanus) [11-14, 16, 18, 20, 23, 28]. Specifically, polyanhydrides based upon 1,6-
bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) have been studied extensively because of their amphiphilic properties, controlled 
protein release and protein stabilization capabilities, immune modulation, and cellular 
compatibility [9, 21, 22, 24, 25, 27]. These polymers can also be functionalized to target specific 
cellular receptors [26]. Upon degradation, CPTEG:CPH copolymers result in small changes in 
pH (7.6 to 7.1) unlike other systems (i.e., PLGA), which result in much greater decreases in 
pH to as low as 2.6 [18, 29-32]. These properties make this polymer system a promising 
candidate for tissue engineering applications combined with targeted delivery and/or surface 
functionalization. 
 
The focus of this work was to investigate amphiphilic CPTEG:CPH polyanhydride 
copolymer films for their ability to control protein release and stability while providing a 
non-toxic, immune-stealthy, and cell conducible environment for neural stem cell growth and 
adhesion. The findings indicate that CPTEG:CPH copolymer films provide an ideal non-
fouling substrate for cellular exclusion, but with the incorporation of extracellular matrix 
proteins, cellular adhesion is restored. Additionally, by altering the chemistry of the polymer, 
this polymer system was capable of modulating immune stimulation, protein release kinetics, 
and cellular differentiation. These studies were performed using a high throughput, 
combinatorial approach, which enabled the rapid assessment of protein-polymer and cell-
polymer interactions.  
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9.3 Materials and Methods 
Polymer library synthesis and characterization 
CPH and CPTEG monomers were synthesized as described previously [33, 34]. CPTEG:CPH 
copolymer film libraries were synthesized via a melt polycondensation reaction in multi-well 
substrates utilizing a robotic deposition apparatus, as reported previously [19, 20, 22, 34]. 
Copolymer chemistry and molecular weight were determined by proton nuclear magnetic 
resonance (1H NMR) spectroscopy using a Varian VXR 300 MHz spectrometer (Varian Inc., 
Palo Alto, CA). Gel permeation chromatography (GPC) was also used to measure the 
polymer molecular weight with a Waters GPC chromatograph (Milford, MA). 
 
Fabrication of protein encapsulated and blank (no protein) film libraries 
Blank and laminin-loaded combinatorial film libraries were fabricated from the polymer 
libraries as described previously [19, 22]. Briefly, laminin and methylene chloride were added 
to the polymer film library, sonicated, and the protein/polymer solution in each well was 
separately dispensed onto glass coverslips and allowed to dry resulting in a protein-
encapsulated film library.  
 
High throughput protein release 
Following encapsulation of laminin into the polymer films, the films were placed in a 24-
well polystyrene plate, and 2 mL PBS buffer (0.1 mM, pH 7.6) added to each well. The plate 
was sealed to prevent evaporation and incubated in a horizontal shaker at 37°C and 100 rpm 
for the duration of the experiment. At incremental time points, samples of the supernatant 
were removed and replaced with fresh PBS buffer to maintain constant sink conditions. 
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Laminin concentration in each sample was determined with the micro bicinchoninic acid 
(BCA) assay (Thermo Scientific, Rockford, IL), which was carried out in triplicate. Protein 
release at each time point was normalized by the total amount of protein encapsulated into 
the film which is presented as mass fraction of released laminin [19]. 
  
Culture and stimulation of dendritic cells (DCs) 
All procedures involving animals were conducted in accordance with procedures that were 
approved by the Iowa State University Institutional Animal Care and Use Committee. Bone 
marrow derived dendritic cells (BMDCs) were isolated from C57BL/6 mice (ISU Laboratory 
Animal Resource Facility, Ames, IA) and cultured using a previously developed method [21, 
22, 24, 26, 27]. BMDCs were grown in DC culture medium (RPMI containing 1% L-glutamine, 
1% penicillin-streptomycin solution, 2% HEPES, 0.5% gentamycin, 0.1% β-
mercaptoethanol, and 10% heat inactivated fetal bovine serum (FBS)) supplemented with 
granulocyte macrophage colony stimulating factor (GM-CSF) (10 ng/mL). After nine days of 
culture, DCs were incubated for 48 h with the different treatments: polymer films 
(poly(CPTEG), 75:25 CPTEG:CPH, 50:50 CPTEG:CPH, 25:75 CPTEG:CPH, and 
poly(CPH), at a concentration of 1.5 mg/coverslip), no stimulation (NS, negative control), 
and lipopolysaccharide (LPS, 200 ng/mL, positive control). 
 
Cell surface marker expression 
The expression of cell surface markers including CD11c, CD86, CD40, MHC I, and MHC II 
was assessed with flow cytometry as described elsewhere [22, 27]. The samples were run on a 
Becton-Dickinson FACSCanto flow cytometer (San Jose, CA) and analyzed with FlowJo 
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(TreeStar Inc, Ashland, OR).  
 
Cytokine production 
Following incubation with the treatments, supernatants from DC cultures were collected and 
assayed for cytokines, TNF-α, IL-6, and IL-12p40, using the Luminex® Multiplex assay 
(Austin, TX) [22, 27].  
 
MTT cellular toxicity assay 
The CellTiter 96® Non-Radioactive Cell Proliferation Assay MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) (Promega, Madison, WI) was used to determine the 
cellular viability of DCs incubated with the polymer films for 48 h. The DCs were incubated 
with the MTT assay for 3 h and the cell viability was quantified by measuring the optical 
density.  
 
Culture and stimulation of human neural progenitor cells  
Human neural stem/progenitor cells (hNPCs), isolated from 16-18-week fetal cortex, were 
purchased from Lonza (Allendale, NJ) [35]. The hNPCs were cultured as neurospheres in 
maintenance medium (a proprietary medium, Bulletkit, Lonza) further supplemented with 10 
ng/mL human recombinant basic fibroblast growth factor (bFGF) (Promega, Madison, WI) 
and 20 ng/mL epidermal growth factor (EGF) (Gibco, Grand Island, NY) [35]. This 
maintenance medium is referred to as MM. At day 0 the cells were plated at ~10 
neurospheres per well (each well containing a 12-mm glass coverslip coated with the 
different polymer film treatment groups) in a 24 well plate in 500 μL of differentiation 
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medium (a proprietary medium, Bulletkit, Lonza) further supplemented with 20 ng/mL 
recombinant human brain-derived neurotrophic factor (BDNF; Sigma-Aldrich, St. Louis, 
MO). The differentiation medium is referred to as DM. The polymer film treatment groups 
included poly(CPTEG), 75:25 CPTEG:CPH, 50:50 CPTEG:CPH, and 25:75 CPTEG:CPH 
(blank or 1% laminin loaded in the polymer film) at a polymer coating of 1.5 mg/coverslip. 
The control treatment groups included laminin-coated coverslips incubated either in DM with 
BDNF as a positive control (laminin DM) or in MM as a negative control (laminin MM). 
Cultures with the different treatment groups were maintained for 7 days. Culture media were 
replenished with 350 μL of fresh media at days 3 and 5. 
 
Immunocytochemistry on hNPCs 
Following the seven day incubation period, the hNPCs were immunolabeled. The coverslips 
containing the cells were rinsed in 0.1 M phosphate (PO4) buffer and then fixed with 4% 
paraformaldehyde in 0.1 M PO4 buffer for 30 min. Following fixation, the cells were washed 
in PBS and then incubated with the primary TUJ1 antibody (mouse monoclonal IgG, R&D 
Systems, Minneapolis, MN) diluted (1:200) in blocking solution {0.4% BSA (Sigma 
Aldrich), 0.2% Triton X-100 (Fisher Scientific), and 2.5% normal goat serum (Jackson 
ImmunoResearch Inc., West Grove, PA)} overnight at 4°C. The next day the cells were 
rinsed in PBS and incubated with a goat anti-mouse secondary antibody (Cy5-conjugated, 
Jackson ImmunoResearch Inc.) diluted (1:500) in the same blocking solution for 2 h. Cells 
on the coverslips were rinsed in PBS and then incubated with a Alexa Fluor 488 (AF488)-
conjugated primary MAP2B antibody (mouse monoclonal IgG, BD Pharmingen, San Diego, 
CA) and a Cy3-conjugated primary GFAP antibody (mouse monoclonal IgG, Sigma-Aldrich, 
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St. Louis, MO) diluted in the blocking solution (1:18 and 1:400, respectively) overnight at 
4°C. The following day cells on the coverslips were rinsed in PBS. After nuclei were 
counterstained with 1 μM 4’,6-diamidino-2-phenylindole dilactate (DAPI) and the 
preparations were mounted on microscope slides with Gel Mount (Fisher Scientific) for 
fluorescence microscopy analysis.  
 
Microscopy, image acquisition, and data analysis 
Epifluorescence microscopy was carried out with an upright fluorescence microscope (Nikon 
Microphot FXA, Nikon Inc., Garden City, NY) equipped with a Retiga 2000R digital camera 
controlled by QCapture software (QImaging, Surrey, BC, Canada). A minimum of eight 
images with an average of 222 cells per image was taken per fluorochrome per treatment 
group using a 20X objective. Image J software (NIH, Bethesda, MD) was used to analyze the 
microscopy images. To calculate the percentage of immunoreactive cells, the number of cells 
immunoreactive for each antibody was divided by the total number of cells (DAPI-stained 
nuclei).  
 
Statistical analysis 
JMP software (SAS Institute, Cary, NC) was used to make comparisons between different 
treatments were determined using a model ANOVA with Tukey’s HSD as indicated by 
letters above each bar. Differing letters represent difference between treatments. 
Comparisons between treatments and controls were made using the student’s T-test and 
indicated by an asterisk above the bars. 
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9.4 Results 
Polymer characterization and protein release 
The NMR and GPC characterization indicated that polymer molecular weight, structure, and 
composition were as intended and in agreement with previous studies [23, 34, 36]. High 
throughput laminin release studies from CPTEG:CPH copolymer films (Figure 9.1) were 
carried out because laminin is an adhesion protein for cellular binding to substrates [37-39]. 
Figure 9.1 shows that laminin was released in a controlled manner over time as a function of 
polymer chemistry. By increasing the content of the less hydrophobic CPTEG in the 
copolymer, protein release rates were higher.  
 
Polyanhydride libraries are biocompatible and induce low levels of immune response 
To test the toxicity of polyanhydride film libraries to primary cells, dendritic cells (DCs), 
which are professional antigen presenting cells of the immune system, were incubated with 
varying concentrations of 50:50 CPTEG:CPH copolymer films and cell viability was 
examined by the MTT assay (Figure 9.2A). All polymer concentrations below 16.9 mg/mL 
resulted in no statistical difference for the cell viability compared to the “no polymer” (NP) 
positive control. This result signifies that a wide range of polymer coating or scaffold 
thicknesses could be utilized with this system.  
 
To test the effects of the film libraries on induction of an immune response, DCs were 
incubated on the polymer films for two days. Supernatants were analyzed for secreted 
cytokines, TNF-α, IL-6, and IL-12p40, and cells were stained for expression of cell surface 
markers, MHC I, MHC II, CD40 and CD86, and analyzed by flow cytometry. Secretion of 
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these cytokines and expression of these cell surface markers are indicators of immune 
activation and DC maturation [40]. The results showed that the CPTEG:CPH polymer films 
cause DCs to down-regulate cytokine secretion (IL-12p40 and IL-6) compared to the NP 
control (Figure 9.2B). TNF-α was below detection limits for all treatments except LPS. 
Additionally, low levels of cell surface marker expression were observed (Figure 9.2C). Both 
cell marker expression and cytokine production appeared to be modulated in a chemistry-
dependent manner. These findings suggest that there may be an optimal copolymer 
composition, such as 50:50 CPTEG:CPH, which is capable of achieving the lowest level of 
immune stimulation.  
 
Adhesion of hNPCs to the polymer library is controlled by polymer chemistry 
Human neural stem/progenitor cells (hNPCs) were incubated for seven days with the 
polymer film library and investigated for their ability to adhere and differentiate. Initial 
studies evaluated the adhesion of hNPCs on blank or laminin-encapsulated polymer film 
libraries including poly(CPTEG), 75:25 CPTEG:CPH, 50:50 CPTEG:CPH, and 25:75 
CPTEG:CPH. The results indicated that blank polymer films provided a non-fouling 
background preventing cellular adhesion with all polymer chemistries (data not shown). 
However, when laminin was encapsulated into the polymer films, cellular adhesion was 
restored in for CPH-rich polymer film chemistries (data not shown). These results indicate 
that the biological functionality of laminin was preserved upon encapsulation into the 
polymer films. In addition, CPTEG-rich polymer chemistries resulted in minimal cellular 
adhesion (even with laminin encapsulated into the polymer) (data not shown), which is likely 
a result of the ethylene glycol [1, 41] incorporated into the polymer backbone.  
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Differentiation of hNPCs is controlled by polymer chemistry 
The three polymer film chemistries with adequate cellular adhesion (75:25 CPTEG:CPH, 
50:50 CPTEG:CPH, and 25:75 CPTEG:CPH) were studied for their influence on hNPC 
differentiation after a 7 day co-incubation. Figure 9.3 suggests that film chemistry controlled 
the differentiation of hNPCs with 50:50 CPETG:CPH resulting in the lowest percentage of 
hNPCs immunoreactive for microtubule associated protein 2B (MAP2B), a marker of 
immature neurons. The other two chemistries resulted in significantly higher percentages of 
MAP2B-immunoreactive cells. The percentages of cells immunoreactive for beta III tubulin 
(TUJ1, marker of developing neurons) or glial fibrillary acidic protein (GFAP, glial cell 
marker) revealed increasing trends when in the presence of CPTEG-rich chemistries. The 
data in Figure 9.3 suggest that 75:25 CPTEG:CPH polymer films enhance the most hNPC 
differentiation into both astrocytes and neurons compared with other film treatments and 
control treatments {positive control: laminin-coated glass coverslip with NP film in 
differentiation media (laminin DM); negative control: laminin-coated glass coverslip with NP 
film in maintenance media (laminin MM)}.  
 
Supplementary Figure 9.1 presents the percentages of hNPCs that were subcellular 
immunolabeled for MAP2B (Supplementary Figure 9.1A) and TUJ1 (Supplementary Figure 
9.1B), respectively. The data in Supplementary Figure 9.1A suggest that higher fraction of 
hNPCs were undergoing neuronal differentiation when they were incubated on CPTEG-rich 
polymer films (75:25 and 50:50 CPTEG:CPH) than on 25:75 CPTEG:CPH films. In addition, 
the percentage of cells immunoreactive for MAP2B in both cell body and neurites was higher 
when the cells were cultured on 75:25 CPTEG:CPH films than CPH-rich polymer films. 
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Supplementary Figure 9.1B also demonstrated increasing trends for the percentages of TUJ1-
positive hNPCs (immunolabeled in both cell body and neurites) when incubated with 
increasing CPTEG-content in the polymer film.  
 
Images of each treatment group and marker can be observed in Figure 9.4 and corroborate 
the data presented in Figure 9.3. By quadruple labeling the hNPCs (DAPI-nucleus, AF488-
MAP2B, Cy5-TUJ1, and Cy3-GFAP), double positive cell populations for the differentiation 
markers were assessed as shown in Figure 9.5. Figure 9.5A indicates that cells 
immunoreactive for MAP2B are also largely positive for TUJ1 or GFAP, especially when 
incubated on CPH-rich polymer films. However, cells immunoreactive for TUJ1 or GFAP 
are less positive for each other, but follow the same chemistry dependent trend (Figures 9.5B 
and 9.5C). The hNPC populations positive for MAP2B appeared to be more influenced by 
polymer film chemistry in their immunoreactivities for TUJ1 or GFAP than populations 
positive for TUJ1 or GFAP, which only resulted in chemistry dependent trends for co-
labeling with GFAP or TUJ1, respectively. When examining the entire hNPC population 
(based upon DAPI count) (Supplementary Figure 9.2), the data indicate an opposite 
chemistry trend with CPTEG-rich polymer films influencing the most double positive 
expression of cells for TUJ1 and GFAP, and GFAP and MAP2B. In contrast, double positive 
cells for both neuronal makers, TUJ1 and MAP2B, trended toward CPH-rich chemistries. 
 
9.5 Discussion 
Many current approaches to tissue engineering scaffolds or implant coatings have focused on 
the use of surface functionalization or controlled release of biological signals to promote 
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cellular adhesion, growth, vascularization, differentiation, etc. and/or to inhibit the growth 
and viability of infectious microorganisms [1, 2]. In this regard, CPTEG:CPH copolymers 
represent a biodegradable delivery system capable of both controlled release and surface 
functionalization. In this work these copolymers were demonstrated to release laminin in a 
chemistry-dependent manner, which was a strong function of the hydrophobicity of the 
polymer film (Figure 9.1). All the polyanhydride chemistries tested in this work 
demonstrated the ability to preserve the functionality of laminin. This data is consistent with 
other work from our laboratory on the protein stabilization capabilities of this amphiphilic 
polymer system [11, 16, 18, 20, 23]. In those studies, the stabilization of fragile recombinant 
proteins as well as more robust globular proteins was shown to be strongly dependent upon 
polymer chemistry, with the amphiphilic chemistries providing the best environment for 
preservation of protein activity (and structure). Recently, Carrillo-Conde et al. demonstrated 
that CPTEG:CPH nanoparticles can be functionalized with carbohydrates with an eye 
towards targeting DCs for immune activation [26]. That approach could be applied to 
functionalize the polymer films in this work for promoting cell-specific adhesion and growth 
and/or for reducing bacterial adhesion and growth. Bactericidal activity of a tissue 
engineering scaffold or implant coating would be a key advancement for reducing implant 
infections, especially intracellular bacteria, which cannot be cleared by antibiotics and pose a 
threat to implant viability [1].  
 
Biocompatibility and immune acceptance, specifically low inflammatory responses, of the 
implant by the host often dictate acceptance of the implant and in vivo viability. Materials 
capable of inducing low immune recognition would be ideal candidates for tissue engineering 
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applications as coatings to non-inflammatory implants or implants themselves. DCs were 
used to study the effect of CPTEG:CPH polymer films on cellular toxicity, expression of 
surface markers responsible for DC maturation and antigen presentation (MHC II, MHC I, 
CD86 and CD40), and secretion of both inflammatory and immune activating cytokines 
(TNF-α, IL-6, and IL-12p40). This work has demonstrated that the CPTEG:CPH polymer 
film system modulated the immune response of DCs in a chemistry dependent manner 
(Figure 9.2). Moderate to low CPTEG-containing copolymer compositions demonstrated 
simulation levels no higher than the negative (NP) control group. This indicates that these 
films could be stealth-like to the immune system. Furthermore, all the chemistries studied 
maintained background levels or decreased production of the pro-inflammatory cytokines 
TNF-α and IL-6 (Figure 9.2B). These data suggest that these films may elicit weak 
inflammatory responses in vivo. In other related work from our laboratories, when 
nanoparticles made of these polymers were administered intranasally or subcutaneously, very 
low levels of inflammation were observed [42]. Since nanoparticles can be phagocytosed, it is 
reasonable to expect that the same chemistry in non-phagocytic geometries (i.e., film, 
coating, scaffold) would elicit even lower levels of inflammation similar to what was 
observed in vitro [22]. 
 
Stealth-like behavior enabling protection from immune activation and clearance by the 
immune system are important characteristics for implant or scaffold acceptance and tissue 
integration. However, it is also important that cell survival, adhesion, and differentiation 
within the polymer are conducive for cellular integration and tissue regeneration. As shown 
in Figure 9.3A, the CPTEG:CPH films were biocompatible at concentrations thirty-fold 
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higher than those administered in vivo [15, 43]. Adhesion and differentiation of hNPCs was also 
enabled by this system in a chemistry-dependent manner. Adhesion was not favored for the 
CPTEG-rich chemistries due to the ethylene glycol content in the backbone of poly(CPTEG). 
This is consistent with other studies in which low protein adsorption was observed on the 
surface of microparticles composed of CPTEG-rich chemistries [10].  
 
Cellular differentiation also appears to be influenced by chemistry with CPTEG-rich 
compositions influencing the most overall expression of cells positive for neuronal markers 
(Figures 9.3 and 9.4). This suggests that 75:25 CPTEG:CPH has the ability to enhance 
differentiation of hNPCs into neurons and glial cells. In addition, 50:50 CPTEG:CPH may 
also be able to promote neuronal differentiation as indicated by the higher fraction of hNPC 
cell bodies immunoreactive for MAP2B (Supplementary Figure 9.1A). This work 
demonstrates the capabilities of CPTEG:CPH polymer films to control cellular adhesion and 
differentiation in a chemistry-dependent manner while providing a system capable of 
releasing biologically relevant proteins for further controlling cellular behavior. By 
employing a combinatorial platform approach, these protein-material and cell-material 
interactions were rapidly screened, which will facilitate the rational design of tissue 
engineering systems composed of biodegradable polyanhydrides. 
 
9.6 Conclusions 
Amphiphilic polyanhydride films provide a biologically tunable environment capable of 
overcoming many of the challenges associated with tissue engineering constructs. They were 
capable of preserving protein structure while controlling protein release, which is integral for 
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dictating cellular behavior (adhesion, differentiation, etc.). The polymer films also 
demonstrated immune stealth characteristics indicated by background level stimulation of 
DCs and low inflammatory signaling. These attributes are important for implant host 
acceptance, whereas other properties promoting tissue specific cell interactions are vital for 
implant integration into the host. This amphiphilic polymer film system also demonstrated 
the capability to promote and control hNPC adhesion and differentiation. A copolymer 
containing 50% CPTEG and 50% CPH may present optimal properties for neural tissue 
engineering with hNPCs by limiting immune recognition while providing a conducible 
environment for cellular adhesion and differentiation. These amphiphilic polymers may 
provide an excellent platform technology for tissue engineering constructs.  
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9.9 List of Figures 
 
Figure 9.1: Fractional release of laminin from CPTEG:CPH copolymer film libraries. The 
CPTEG-rich films released laminin most rapidly, whereas CPH-rich films released laminin 
the slowest. Error bars represent standard deviation and six independent experiments were 
carried out.  
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Figure 9.2: Biocompatibility and immune stimulation capabilities of CPTEG:CPH polymer 
films. A) Viability of DCs incubated with 50:50 CPTEG:CPH films at varying 
concentrations; B) cytokine production (TNF-α was below detection limits for all treatments 
except LPS) and C) cell marker expression of DCs incubated with polymer film libraries. 
Average IL-12p40, IL-6, and TNF-α concentrations for cells stimulated with LPS were 
55900, 101500, and 4600 pg/mL respectively. In A), asterisks indicate statistical significance 
from the NP control group and in B) and C), letters indicate statistical significance between 
treatments. Three independent experiments were carried out with replicates of two in each 
experiment, and error bars represent standard error of the mean. 
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Figure 9.3: Percentage of hNPCs displaying neuronal (MAP2B and TUJ1) or glial (GFAP) 
differentiation. The CPTEG-rich films best enhanced hNPC differentiation. Letters indicate 
statistical significance between treatments, eight different images were analyzed with an 
average of 222 cells per image, and error bars represent standard deviation. 
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Figure 9.4: Representative epifluorescent images of hNPCs stained for DAPI (blue, column 
1), MAP2B (neuronal marker, AF488 green, column 2), TUJ1 (neuronal marker, Cy5 red, 
column 3), and GFAP (glial cell marker, Cy3 yellow, column 4), after incubation with 25:75 
CPTEG:CPH, 50:50 CPTEG:CPH, 75:25 CPTEG:CPH, laminin-coated coverslip in DM 
(positive control, Laminin DM), and laminin-coated coverslip in MM (negative control, 
Laminin MM). The hNPCs readily adhered to CPH-rich polymer films and strongly 
expressed differentiation markers. 
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Figure 9.5: CPH-rich chemistries resulted in the most double positive hNPC populations for 
MAP2B + TUJ1, MAP2B + GFAP, TUJ1 + GFAP, and GFAP + TUJ1 (MAP2B and TUJ1 = 
neuronal markers and GFAP = glial cell marker). A) The percentage of MAP2B+ hNPCs also 
positive for TUJ1 or GFAP; B) the percentage of TUJ1+ hNPCs also positive for MAP2B or 
GFAP; and C) the percentage of GFAP+ hNPCs also positive for MAP2B or TUJ1. Letters 
indicate statistical significance between treatments, eight different images were analyzed 
with an average of 200 cells per image, and error bars represent standard deviation. 
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9.10 Supporting Information 
 
Supplementary Figure 9.1: CPH-rich films best enhanced hNPC differentiation. Subcellular 
immunolabeling (cell body and neurite = complete differentiation, cell body only = early 
stage differentiation, total = cell body and neurite + cell body) indicating variable levels of 
neuronal differentiation for A) MAP2B and B) TUJ1. Letters indicate statistical significance 
between treatments, eight different images were analyzed with an average of 200 cells per 
image, and error bars represent standard deviation. 
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Supplementary Figure 9.2: CPTEG-rich films best promoted the expression of total double 
positive hNPCs for TUJ1 + GFAP and GFAP + MAP2B (MAP2B and TUJ1 = neuronal 
markers and GFAP = glial cell marker). The percentages of total hNPCs double positive for 
MAP2B, TUJ1, and GFAP were compared among the polymer chemistries. Letters indicate 
statistical significance between treatments, eight different images were analyzed with an 
average of 200 cells per image, and error bars represent standard deviation. 
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10.1 Abstract 
Techniques in materials design, immunophenotyping, and informatics can be valuable tools 
for using a molecular based approach to design vaccine adjuvants capable of inducing 
protective immunity that mimics a natural infection but without the toxic side effects. This 
work describes the molecular design of amphiphilic polyanhydride nanoparticles that activate 
antigen presenting cells in a pathogen-mimicking manner. Biodegradable polyanhydrides are 
well suited as vaccine delivery vehicles due to their adjuvant-like ability to: 1) enhance the 
immune response, 2) preserve protein structure, and 3) control protein release. The results of 
these studies indicate that amphiphilic nanoparticles possess pathogen-mimicking properties 
as evidenced by their ability to activate dendritic cells similarly to LPS. Specific molecular 
descriptors responsible for this behavior were identified using informatics analyses, including 
the number of backbone oxygen moieties, percent of hydroxyl end groups, polymer 
hydrophobicity, and number of alkyl ethers. Additional findings from this work suggest that 
the molecular characteristics mediating APC activation are not limited to hydrophobicity but 
vary in complexity (e.g., presentation of oxygen-rich molecular patterns to cells) and elicit 
unique patterns of cellular activation. The approach outlined herein demonstrates the ability 
to rationally design pathogen-mimicking nanoparticle adjuvants for use in next-generation 
vaccines against emerging and re-emerging diseases. 
 
10.2 Introduction 
Successful vaccines induce protective immune responses that mimic those induced by a 
natural infection but do not elicit the negative effects associated with disease [1]. To do so, 
they must signal to the innate immune system using mechanisms similar to those employed 
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by pathogens. Upon infection, the innate immune system is activated by pathogen-associated 
molecular patterns (PAMPs), such as lipopolysaccharide (LPS) found on the surface of gram 
negative bacteria, which interact with Toll-like receptors (TLRs) and other pattern 
recognition receptors (PRRs) on the surface of antigen presenting cells (APCs), including 
dendritic cells (DCs) [2, 3]. PAMPs contain repetitive molecular patterns that are recognized as 
“danger signals” by the host [3]. Moreover, PAMPs are often comprised of insoluble, 
hydrophobic moieties and are presumed to interact with PRRs, thereby providing signals that 
activate the innate immune system [4, 5]. In contrast, the soluble antigens and adjuvants found 
in current vaccine formulations cannot provide the same degree of continued stimulation. An 
opportunity exists to exploit the material properties of biodegradable polymers in order to 
rationally design vaccine adjuvants that mimic the behavior of pathogens, including 
prolonged in vivo residence times capable of providing extended immune activation and 
continued stimulation of APCs, without inducing the deleterious effects of disease. 
 
Polyanhydrides are biodegradable materials that have been well documented to provide 
sustained delivery of proteins and stabilization of vaccine antigens [6-12]. Copolymers based 
upon sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane (CPH), and 1,8-bis-(p-
carboxyphenoxy)-3,6-dioxaocatane (CPTEG) have been studied as antigen carriers and 
adjuvants. These copolymers degrade into non-toxic, non-mutagenic degradation products 
and have demonstrated biocompatibility both in vivo and in vitro at concentrations expected 
for human use [13-16]. Some amphiphilic polyanhydrides have also been reported to exhibit 
adjuvant characteristics capable of enhancing the adaptive immune response [13, 16].  
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When designing vaccine adjuvants, it is integral to understand the molecular properties of the 
adjuvant responsible for immune cell activation that would facilitate the induction of long-
lived, protective immunity. In this work, we investigated the molecular properties of 
polyanhydride nanoparticles responsible for their robust stimulation of DCs. A simultaneous 
investigation of nanoparticle internalization and activation of DCs was complemented by 
informatics analysis to identify important polymer descriptors responsible for mimicking the 
adjuvant capabilities of the PAMP, LPS. While many previous studies have investigated the 
expression of cell surface markers and production of cytokines caused by stimulation with 
polymeric adjuvants [12, 17, 18], this is the first study to report the complex relationship between 
nanoparticle internalization, DC activation, and polymer chemistry (i.e., through polymer 
descriptors). This is also the first study to present a direct comparison of cellular activation 
between DCs that have engulfed the nanoparticles and those that have not in the same 
culture. These studies identified molecular descriptors of polyanhydrides that are responsible 
for DC activation in a manner that closely resembles a pathogen-mimicking profile. The 
results indicate that polyanhydride nanoparticles may provide ‘danger signals’ to APCs 
through specific molecular descriptors resulting in innate immune activation. 
 
10.3 Materials and Methods 
Materials 
The chemicals utilized in the monomer synthesis include: 1,6-dibromohexane, tri-ethylene 
glycol, 4-hydroxybenzoic acid, 1-methyl-2-pyrrolidinone, 4-p- and 1,6-dibromohexane; these 
were purchased from Sigma Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile was purchased 
from Apollo Scientific (Cheshire, UK); and sulfuric acid, acetonitrile, dimethyl formamide 
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(DMF), toluene, and potassium carbonate were obtained from Fisher Scientific (Fairlawn, 
NJ). Chemicals for the polymerization and nanoparticle fabrication include petroleum ether, 
pentane, acetic anhydride, chloroform, and methylene chloride; all were purchased from 
Fisher Scientific. Deuterated chemicals for NMR analysis include chloroform and dimethyl 
sulfoxide (DMSO; Cambridge Isotope Laboratories, Andover, MA). β-mercaptoethanol, E. 
Coli lipopolysaccharide (LPS), and rat immunoglobulin (rat IgG) were purchased from 
Sigma Aldrich and brefeldin A from eBioscience (San Diego, CA). The materials required 
for the DC culture medium include: granulocyte macrophage colony stimulating factor (GM-
CSF), purchased from PeproTech (Rocky Hill, NJ); HEPES buffer, RPMI 1640, penicillin-
streptomycin, and L-glutamine, purchased from Mediatech (Herndon, VA); and heat 
inactivated fetal calf serum, purchased from Atlanta Biologicals (Atlanta, GA). Materials 
used for flow cytometry included: permeabilization buffer (10x) and intracellular (IC) 
fixation buffer, purchased from eBioscience (San Diego, CA); unlabeled anti-CD16/32 FcγR, 
purchased from Southern Biotech (Birmingham, AL); unlabeled hamster IgG, peridinin-
chlorophyll proteins-Cy5.5 (PerCP/Cy5.5) conjugated anti-mouse IL-12/23 p40 (clone 
C17.8), phycoerythrin (PE) conjugated anti-mouse IL-6 (clone MP5-20F3), biotin conjugated 
anti-mouse MHC II (I-Eκ) (clone 14-4-4S), phycoerythrin-Cy5 (PE/Cy5) conjugated anti-
mouse CD11c (clone N418), fluorescein isothiocyanate (FITC) conjugated anti mouse/rat 
MHC Class II (I-Eκ) (clone 14-4-4S), PE conjugated anti-mouse MHC Class I (H-2Kd/H-
2Dd)(clone 34-1-2S), allophycocyanin (APC) anti-mouse CD40 (clone 1C10), phycoerythrin-
Cy7 (PE/Cy7) anti-mouse CD86 (clone GL-1), Alexa Fluor® 700 anti-mouse CD11c (clone 
N418), and biotin conjugated anti-mouse CIRE (DC-SIGN or CIRE) (clone 5H10; and 
corresponding isotypes: PerCP-Cy5.5 conjugated rat IgG2a N, PE conjugated rat IgG2 N, 
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biotin conjugated mouse IgG2a N, PE/Cy5 rat IgG2a N (clone eBR2a), PE-conjugated rat 
IgG2a (clone eBR2a), APC rat IgG2a N (clone eBR2a), PE/Cy7 conjugated rat IgG2b (clone 
KLH/G2b-1-2), Alexa Fluor® 700 conjugated Armenian hamster IgG (clone eBio299Arm), 
and biotin conjugated rat IgG2a (clone eBR2a); and APC-Cy7-conjugated streptavidin. All of 
these reagents were purchased from eBioscience. Cadmium selenide quantum dots (QDs) 
(emission at 630nm) were a gift from Dr. Aaron Clapp at Iowa State University. 
 
Polymer synthesis, nanoparticle fabrication, and characterization  
SA monomer was purchased from Sigma Aldrich. 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
monomer, 1,8-bis(p-carboxyphenoxy)-3,6-dioxaocatane (CPTEG), and conventional 
CPTEG:CPH and CPH:SA polymers were synthesized as described previously [19-22]. 
Combinatorial discrete libraries of CPTEG:CPH and CPH:SA copolymers were synthesized 
at high throughput as described previously [9, 10, 17, 18]. Following synthesis, the polymers were 
dissolved in a solvent (methylene chloride), QDs added to the dissolved polymer (nothing 
was added at this step for blank particles), dispersed by sonication at 40 Hz for 30 s, and then 
rapidly precipitated into a non-solvent (pentane) for the formation of nanoparticle libraries [9, 
10, 18]. These libraries were dried under vacuum drying or via rapid filtration and stored under 
dry conditions until use in the cellular assays. Conventional nanoparticles were fabricated 
with previously described methods [16, 23]. The polymer libraries were characterized by 1H 
nuclear magnetic resonance (NMR) spectroscopy. The nanoparticle libraries were imaged 
using scanning electron microscopy (SEM) to assess size and morphology. 
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Culture and stimulation of murine DCs 
All experiments involving animals were carried out in accordance with procedures approved 
by the Iowa State University Institutional Animal Care and Use Committee. DCs were grown 
as described previously [12, 18] and stimulated with either 200 ng/mL lipopolysaccharide (LPS; 
a positive control), 125 μg/mL of QD-loaded CPTEG:CPH copolymer nanoparticles of 
various molar ratios (60:40, 50:50, 40:60, 30:70, 25:75, 20:80, and 10:90), QD-loaded 
CPH:SA copolymer nanoparticles of various molar ratios (0:100, 13:87, 25:75, 37:63, 50:50, 
and 63:37) or left untreated (NS; non-simulated, negative control). Treatments were applied 
to the DCs on day nine post-harvest and incubated for 48 h. Flow cytometry was then 
performed to assess the phenotype of the DCs. In all cases, cells were > 90% positive for the 
DC specific marker, CD11c (data not shown). To account for QD release due to particle 
degradation which would result in cells “false positive” for particles, a released QD control 
(background) was subtracted from each treatment group. In this control experiment, QD-
loaded nanoparticles of all chemistries were allowed to incubate in DC culture medium for 
48 h. After the incubation, the particles were centrifuged and the supernatants containing the 
released QDs were added to DCs for 48 h to account for any fluorescence caused by the 
uptake of released QDs as opposed to internalization of QD-loaded nanoparticles. For 
experiments investigating cytokine production via flow cytometry, brefeldin A was 
administered at the same time as the treatments to prevent secretion of the protein from the 
cells. 
 
For the experiments investigating cytokine production, brefeldin A was administered at the 
same time point as the treatments to prevent protein transport out of the cells. On day 11, 
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supernatants were collected for cytokine analysis and cells were stained for flow cytometry.  
 
Flow cytometry 
After stimulation, DCs were assessed for the expression of MHC I, MHC II, CD40, CD86, 
and CIRE as described previously [12, 18]. To detect the intracellular cytokines IL-12p40 and 
IL-6, cells were labeled according to the manufacturer’s recommended protocol 
(eBioscience). No differences were observed in expression of MHC I, MHC II, CD86, CD40 
or CIRE when DCs were cultured with nanoparticles fabricated combinatorially or 
conventionally (Supplementary Figure 10.1). 
 
Statistical and informatics analyses  
Statistical analysis was performed using JMP® statistical software. Two-group comparisons 
were made using a student’s T-test whereas multiple-group comparisons were made with 
Tukey’s HSD in which case the data was log transformed. 
 
Principal Component Analysis (PCA), a dimensionality reduction technique, was employed 
to provide a straightforward and parsimonious description of the covariance structure [24, 25]. 
The principal components (PCs) are linear combinations of the original variables, and present 
new axes that represent the directions with maximum variance. The projection of the original 
multi-dimensional data to the two-dimensional space constructed by the first and second PCs 
provides a means of data visualization and interpretation and can uncover unknown 
relationships, thereby enabling new data interpretations [24, 25]. In this work, PCA was used to 
uncover the latent features of the DC activation data and explain the relationships between 
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polymer chemistry, cell marker expression, and cytokine production. The PCA analysis for 
DC activation (Figure 10.4F) used double positive populations based upon all combinations 
of MHC II, CD40, CD86, IL-6 and IL-12p40 data. Partial least squares (PLS) regression 
connected the descriptor data set with the results of the PC analyses. By projecting the data 
onto a high-dimensional hyperplane defined by the PCA analysis of training data, the impact 
of the descriptors on the property were identified, while taking co-linearity into account [26]. 
 
10.4 Results 
Nanoparticle internalization is required for enhanced CD40 expression and cytokine 
production but not for enhanced expression of MHC II and CD86 
Bacterial internalization by APCs is an important step in cellular activation and immune 
signaling [27-29]. The CPH:SA and CPTEG:CPH nanoparticles were, therefore, tested for their 
ability to be internalized by DCs. Incubation of CPTEG-rich and SA-rich chemistries with 
DCs resulted in an average of ~6% and ~30% nanoparticle-positive cells, respectively 
(Figure 10.1). The observed positive correlation between nanoparticle internalization and 
decreasing hydrophobicity is consistent with that observed for cell surface marker expression 
and cytokine secretion (Supplementary Figures 10.1 and 10.2). Moreover, these particle 
chemistry trends are in agreement with previous work from our laboratories assessing 
internalization of particles by THP-1 human monocytes and murine DCs via confocal 
microscopy [12, 23]. 
 
Previous studies from our laboratory have demonstrated that DC activation is dependent 
upon nanoparticle chemistry [12, 18]; however, these studies did not directly assess the 
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activation of DCs relative to the presence of internalized nanoparticles. Thus, we sought to 
determine the effect of nanoparticle internalization and chemistry on DC activation. The 
addition of SA- or CPTEG-rich nanoparticles to DC cultures provided a greater enhancement 
of cell surface marker expression (Figure 10.2) and cytokine production (Figure 10.3) as 
compared to CPH-rich nanoparticles. Strikingly, nanoparticle internalization was necessary 
for increasing surface CD40 expression and the production of the cytokines IL-6 and IL-
12p40 (Figures 10.2E, 10.2F and 10.3). In contrast, enhancement of MHC II and CD86 
surface expression on DCs was not dependent on nanoparticle internalization, as evidenced 
by no significant difference in expression levels between nanoparticle-negative and -positive 
populations (Figure 10.2A-D).  
 
Amphiphilic 50:50 CPTEG:CPH nanoparticles mimic LPS by creating DC populations that 
are similar in activation phenotype 
To date, analysis of DC activation has focused on single parameters (i.e., MHC II or IL-6 
expression). However, expression of antigen presenting and co-stimulatory molecules and 
secretion of cytokines by DCs act simultaneously to orchestrate an adaptive immune 
response, including activation of T cells and differentiation of B cells into plasma cells [30]. 
To study the relationship between nanoparticle chemistry and DC activation, CD11c-positive 
cell populations were analyzed for their simultaneous production of cytokines and expression 
of cell markers. This analysis focused on the three treatment groups (LPS, poly(SA), and 
50:50 CPTEG:CPH) that induced the most significant increases in DC activation and 
produced the largest percentages of cells that were positive for surface markers and 
cytokines. The other treatment groups (CPH-rich and non-stimulated) were not included in 
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this analysis because their double positive DC populations were too small. We studied only 
DCs that were double positive for two of the following parameters: MHC II, CD86, CD40, 
IL-12p40, or IL-6 (Figure 10.4A-E). The analysis was performed by singling out cells 
positive for one event (i.e. MHC II) and within that population, identifying cells also positive 
for another event (i.e. CD86, CD40, IL-12p40, or IL-6). The results revealed remarkably 
similar activation trends between DCs treated with the amphiphilic 50:50 CPTEG:CPH 
nanoparticles and LPS (Figure 10.4). In contrast, the activation phenotype of DCs treated 
with poly(SA) nanoparticles was dissimilar to the phenotype created by LPS stimulation. 
PCA of this data confirmed that 50:50 CPTEG:CPH is significantly more similar to LPS than 
poly(SA) and that poly(SA) and LPS are not similar in terms of DC activation (Figure 
10.4F). Together, these data suggest that while both nanoparticle groups stimulate DCs, the 
amphiphilic 50:50 CPTEG:CPH nanoparticles activate the DCs in a similar manner to LPS 
while poly(SA) nanoparticles do not. 
 
Use of informatics analysis to identify descriptors responsible for the pathogen-mimicking 
behavior of the amphiphilic 50:50 CPTEG:CPH nanoparticles  
Additional informatics analyses were performed to assess the similarities between the 
molecular descriptors for LPS and 50:50 CPTEG:CPH nanoparticles that are important for 
DC activation. Specifically, PLS analysis was used to identify which aspects of the molecular 
structure of 50:50 CPTEG:CPH led to the LPS-like behavior. The relationship between 
nanoparticle chemistries (50:50 CPTEG:CPH and poly(SA)) and LPS was quantitatively 
defined by comparing a list of molecular descriptors with PCA positions of the chemistries, 
whereby PCA served as a parameterization of the chemistries based on DC activation. Figure 
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10.5A shows the descriptors that were studied and Figure 10.5B shows the relationships 
between the descriptors and DC activation data. The descriptor library combined 
experimentally measured descriptors with those defined by Bicerano [31]. The descriptors 
with negative impact values in Figure 10.5B make the formulations less similar to LPS, while 
descriptors with higher impact values make the formulations more likely to be pathogen-
mimicking. Based on this analysis, number of backbone oxygen moieties, percent of 
hydroxyl end groups, polymer hydrophobicity, and number of alkyl ethers were identified as 
the key descriptors responsible for the pathogen-mimicking activation of DCs by the 
amphiphilic 50:50 CPTEG:CPH nanoparticles.  
 
10.5 Discussion 
In this work, nanoparticle chemistry and hydrophobicity were found to play an integral role 
in particle internalization by DCs (Figure 10.1). Once internalized, these properties continued 
to influence cell surface marker expression (Figure 10.2) and cytokine production (Figure 
10.3). The least hydrophobic polymer chemistries, poly(SA) and 60:40 CPTEG:CPH, 
exhibited the greatest internalization by DCs (Figure 10.1); however, it is unlikely that 
hydrophobicity alone dictated this cellular response. These results are consistent with 
previous reports demonstrating that SA-rich polymer chemistries are efficiently taken up by 
APCs via both phagocytosis and endocytosis whereas CPH-rich nanoparticles are solely 
taken up by endocytosis and to a lesser degree [23]. We therefore hypothesize that cellular 
internalization of the nanoparticles may be a function of other polymer-associated molecular 
patterns and descriptors. The patterns found in conserved, molecular signatures on pathogens 
are important signals of ‘danger’ to APCs, and include molecules such as LPS and flagella 
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[3]. It is interesting to note that Seong and Matzinger have proposed that one of these ‘danger 
signals’ could be hydrophobicity [32]. It is known that hydrophobic polystyrene particles are 
readily taken up by APCs [33]; however, they induce very little activation of APCs (data not 
shown), which indicates that to achieve activation, a compilation of chemical and physical 
signals is required. A hydrophobic homopolymer like poly(SA) contains SA repeat units, 
whereas the amphiphilic 50:50 CPTEG:CPH copolymer presents alternating repeat units of 
CPTEG and CPH, together with a large number of backbone oxygen moieties and hydroxyl 
end groups. The reactivity ratios of the monomers in the 50:50 copolymer [19, 20] lead to 
alternating patterns of oxygen-rich CPTEG and CPH monomers that are presented to the cell. 
The presence of such patterns in these amphiphilic copolymers may explain why they are 
readily internalized. Poly(SA) particles may mimic a hydrophobicity-related ‘danger signal’ 
[32], while amphiphilic CPTEG-rich particles may be internalized due to their ethylene glycol 
backbone that enables rapid degradation of the anhydride bonds in an aqueous environment 
and exposure of hydroxyl end groups to the APCs. Of note, hydroxyl end group and oxygen 
backbone moieties are also found associated with many components of pathogens and are 
known to influence pathogen internalization [34]. 
 
When designing vaccine adjuvants to enhance the immune response and to release 
encapsulated antigens, it is desirable for the adjuvant to be capable of mimicking the immune 
activation of DCs induced by a pathogen or natural infection. This includes upregulation of 
adhesion receptors (for migration to draining lymph nodes), antigen presentation machinery, 
and T cell co-stimulatory molecules. However, it is important that the adjuvants induce 
limited production of pro-inflammatory cytokines to prevent immune-mediated host tissue 
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damage. The polyanhydride nanoparticle adjuvants, 50:50 CPTEG:CPH and poly(SA), 
demonstrated the ability to enhance surface expression of MHC I, MHC II, CD86 and CIRE 
to levels greater than or equal to that induced by stimulation with the known PAMP, LPS 
(Supplementary Figure 10.1). These nanoparticle formulations were also able to enhance 
cytokine production in a chemistry dependent manner (Supplementary Figure 10.2). These 
data support our previous studies demonstrating that polyanhydride nanoparticles are 
biocompatible and induce significantly less cytokine secretion as compared to LPS [12, 18]. In 
contrast to “off-the shelf” materials like poly(lactic-co-glycolic acid) (PLGA), alginate, or 
chitosan, the SA- and CPTEG-rich nanoparticles were capable of enhancing expression of 
CIRE, MHC I, MHC II, and IL-12p40 production over non-stimulated cells [35, 36]. 
 
Further analyses revealed that nanoparticle internalization was required for the enhanced 
expression of CD40 and production of IL-12p40 and IL-6 whereas expression of CD86 and 
MHC II was found to be independent of nanoparticle internalization (Figure 10.2 and 10.3). 
This “bystander” effect observed for enhanced MHC II and CD86 expression by 
nanoparticle-negative DCs indicates that these molecules can be indirectly upregulated, 
possibly through communication with nanoparticle-positive cells. Our observations are 
consistent with previous studies describing that upregulation of surface MHC II and CD86 
expression is less dependent or even completely independent of bacterial association and 
internalization as compared to expression of CD40 [27, 28]. In addition, IL-12p40 and IL-6 
production has been shown to be inhibited by preventing the association of DCs with 
bacterial cells [27-29]. While dependent on bacterial association, production of IL-12p40 [29] 
and IL-6 [27] can be independent of phagocytosis. Together, our data demonstrate that CD40 
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signaling and production of IL-12p40 and IL-6 are controlled by particle internalization, 
which reveals an important pathogen-mimicking characteristic of polyanhydride 
nanoadjuvants. 
 
Upon detection of a pathogen, APCs upregulate expression of antigen presentation and co-
stimulatory molecules as well as secrete cytokines in order to efficiently activate naïve T 
cells and promote the differentiation of B cells [30]. In this work, the combinatorial approach 
enabled the identification of two nanoparticle adjuvants, poly(SA) and 50:50 CPTEG:CPH, 
which possess the ability to markedly enhance cell surface expression and cytokine 
production. Thus, these two adjuvants were investigated further for their influence on DC 
cell surface marker expression and cytokine production using a differential, population-based 
analysis. Both the amphiphilic 50:50 CPTEG:CPH nanoparticles and LPS induced surface 
expression of CD86 on DCs that were also positive for MHC II, CD40, IL-12p40 or IL-6 
(Figure 10.4). These treatments also induced surface expression of MHC II on DCs that were 
also expressing CD86, CD40, IL-12p40 or IL-6 (Figure 10.4). Alternatively, poly(SA) 
nanoparticles stimulated CD40 expression on DCs positive for MHC II, CD86, IL-12p40 or 
IL-6, as well as induced IL-6 production from DCs that were also positive for MHC II, 
CD86, CD40 or IL-12p40 (Figure 10.4). These observations are consistent with previous 
work demonstrating that CD40 triggering induced maintenance of high levels of MHC II and 
upregulation of CD58, CD80, and CD86 [37]. Moreover, the phenotype MHC IIhigh, co-
stimulatory moleculehigh, and cytokinehigh is indicative of fully mature DCs [38]. Together, 
these data indicate that polyanhydride nanoparticles are capable of inducing a mature DC 
phenotype. 
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The results presented herein indicate that while both SA-rich and CPTEG-rich polymer 
chemistries stimulate DCs, they are likely doing so through different pathways. In contrast to 
SA-rich nanoparticles, the amphiphilic 50:50 CPTEG:CPH nanoparticles activated DCs in a 
manner similar to that observed for LPS. These findings were validated with PCA (Figure 
10.4F), which confirmed the similarities between 50:50 CPTEG:CPH nanoparticles and LPS 
and their dissimilarity to poly(SA) nanoparticles. Toll-like receptor agonists, such as LPS, 
have hydroxyl end groups and oxygen moieties in their backbone structure [3, 39], which may 
be responsible for the similarities in DC activation observed between LPS and 50:50 
CPTEG:CPH nanoparticles. LPS is an amphiphilic molecule containing lipid A (hydrophobic 
and hydrophilic regions), a variable hydrophilic O-polysaccharide, and core polysaccharide 
portions [40]. The number, length, pattern, and location of the acyl chains [34, 40] as well as 
structural changes to these chains alter the bioactivity of the lipid A [34, 40, 41]. These results 
exemplify the importance of LPS structure, specific molecular oxygen patterns, and carbon 
chains to its bioactivity. Additionally, LPS and bacteria have thermal properties comparable 
to that of 50:50 CPTEG:CPH, which may also contribute to the observed similar cellular 
interactions [42, 43]. Lower phase transition temperatures between the liquid crystalline and gel 
state of LPS have been shown to increase its endotoxic activity [44]. Previous investigations 
indicate that structural properties are capable of influencing cellular behavior, such as the 
oxygen content in the polymer backbone dictating cellular growth [45] and nanoparticle 
hydroxyl end group chemistry activating DCs via the complement pathway [46]. 
 
The informatics analysis employed in this work identified specific molecular descriptors of 
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polyanhydrides that were responsible for the LPS-like activation of DCs. Specifically, 
number of backbone oxygen moieties, percent of hydroxyl end groups, hydrophobicity, and 
number of alkyl ethers were identified as the key properties influencing this pathogen-
mimicking behavior (Figure 10.5). These analyses indicate that polymer chemistry markedly 
influences cytokine production and expression of cell surface markers in a pathogen-
mimicking manner. The high throughput approach used in these studies to investigate a 
library of polyanhydride nanoparticles on DC activation resulted in the identification of 
amphiphilic polyanhydride nanoparticles with similar DC activation properties as LPS 
without the toxic side effects. This methodology has important implications for rational 
design of adjuvants for use in next-generation vaccines against emerging and re-emerging 
diseases. 
 
10.6 Conclusions 
The combinatorial approach developed in this work enabled the rapid investigation of the 
effects of polymer chemistry on nanoparticle internalization and activation of DCs. Our 
studies identified amphiphilic polyanhydride nanoparticles that possess pathogen-mimicking 
properties with respect to their capacity to activate DCs. Chemistry-dependent trends were 
observed, with the least hydrophobic chemistries (SA and CPTEG-rich) promoting the 
greatest internalization of nanoparticles and the production of cytokines by DCs. The same 
chemistry-dependent trends were observed for elevated expression of antigen presenting, T 
cell co-stimulatory, and migration-associated molecules. This work indicates that the signals 
associated with activating APCs are not just limited to hydrophobicity and are more likely to 
vary in complexity (e.g., presentation of oxygen-rich molecular patterns to cells) and elicit 
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unique forms of cellular activation. Other parameters, such as amphiphilicity, surface 
composition, thermal properties, and structural properties may also play key roles in innate 
immune activation.  
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10.9 List of Figures 
  
 
Figure 10.1: SA- and CPTEG- rich polyanhydride nanoparticles are internalized by dendritic 
cells. The percentage of nanoparticle-positive DCs after incubation with: A) CPH:SA 
nanoparticles or B) CPTEG:CPH nanoparticles. Data are represented as the mean ± SEM. N= 
6 of three separate experiments. Treatments with different letters are significantly different 
from one another at p-value < 0.049. 
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Figure 10.2: Nanoparticle internalization by DCs is important for CD40 expression but not 
CD86 or MHC II expression. Percent of DC populations that internalized (nanoparticle+) or 
did not internalize (nanoparticle-) (A) CPH:SA nanoparticles or (B) CPTEG:CPH 
nanoparticles that were also positive for MHC II. Percent of DC populations that did or did 
not internalize (C) CPH:SA nanoparticles or (D) CPTEG:CPH nanoparticles that were also 
positive for CD86. Percent of DC populations that did or did not internalize (E) CPH:SA 
nanoparticles or (F) CPTEG:CPH nanoparticles that were also positive for CD40. Data are 
represented as the mean ± SEM. N=4 of three separate experiments. * represents a 
statistically significant difference between nanoparticle+ and nanoparticle- groups within a 
group at p-value < 0.04.  
272 
 
 
 
 
Figure 10.3: Nanoparticle internalization by DCs is important for cytokine production and is 
dependent upon nanoparticle chemistry. Percent of DC populations that internalized 
(nanoparticle+) or did not internalize (nanoparticle-) (A) CPH:SA nanoparticles or (B) 
CPTEG:CPH nanoparticles that were also positive for IL-12p40. Percent of DC populations 
that did or did not internalize (C) CPH:SA nanoparticles or (D) CPTEG:CPH nanoparticles 
that were also positive for IL-6. Data are represented as the mean ± SEM. N=4 of three 
separate experiments. * represents a statistically significant difference between nanoparticle+ 
and nanoparticle- groups within a treatment at p-value < 0.026.  
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Figure 10.4: LPS or 50:50 CPTEG:CPH nanoparticle treatment of DCs revealed similar 
populations of double positive DCs while different double positive DC populations were 
generated following treatment with poly(SA) nanoparticles. Data are graphed as the 
percentage of CD11c+ DCs positive for (A) MHC II, (B) CD86, (C) CD40, (D) IL-12p40 or 
(E) IL-6 that were also positive for a second surface marker or cytokine. Data are represented 
as the mean ± SEM. N=6 of three separate experiments. Treatments with different letters are 
significantly different from one another at p-value < 0.044. F) PCA plot of the double 
positive DC population data validating that LPS and 50:50 CPTEG:CPH were similar to one 
another while poly(SA) was different from those two treatments.  
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Figure 10.5: Identification of –OH end groups, oxygen content, alkyl ether, and 
hydrophobicity as important pathogen-mimicking structural descriptors. A) Molecular 
descriptors (1-23) for the enumeration of the features of polyanhydrides and LPS. The 
structure descriptors are defined by Bicerano [31]. B) Partial least squares analysis was used to 
identify the polymer descriptors with the most pathogen-mimicking impact on dendritic cell 
activation. 
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Supplementary Figure 10.1: CPTEG- and SA-rich nanoparticles synthesized combinatorially 
activate DCs similarly to conventionally fabricated nanoparticles. A) SEM photomicrographs 
of combinatorially (black bars) and conventionally (white bars) fabricated nanoparticles 
demonstrate similar size distributions and surface morphology. Mean fluorescence intensity 
(MFI) of (B) MHC I, (C) MHC II, (D) CD86, (E) CD40 and (F) CIRE on DCs incubated 
with combinatorially or conventionally fabricated CPH:SA and CPTEG:CPH nanoparticles. 
Non-stimulated (NS) cells were the negative control and LPS-stimulated cells were the 
positive control. Data are represented as the mean ± SEM. N=6 of three separate 
experiments. There were no statistically significant differences between the two groups for 
expression of any markers.  
 
Validation of combinatorial synthesis and nanoparticle fabrication 
Previous work from our laboratories has demonstrated that conventionally synthesized 
polyanhydride nanoparticles enhance cell surface expression of markers associated with DC 
activation as well as induce DCs to produce pro-inflammatory cytokines [12, 18]. In this work, 
polyanhydride nanoparticles were synthesized using a combinatorial methodology [8, 9, 18] and 
validated against those synthesized conventionally (i.e., using “one-sample-at-a-time” 
nanoprecipitation) using platforms for physicochemical characterization and DC activation. 
The 1H NMR characterization indicated that the combinatorially synthesized copolymers 
resulted in identical polymer peaks and showed similar molecular weights to those 
synthesized conventionally (~10,000-18,000 g/mol) [6, 7, 11, 12, 16, 21-23]. Scanning electron 
microscopy was employed to make visual assessments between conventionally and 
combinatorially fabricated nanoparticles. The average size was found to be ~200 nm, once 
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again consistent with the size range of nanoparticles fabricated conventionally 
(Supplementary Figure 10.1A) [16, 23]. 
 
Immune activation studies were also performed to validate the similarities in cell surface 
marker expression between the DCs treated with combinatorial and conventional 
nanoparticles. No significant differences were observed in DC expression of MHC I, MHC 
II, CD86, CD40 or CIRE when cells were cultured with nanoparticles fabricated by either 
method (Supplementary Figure 10.1). Also in agreement with previously published data [12, 
18], combinatorially synthesized SA- and CPTEG-rich nanoparticles induced the greatest 
expression of cell surface markers. Specifically, stimulation with SA-rich copolymers 
enhanced DC expression of CD40 and MHC I whereas treatment with the amphiphilic 
CPTEG-rich copolymers were best at enhancing the expression of MHC II, CD86 and CIRE. 
Similar to the hydrophobicity trends observed for surface marker expression, the percentage 
of DCs positive for secretion of the cytokines IL-6 and IL-12p40 increased with decreasing 
nanoparticle hydrophobicity (Supplementary Figure 10.2). 
 
Supplementary Figure 10.2: Cytokine production is induced by nanoparticles co-incubated 
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with DCs in a chemistry-dependent manner. Percentage of DCs positive for either IL-12p40 
and IL-6 when cultured with (A) CPH:SA nanoparticles, (B) CPTEG:CPH nanoparticles, and 
(C) control treatments (LPS = positive control and NS = negative control). Data are 
represented as the mean ± SEM. N=6 of three separate experiments. * indicates statistical 
significance from NS (p-value < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
280 
 
 
 
Chapter 11: High Throughput Evaluation of In vivo 
Biodistribution of Polyanhydride Nanoparticles 
 
A paper to be submitted for publication in Small 
Latrisha K. Petersen1, Lucas Huntimer2, Katherine Walz1, Amanda Ramer-Tait2, Michael J. 
Wannemuehler2, and Balaji Narasimhan1* 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Adjuvants, polyanhydride nanoparticles, in vivo, biodistribution, depot 
_______________________________________ 
1Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 
50011 
2Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, 
Ames,  
IA 50011 
281 
 
 
 
11.1 Abstract 
Several challenges are associated with current vaccine strategies some of which include 
repeated immunizations, which can restrict patient compliance, and limited immunization 
routes, which could hinder immune protection when applied differently than the pathogen 
infection route. Thus, there is a need for vaccine adjuvants capable of multi-route 
administration and prolonged antigen release through mucoadhesion to the respiratory tract 
or by providing a depot within tissue. In this work, we utilized a combinatorial platform to 
investigate the in vivo biodistribution, depot effect, and mucoadhesion of polyanhydride 
nanoparticles as dictated by nanoparticle chemistry and administration route (parenteral and 
intranasal). This was achieved by employing a live animal imaging system with near infrared 
fluorescent markers to simultaneously investigate these parameters. All nanoparticle 
chemistries resulted in rapid dispersal when delivered intranasally and provided a long-term 
depot when administered parenterally. Chemistry-dependent trends were identified; 
specifically, intranasally administered amphiphilic and hydrophobic polyanhydride 
nanoparticles demonstrated superior mucoadhesive properties, enabling prolonged residence 
in lung tissue. Parenterally administered amphiphilic nanoparticles demonstrated the longest 
injection site residence time. These results provide new chemistry- and route-dependent 
insight into the biodistribution and tissue-specific targeting of these nanoparticle-based 
vaccine adjuvants for improved antigen delivery, depot, and dispersion. 
 
11.2 Introduction 
Biodegradable polymers have the advantage of delivering biological molecules at controlled 
rates, limiting the need for repeated treatments [1-5]. This characteristic has beneficial 
282 
 
 
 
implications in vaccine delivery, as it promotes continual antigen exposure and the 
subsequent development of immunological memory. Many conventional vaccination 
methods include frequent administrations of the antigen to achieve protective immunity 
against pathogens. When these administrations are performed via injections, they are often 
painful and lead to poor patient compliance [6-9]. It has been suggested that the best way to 
achieve vaccine efficacy is by vaccinating through the same route that the pathogen uses to 
infect the host [10]. In this regard, intranasal delivery has several advantages over parenteral 
routes for vaccination against respiratory pathogens. This needle-free approach does not 
require trained personnel, has increased patient compliance, and is capable of enhancing both 
mucosal and systemic immune responses [11]. The major drawback of this administration 
method is the relatively poor immunogenicity of the protein antigens that are used in non-
adjuvanted vaccines [7,11]. Often there is rapid mucociliary clearance of these antigens [11], 
which can to result in short respiratory tract residence times and minimal immune response 
[12,13]. Thus, there is a need for biocompatible, mucoadhesive, vaccine adjuvants that have 
administration route versatility and control over antigen release, ultimately enabling more 
effective disease prevention and treatment.  
 
Polyanhydrides are a class of biodegradable, non-toxic, non-mutagenic materials that are 
capable of encapsulating and delivering biological molecules in vivo. These polymers are 
capable of being formulated into nanoparticles enabling administration intramuscularly or 
intranasally [4,5]. Nanoparticles based upon copolymers of sebacic acid (SA), 1,6-bis-(p-
carboxyphenoxy hexane) (CPH), and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaocatane) 
(CPTEG) have been shown to exhibit tunable properties, including high protein loading 
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efficiency, tailored protein release kinetics, and immunomodulatory adjuvant behavior [14-28]. 
Amphiphilic copolymers based on CPTEG and CPH have also demonstrated the ability to 
enhance cell surface marker expression similar to lipopolysaccharide (LPS), a pathogen 
associated molecular pattern (PAMP) which is found on the outer membrane of Gram-
negative bacteria, without the toxic side effects associated with extreme levels of cytokine 
production [15,24,27,28]. They have been shown to possess (non-specific) “pathogen-mimicking” 
properties, making them ideal vaccine adjuvants [14,27,28]. These properties are essential for 
targeting the correct areas of the immune system and enabling proper exposure of antigen to 
promote immunological memory. Recently, long-term protection against a lethal challenge of 
Yersinia pestis was achieved with a single-dose intranasal vaccine composed of antigen-
encapsulated polyanhydride nanoparticles [5]. Additionally, polyanhydrides have shown the 
capability to preserve the functionality of encapsulated proteins upon release [17-22,25,29]. Many 
of these characteristics are controlled by copolymer chemistry and therefore by selecting the 
polymer chemistry, these properties can be modulated to fit the desired application.  
 
While a significant amount of work has been done in vitro to assess polyanhydride 
nanoparticle performance in terms of protein release, protein stability, cellular uptake, and 
cellular activation, little work to date has investigated the biodistribution or trafficking of 
theses nanoparticles in vivo as a function of administration route and nanoparticle chemistry. 
To design efficacious vaccine delivery systems capable of mimicking the infection route of a 
pathogen, knowledge of the distribution and dispersal of this delivery system is essential. 
Additionally, the residence time of these nanoparticles in vivo remains largely unknown and 
is integral to understand the depot and delivery capabilities of this platform. We present data 
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herein defining the in vivo biodistribution and residence times of polyanhydride nanoparticles 
administered by various routes. These studies were performed using a high throughput, 
combinatorial approach with a live animal imaging system and near infrared fluorescent 
markers to simultaneously investigate the effect of several chemistries or administration 
routes in individual mice. 
 
11.3 Materials and Methods 
Materials 
The chemicals utilized in the monomer synthesis include: 4-p-fluorobenzonitrile, purchased 
from Apollo Scientific (Cheshire, UK); 1-methyl-2-pyrrolidinone, 1,6-dibromohexane, tri-
ethylene glycol, 4-hydroxybenzoic acid, 4-p- and 1,6-dibromohexane; these were purchased 
from Sigma Aldrich (St. Louis, MO); and dimethyl formamide (DMF), toluene, sulfuric acid, 
acetonitrile, and potassium carbonate were obtained from Fisher Scientific (Fairlawn, NJ). 
Chemicals for the polymer synthesis and nanoparticle fabrication pentane, methylene 
chloride, acetic anhydride and chloroform; all purchased from Fisher Scientific. Deuterated 
chemicals for NMR analysis included chloroform and dimethyl sulfoxide (Cambridge 
Isotope Laboratories, Andover, MA). Fluorescent dyes for in vivo imaging included: Texas 
Red®-X succinimidyl ester (TR) was purchased from Invitrogen (Carlsbad, CA) and 
VivoTag 680 (VT680) and VivoTag 800 (VT800) were purchased from Perkin Elmer. 
SKH1-E mice were obtained from Charles River (Wilmington, MA) and housed under 
specific pathogen-free conditions. Animal procedures were conducted with the approval of 
the Iowa State University Institutional Animal Care and Use Committee. 
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Combinatorial polymer synthesis, nanoparticle fabrication, and characterization 
SA monomer was purchased from Sigma Aldrich. 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
monomer and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaocatane) (CPTEG) were synthesized as 
described previously [30]. CPTEG:CPH and CPH:SA copolymers were combinatorially 
synthesized as described before [23,27,29,31]. The polymers were dissolved in methylene 
chloride, fluorescent dye was added to the dissolved polymer, the dye-polymer solution was 
dispersed by sonication at 40 Hz for 30 s, and rapidly precipitated into a non-solvent 
(pentane) for the formation of multiple dye-loaded nanoparticle chemistries. They were dried 
using rapid filtration and stored under dry conditions at -20 °C until use in vivo. The 
polymers were characterized by 1H nuclear magnetic resonance (NMR) spectroscopy and gel 
permeation chromatography (GPC) and the nanoparticles were imaged using scanning 
electron microscopy (SEM).  
 
Nanoparticle administration in vivo and image capture of mice and organs 
Nanoparticles were suspended in sterile saline and sonicated at 15 Hz for 30 s to uniformly 
disperse the particles. SKH-1 mice were anesthetized with isoflurane and administered 50 μL 
of the desired treatment (dye-loaded nanoparticles, dye only, or saline). In this study, three 
routes of administration were studied: subcutaneous (SC; in the nape of the neck), 
intramuscular (IM; in the inner thigh) and intranasal (IN, in the nares). The nanoparticle 
chemistries studied were 50:50 CPTEG:CPH, 50:50 CPH:SA, 20:80 CPTEG:CPH, and 20:80 
CPH:SA. In the route-dependent study, 50:50 CPTEG:CPH and 50:50 CPH:SA nanoparticles 
were encapsulated with TR for SC administration, VT800 for IN administration, and VT680 
for IM administration. For the chemistry-dependent IN study, 50:50 CPTEG:CPH and 50:50 
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CPH:SA were loaded with VT680 and 20:80 CPTEG:CPH and 20:80 CPH:SA with VT800. 
A total of 166.66 μg of dye-loaded nanoparticles were administered per route. Control groups 
were included for each combinatorial study, which consisted of mice that only received one 
treatment. Additionally, dye only and saline controls were administered for each route. X-ray 
and fluorescent images of both the anterior and posterior sides of each mouse were obtained 
using the In vivo Multispectral FX Pro (Carestream, Rochester, NY) at 3 h, 6 h, 12 h, 24 h, 3 
days, 7 days, and 14 days. The TR, VT680, and VT800 dyes were imaged at excitation 
wavelengths of 540nm, 670nm, and 760nm and emission wavelengths of 600nm, 750nm, and 
830nm respectively. On day 14, the mice were imaged and euthanized. Ex vivo tissue 
analysis of the liver, spleen, kidneys, lungs, and injection sites was performed to determine 
nanoparticle presence. Briefly, the tissues were removed, washed with ethanol, and imaged. 
Both sides of the organs were imaged utilizing the same methods as described for imaging 
live animals. 
 
Image analysis 
Sixteen-bit mouse and organ tiff images were analyzed with Image J (NIH, Bethesda, MD). 
Images were inverted and background was subtracted based upon a rolling ball radius of 50, 
150, and 150 from each fluorescent image for TR, VT680, and VT800, respectively. Images 
were stacked and circular regions of interest (ROIs) created for the mouse around the head, 
neck, chest, lower abdomen, and leg injection sites and outlined ROIs were created around 
each organ. Mean fluorescence intensity (MFI) was recorded for each site for each 
fluorescent image. Image overlays were created by stacking the images, creating a color 
composite, and adjusting each channel to the desired color. Macros were created and utilized 
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for all images when determining ROI MFIs and for creating image overlays. 
 
Data and statistical analysis 
All data was normalized to the saline group. JMP software (SAS Institute, Cary, NC) was 
used to make comparisons between treatments and the negative (saline) control using the 
student t-test and comparisons between different treatments (route or chemistry) were 
performed using a model ANOVA with Tukey’s HSD. 
 
11.4 Results 
Polymer and nanoparticle characterization 
1H NMR was used to determine the molecular weight and chemical structure of the 
combinatorially synthesized polyanhydrides for this work. The polymers were found to be 
within the expected molecular weight range (10,000 to 18,000 Da), which is in agreement 
with previously published work [18-20,30]. SEM imaging of the dye-loaded nanoparticles 
revealed results consistent with previous studies, with average particle sizes of ~200 nm and 
uniform surface morphology across chemistries (data not shown) [5,24,29,32]. The chemical and 
structural characterization of the dye-loaded nanoparticles was also consistent across 
chemistries and batches and with previous work [23,29]. 
 
Biodistribution and depot effect of nanoparticles is influenced by route of administration 
In these studies, 50:50 CPTEG:CPH or 50:50 CPH:SA nanoparticles were administered via 
three different routes, SC, IM, or IN. Nanoparticles for each route were labeled with a 
different fluorescent dye TR (SC), VT680 (IM), and VT800 (IN). Figure 11.1 presents 
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representative time course images of mice administered 50:50 CPTEG:CPH nanoparticles 
(M1) or 50:50 CPH:SA nanoparticles (M2) via three different routes. Nanoparticles 
administered IN remained detectable in the mouse for approximately 24 h, whereas 
nanoparticles administered SC or IM resided in the mice at least 14 days (Figure 11.1). When 
compared with the dye only control group for IM or SC administration, the nanoparticles 
exhibited a significantly longer residence time at the site of injection (data not shown). 
Separated images for each fluorescent channel are shown in Supplementary Figure 11.1A. 
The nanoparticles delivered intranasally dispersed throughout the body of the mouse. 
Alternatively, little fluorescence was detected in the tissue at any other site other than the 
injection site for nanoparticles administered SC or IM. Figure 11.2, which is a graphical 
representation of the images in Figure 11.1, compares different injection sites for 50:50 
CPTEG:CPH (Figure 11.2A) and 50:50 CPH:SA (Figure 11.2B) nanoparticles. Nanoparticles 
injected IM deposited fluorescent signal the longest at the injection site while the 
nanoparticles injected SC appeared to diminish in fluorescence intensity the fastest (Figure 
11.2). At the parenteral administration sites (i.e., SC and IM), 50:50 CPTEG:CPH 
nanoparticles lingered longer than the 50:50 CPH:SA particles. Both nanoparticles 
chemistries were found to behave similarly when administered IN, moving rapidly through 
the body of the mouse with minimal nanoparticle fluorescence remaining after 24 h (Figures 
11.2C and D). Importantly, control mice with nanoparticles injected by only one route 
revealed similar biodistribution trends as mice administered nanoparticles via all three routes 
(Supplementary Figure 11.1). 
 
Despite the fact that fluorescence was below detection levels in the chest area of the mouse 
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after 24 h, examination of the excised organs indicates that nanoparticles are still present in 
the lung tissue after 14 days (Figure 11.3 and Supplementary Figure 11.2). It is important to 
note that the lack of fluorescence in the whole mouse images when the nanoparticles were 
delivered intranasally (Figures 11.1 and 11.2) is likely due to the blockage of fluorescent 
signal in deep tissue [33]. Additionally, injection sites for each administration route indicate 
that while similar levels of fluorescence were determined in the whole mouse images, actual 
fluorescence in the injection site tissue is greatest for IM-administered nanoparticles. These 
findings indicate that the IM administration of nanoparticles provides the longest depot of 
residing nanoparticles; however, nanoparticles administered via SC or IN routes dissipate 
rapidly and distribute to distal tissues of the body.  
 
Nanoparticle chemistry dictates lung tissue adhesion and clearance from the body 
Figure 11.4 presents representative time course images of mice administered 20:80 and 50:50 
CPTEG:CPH nanoparticles (M1) or 20:80 and 50:50 CPH:SA nanoparticles (M2) for the 
chemistry dependent study. As seen in Figure 11.4, CPTEG:CPH and CPH:SA nanoparticles 
appear to move rapidly throughout the mouse body as observed with particles administered 
IN in the first study (Figure 11.1). These images again reveal that most nanoparticles fall 
below detection levels after 24 h. Supplementary Figure 11.3 shows each fluorescent image 
observed separately, which provides a clearer visualization of the biodistribution of each 
nanoparticle chemistry. Figure 11.5 indicates that 20:80 CPH:SA was distributed throughout 
the body the most rapidly and was detectable at significantly higher levels than the other 
nanoparticle chemistries in the lower abdomen. The other nanoparticle chemistries appeared 
to similarly distribute throughout the body, moving from the head to lower abdomen within 
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the first 24 h. Control mice administered only one nanoparticle chemistry per mouse 
demonstrated similar biodistribution patterns to the mice administered multiple chemistries 
(Supplementary Figure 11.3B). 
 
Ex vivo analysis of the organs 14 days post IN immunization revealed fluorescence in the 
lungs, despite the inability to detect fluorescence in vivo after 24 h (Figure 11.6 and 
Supplementary Figure 11.4), indicates that all formulations of nanoparticles are retained in 
the lungs for at least 14 days.  
 
11.5 Discussion 
The use of polyanhydride particle systems as vaccine adjuvants provides many advantages 
over current options because they eliminate the need for frequent administrations.  Moreover, 
they provide an antigen depot and can adjuvant the immune system through non-specific 
stimulation of antigen presenting cells. To further explore their use in vivo, we utilized a 
combinatorial approach for the simultaneous investigation of the effect of route and 
chemistry on in vivo biodistribution, trafficking, and residence time of polyanhydride 
nanoparticles. This approach facilitated multiple studies to be carried out per mouse, which 
reduced the number of experimental subjects, time, and cost. The high throughput studies 
revealed that polyanhydride nanoparticles provide a depot for antigen release and are retained 
in deep tissue after immunization. Many of these nanoparticles (50:50 CPTEG:CPH and 
50:50 CPH:SA) were also identified to possess unique mucoadhesive properties, making 
them ideal for intranasal vaccination against respiratory pathogens. These two chemistries 
were found to optimal for long-term presence at the IM or SC injection sites or within deep 
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lung tissue following IN administration. This combinatorial in vivo approach to investigate 
nanoparticle biodistribution provides a framework for optimizing polymer chemistry 
formulations and delivery routes for individual applications. 
 
Depending upon the infectious pathogen, vaccines may be more effective via different 
delivery routes. Additionally, the use of a tunable delivery system capable of prolonged 
antigen release could eliminate the need for repeated administrations. Our work demonstrates 
that polyanhydride nanoparticles reside in the injection site tissue or mucosal membranes for 
at least two weeks (Figures 11.3 and 11.6) when delivered SC, IM or IN, indicating that they 
would be able to provide a sustained release of encapsulated antigen for that same duration of 
time. Figure 11.1 suggests that when injected in less fluid tissue space (IM or SC vs. IN) the 
particles are more restricted to that space, thus encountering less movement, which would 
provide a longer-term antigen depot. External imaging of the mice suggests that parenterally 
administered nanoparticles appeared to have similar residence times of up to 14 days when 
administered IM or SC, and ongoing studies indicate that they are still present after 2 months 
(Figures 11.1 and 11.2 and data not shown). However, upon examination of injection site 
tissue samples, the presence of nanoparticle fluorescence was significantly greater for IM 
administration (Figure 11.3). These observations indicate that nanoparticles indeed have 
different residence times at different parenteral injection sites. Since it is known that these 
particles can be programmed to release their payload over time periods ranging from a week 
to a few months [30,34,35], these results demonstrate the valuable capability of controlling 
antigen release by both nanoparticle chemistry and administration route. Studies have also 
shown that when antigen is loaded into particles and delivered parenterally, higher antibody 
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titers were observed than when the antigen is delivered alone [4]. Not only could the 
prolonged release time of a drug delivery device reduce the dose required for immunization, 
it may also eliminate the need for multiple administrations. Additional studies have shown 
that polyanhydride particles induce low levels of inflammation [36] which suggests minimal 
post-administration side effects for the recipient. These improved characteristics would likely 
increase patience compliance and minimize antigen dose, ultimately leading to more cost-
effective vaccine strategies. 
IN vaccination is thought to be an advantageous delivery method for respiratory pathogens, 
including seasonal influenza, group A streptococcus, and inhaled anthrax. The relatively poor 
immunogenicity of non-adjuvanted antigens and high probability of mucociliary clearance 
often render this vaccination route ineffective [11,37,38]. Thus, vaccination against respiratory 
pathogens with subunit vaccines is primarily administered parenterally. However, a 
limitation with parenteral vaccination is that only serum IgG is induced against the vaccine 
antigen with little production of IgA in the respiratory mucosa, leaving the upper airways 
unprotected [11]. The polyanhydride nanoparticles investigated in this work demonstrated 
prolonged residence in deep lung tissue at least 14 days following IN administration (Figures 
11.3 and 11.6). The nanoparticles delivered IN dispersed throughout the body of the mouse; 
an observation seen only after IN administration (Figures 11.1 and 11.2). This phenomenon 
likely promotes an interaction between the particles and the mucosal membranes of the upper 
and lower respiratory tract, in addition to facilitating creation of a depot for antigen release 
and development of immunological memory. Based upon the close association between the 
nanoparticles and the mucosal lung tissue (Figures 11.3 and 11.6), it is predicted that these 
rapidly dispersed nanoparticles are primarily adhering to the tissues of the respiratory system. 
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Nanoparticles that do not adhere are likely passed through the digestive tract and excreted 
(Figures 11.4 and 11.5).  
 
This work has also demonstrated that nanoparticle chemistry plays an integral role in tissue 
residence time and biodistribution of nanoparticles when delivered IN (Figures 11.4-11.6). 
Nanoparticles made of 20:80 CPH:SA dispersed throughout the body most rapidly, while the 
other nanoparticle formulations resided longer in the respiratory tract (Figures 11.4 and 
11.5). This may be a result of the lower hydrophobicity, higher Tg (Table 11.1), and faster 
degradation properties of 20:80 CPH:SA. These properties make 20:80 CPH:SA 
nanoparticles decrease in size more rapidly, rendering them more compatible with the 
internal aqueous environment of the mouse. Moreover, they would move more rapidly 
throughout the body without being stalled in mucosal surfaces or membranes. Previous 
reports indicate that polystyrene particles less than 500 nm have the ability to diffuse through 
the mucin layer in a mucous membrane, indicating that all nanoparticles tested in this work 
would be sufficiently small enough for diffusion [39]. Particle hydrophobicity is also thought 
to play a role in mucosal transport, with the least hydrophobic particles having the highest 
translocation permeability [39]. Work by Szentkuti reported that hydrophobic latex 
nanoparticles 415 nm and smaller rapidly penetrated the mucosal layer attaching to the apical 
membranes of the surface cells, indicating that they are cell-adhesive rather than muco-
adhesive [40]. Therefore, nanoparticle size, Tg, and hydrophobicity (Table 11.1) may all 
influence particle transport and mucosal adhesion. The least hydrophobic nanoparticles with 
lower Tgs, such as 50:50 CPTEG:CPH and 50:50 CPH:SA, may be the best option for 
treatment or vaccination in the respiratory system because of their structure and superior 
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adhesive properties to the mucosal membrane of the lungs (Figures 11.4 and 11.6). The low 
Tg nanoparticles are more flexible and can change shape as dictated by the environment 
[27,28]. It is interesting to note that pathogens and their surface molecules (i.e. LPS 
(lipopolysaccharide)) have similar thermal properties [41,42] to these low Tg nanoparticles. 
Additionally, these nanoparticles, like pathogens, possess mucoadhesive properties, enabling 
their association with the respiratory system. Therefore, vaccination with antigen-loaded 
nanoparticles based upon these polymers would be able to follow a very similar route and 
associate with similar tissues in which the pathogen infects.   
 
When administered IN, these polyanhydride nanoparticles demonstrate equivalent or greater 
residence times at the nasal administration site as other mucoadhesive polymers such as 
N,N,N-trimethylchitosan (TMC), chitosan microspheres, and starch microspheres [37,43]. The 
polyanhydride nanoparticle system may be more effective for vaccination against respiratory 
pathogens because of their ability to associate with lung tissue, a location where TMC was 
not identified [37]. The presence of hydroxyl end groups is predicted to influence bioadhesive 
interactions to mucosal surfaces by increasing the hydrogen bonding with components of the 
mucosal surface (hydroxyl end groups) [44]. As CPTEG:CPH nanoparticles enter an aqueous 
environment, they degrade and expose high levels of hydroxyl end groups which, as 
suggested, may promote hydrogen bonding, resulting in a very intimate interaction between 
the mucosal surface and nanoparticles. This would then make the nanoparticles more 
accessible to APC uptake, activation, migration to the draining lymph nodes. In addition to 
the mucoadhesive properties demonstrated in this work, 50:50 CPTEG:CPH nanoparticles 
also have inherent non-specific “pathogen-like” stimulation of the immune system [15,24,27,28]. 
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Recent work from our laboratories has shown that IN vaccination against pneumonic plague 
with antigen encapsulated into and adjuvanted with 50:50 CPTEG:CPH nanoparticles 
protected mice from lethal Y. pestis challenge better than the antigen alone or antigen 
adjuvanted with MPLA in single dose regimens at 23 weeks post vaccination [5]. Clearly, the 
amphiphilic 50:50 CPTEG:CPH nanoparticles encompass unique mucoadhesive properties 
enabling prolonged antigen exposure for protection against respiratory pathogens. 
 
The advantages of the nanoparticle delivery system for vaccine delivery can be translated to 
drug delivery applications such as treatment of respiratory diseases, internal wound healing 
complications, or control over bacterial and cellular behavior [6,11,37]. Anti-microbials, growth 
factors, or cell-specific adhesion molecules can be delivered more effectively to tissue by 
biodegradable nanoparticles for localized control of bacterial and cellular behavior [45,46]. 
Antibiotics, antivirals, or immune stimulating cytokines (IL-12) may also be more effective 
for post-infection treatment of respiratory pathogens when delivered IN [47] which could be 
improved with the use of a prolonged release, mucoadhesive nanoparticle-based delivery 
system. Several treatment strategies could be improved upon with a nanoparticle based drug 
delivery system capable of providing long-term, targeted therapy in a single administration. 
 
11.6 Conclusions 
The combinatorial in vivo studies described in this work have demonstrated the chemistry- 
and route-dependent biodistribution and depot effect of polyanhydride nanoparticles. This 
approach enabled a rapid investigation of nanoparticle dispersion, depot, and residence time 
as dictated by administration route and nanoparticle chemistry. Amphiphilic 50:50 
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CPTEG:CPH nanoparticles demonstrated the longest residence time at parenteral injection 
sites and would be expected to provide a long-term antigen depot in vivo, allowing for the 
development of immunological memory. Additionally, both 50:50 CPTEG:CPH and 50:50 
CPH:SA nanoparticles demonstrated superior mucoadhesive properties, enabling prolonged 
residence in lung tissue. These mucoadhesive polymer nanoparticles provide new 
opportunities for their use as adjuvants in intranasal and parenteral vaccination. The insights 
gained from these studies will enable the rational design of vaccine and therapeutic drug 
delivery systems for targeted and localized delivery of their payloads over extended time 
periods. 
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11.9 List of Figures 
 
Figure 11.1: Representative mouse images showing differential persistence at the injection 
site of nanoparticles administered via three routes over a two week period. Persistence of IM 
particles > 14 days, persistence of SC particles ~14 days and persistence of IN particles < 1 
day. M1 = mouse administered 50:50 CPTEG:CPH nanoparticles, M2 = mouse administered 
50:50 CPH:SA nanoparticles, and M3 = mouse administered saline. Blue indicates TR-
loaded particles administered SC, red indicates VT680-loaded particles administered IM, and 
yellow indicates VT800-loaded particles administered IN.  
 
 
Figure 11.2: Nanoparticles administered via three routes persisted at the injection site longest 
301 
 
 
 
when administered IM; however, IN particles rapidly disseminated throughout the body. ROI 
analysis of mice depicted in Figure 11.1.  Mice administered 50:50 CPTEG:CPH 
nanoparticles (A) persist at SC and IM injection site longer than that for mice administered 
50:50 CPH:SA nanoparticles (B). 50:50 CPTEG:CPH (C) and 50:50 CPH:SA nanoparticles 
(D) rapidly disperse through the mouse and terminate in the chest area with very little 
particle fluorescence in the lower abdomen area. n = 5 for 50:50 CPTEG:CPH and n=3 for 
50:50 CPH:SA.  Letters indicate statistical significance between each treatment group and 
the asterisk indicates statistical significance from the saline control (p-value < 0.05). 
 
 
Figure 11.3: Nanoparticles were retained in the IM injection site tissue longer than at the 
other two sites. Also, nanoparticles administered IN are targeted to the lungs and retained 
there after 14 days for both A) 50:50 CPTEG:CPH (A) and 50:50 CPH:SA (B) nanoparticles. 
ROI analysis of the mouse organs after 14 days.  No nanoparticle fluorescence was observed 
in the liver, spleen, or kidneys. n = 5 for 50:50 CPTEG:CPH and n=3 for 50:50 CPH:SA. 
Letters indicate statistical significance between each treatment group and the asterisk 
indicates statistical significance from the saline control (p-value < 0.05). 
 
302 
 
 
 
 
Figure 11.4: Representative mouse images indicating that IN administration of two 
nanoparticle chemistries, 50:50 and 20:80 CPH:SA or 50:50 and 20:80 CPTEG:CPH, 
resulted in rapid dispersion of the particles throughout the body within the first 24 hours after 
administration. However, CPTEG:CPH nanoparticles tended to localize in different areas 
than CPH:SA nanoparticles, indicating a differential effect on biodistribution based upon 
nanoparticle chemistry. M1 = mouse administered VT680-loaded 50:50 CPTEG:CPH 
nanoparticles IN (red) and VT800-loaded 20:80 CPTEG:CPH nanoparticles (yellow), M2 = 
mouse administered VT680-loaded 50:50 CPH:SA nanoparticles IN (red) and 20:80 CPH:SA 
VT800-loaded nanoparticles IN (yellow), and M3 = mouse administered saline IN. 
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Figure 11.5: Chemistry played an important role in nanoparticle distribution throughout the 
body.  ROI analysis of mice depicted in Figure 11.4 for A) head, B) neck, C) chest, and D) 
lower abdomen. The 20:80 CPH:SA nanoparticles show significantly greater fluorescence in 
the lower abdomen at initial time points. n = 3 for all groups. Letters indicate statistical 
significance between each treatment group and the asterisk indicates statistical significance 
from the saline control (p-value < 0.05). 
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Figure 11.6: Even though no longer visible in the whole mouse images, all nanoparticle 
chemistries administered IN were targeted to the lungs and retained there for at least 14 days. 
No nanoparticle fluorescence was observed in the liver, spleen, or kidneys. ROI analysis of 
the mouse organs at 14 days post-vaccination.  n = 3 for all groups. Letters indicate statistical 
significance between each treatment group and the asterisk indicates statistical significance 
from the saline control (p-value < 0.05). 
 
11.10 List of Tables 
Table 11.1: Thermal properties and contact angles of polyanhydrides [18, 22, 30, 31]. 
Chemistry Tg (°C) Tm (°C) Contact Angle (°) 
50:50 CPTEG:CPH 8 None 45 
20:80 CPTEG:CPH 18 None 45 
50:50 CPH:SA 11 50 50 
20:80 CPH:SA 50 67 50 
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11.11 Supporting Information 
 
 
Supplementary Figure 11.1: Administration of nanoparticles via three different routes 
simultaneously to the same mouse resulted in similar nanoparticle distribution patterns as 
compared to administration of nanoparticles via each route independently. A) Representative 
mouse images from Figure 11.1 separated by filter channel. M1 = mouse administered 50:50 
CPTEG:CPH nanoparticles, M2 = mouse administered 50:50 CPH:SA nanoparticles, and M3 
= mouse administered saline. B) Images of mice that received administration of nanoparticles 
via only one route. M4 = mouse administered 50:50 CPTEG:CPH SC, M5 = mouse 
administered 50:50 CPTEG:CPH IM, M6 = mouse administered 50:50 CPTEG:CPH IN, M7 
= mouse administered 50:50 CPH:SA SC, M8 = mouse administered 50:50 CPH:SA IM, and 
M9 = mouse administered 50:50 CPH:SA IN. Blue indicates TR-loaded particles 
administered SC, red indicates VT680-loaded particles administered IM, and yellow 
indicates VT800-loaded particles administered IN. 
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Supplementary Figure 11.2: Representative 14 day organ images corresponding to Figure 
11.3 separated by filter channel which indicate that IN administered nanoparticles (yellow) 
are easily observed in the lung tissue while IM (red) and SC (blue) administered 
nanoparticles are easily observed in the injection site tissue and fluorescence in the each 
tissue is indicative of nanoparticle persistence. M1 = mouse administered 50:50 
CPTEG:CPH nanoparticles, M2 = mouse administered 50:50 CPH:SA nanoparticles, and M3 
= mouse administered saline. Blue indicates TR-loaded particles administered SC, red 
indicates VT680-loaded particles administered IM, and yellow indicates VT800-loaded 
particles administered IN. 
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Supplementary Figure 11.3: Each mouse administered nanoparticles of two different 
chemistries results in similar nanoparticle distribution compared to separate mice 
administered nanoparticles of each chemistry independently. A)Representative mouse images 
from Figure 11.4 separated by filter channel which indicate that the nanoparticle of 
CPTEG:CPH chemistries may disperse differently than those of CPH:SA throughout the 
mouse body when administered IN. M1 = mouse administered VT680-loaded 50:50 
CPTEG:CPH nanoparticles IN (red) and VT800-loaded 20:80 CPTEG:CPH nanoparticles 
(yellow) and M2 = mouse administered VT680-loaded 50:50 CPH:SA nanoparticles IN (red) 
and 20:80 CPH:SA VT800-loaded nanoparticles IN (yellow). B) Images of mice that 
received administration of nanoparticles with only one chemistry. M3 = mouse administered 
50:50 CPTEG:CPH IN (red), M4 = mouse administered 20:80 CPTEG:CPH IN (yellow), M5 
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= mouse administered 50:50 CPH:SA IN (red), and M6 = mouse administered 20:80 
CPH:SA (yellow).  
 
 
Supplementary Figure 11.4: Representative 14 day organ images corresponding to Figure 
11.6 separated by filter channel which indicate that IN administered nanoparticles are easily 
observed in the lung tissue even though they are no longer detectable in the whole mouse 
images. M1 = mouse administered VT680-loaded 50:50 CPTEG:CPH nanoparticles IN (red) 
and VT800-loaded 20:80 CPTEG:CPH nanoparticles (yellow) and M2 = mouse administered 
VT680-loaded 50:50 CPH:SA nanoparticles IN (red) and 20:80 CPH:SA VT800-loaded 
nanoparticles IN (yellow). 
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Chapter 12: Conclusions 
While pathogenic microorganisms continue to mutate at a rapid rate and new diseases are 
diagnosed every day, there is an immediate need to develop faster approaches for the 
discovery and development of therapeutic devices to enhance, target, and stabilize protein-
based drugs. This work has focused on creating and utilizing high throughput approaches for 
the rapid optimization of polyanhydrides for use as drug delivery vehicles and vaccine 
adjuvants. A combinatorial framework has been developed to rapidly synthesize and 
characterize libraries of these biomaterials and simultaneously investigate multiple 
protein/polymer, cell/polymer and host/polymer interactions. Using this framework, several 
phenomena were monitored at high throughput and key relationships between polymer 
chemistry and structure, temperature, pH, device geometry, protein release kinetics, protein 
stability, cytotoxicity, immune activation, cellular differentiation, cellular adhesion, in vivo 
biodistribution, and in vivo mucosal adhesion were discovered and validated.  
 
Protein release kinetics from polyanhydride nanoparticles were assessed with a novel 
fluorescent based technique in which decreasing protein release was correlated with 
increasing polymer hydrophobicity and acidic pH release conditions. Protein stability for the 
protective antigen for anthrax (PA) and bovine serum albumin (BSA) was determined upon 
encapsulation, storage, and release from polymer nanoparticles in which CPH-rich (CPH:SA) 
and all CPTEG:CPH chemistries were able to preserve protein structure of BSA under all 
conditions tested. While 50:50 CPTEG:CPH proved most capable of preserving PA activity 
upon encapsulation and release; 50:50 CPTEG:CPH and 20:80 CPH:SA demonstrated 
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excellent storage of PA at elevated temperatures (40 °C) for 2 months.  
 
Immune activation and adjuvant properties were investigated by assessing cytokine 
production and cell surface marker expression of dendritic cells (DCs), which are the primary 
antigen presenting cells of the immune system. This work revealed treads demonstrating ↑ 
cell surface marker expression with ↓ nanoparticle hydrophobicity and ↑ cytokine 
production with ↑ oxygen content in polymer backbone. With the use of informatics tools, 
50:50 CPTEG:CPH was found to possess pathogen-mimicking properties and the specific 
properties responsible for the pathogen-mimicking behavior are hydrophobicity, number of 
backbone oxygen groups, percent of hydroxyl end groups, and number of alkyl ethers.  
 
High throughput, near-red infrared in vivo imaging, enabled rapid identification of the 
superior mucoadhesive properties of 50:50 CPTEG:CPH and 50:50 CPH:SA nanoparticles. 
Biodistribution and adjuvant depot effect were also readily identified, in which route and 
chemistry influenced these properties with intranasally administered 20:80 CPH:SA 
nanoparticles moving the most rapidly through the mouse body and intramuscularly 
administered 50:50 CPTEG:CPH nanoparticles residing in tissue the longest (i.e, depot 
effect).  
 
Taken together these studies will enable the rapid design of polyanhydrides as drug delivery 
devices and vaccine adjuvants. The high throughput methodologies developed in this 
doctoral thesis hold promise to enhance and design new therapeutic treatments and vaccines 
that are necessary to keep up with the rapidly advancing forms of disease. 
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Chapter 13: Future Work 
This research has demonstrated that polyanhydrides are a versatile biodegradable platform 
for drug delivery applications from vaccine adjuvants to delivering therapeutics to tissue 
engineering constructs. The versatility of these materials provides a basis for further research. 
Since these polymers provide protein and cell conducible environments suitable for many 
tissue engineering applications, further studies investigating the polymer mechanical integrity 
and ability to be constructed into a 3D scaffold network are necessary. In addition to tissue 
engineering applications, the use of these polymers as nanoparticle adjuvants for vaccines 
has shown much promise. While many properties such as concentration, chemistry, 
hydrophobicity, oxygen-content, etc., have been investigated for their effect on antigen 
presenting cells (APCs) of the immune system, little work to date has investigated the effect 
of polyanhydride particle shape and size on immune activation. Future work in this area 
many help design vaccine delivery vehicles that better mimic the shape of bacteria or better 
facilitate cellular internalization. Finally, future work combining the broad database of 
knowledge gathered through these combinatorial investigations could be utilized to design 
intranasal, single-dose, dose-sparing vaccine strategies for anthrax, pneumonia and influenza. 
 
13.1 CPTEG:CPH Films: Applications in Drug Delivery and Tissue Engineering 
Multi-component implants, drug-eluting stents, and tissue engineering constructs all rely on 
cellular acceptance by the host and in most cases require the ability to deliver therapeutic 
drugs, cell promoting growth factors, or immunosuppressant cytokines [1-5]. This has been 
investigated as described in the previous chapters (4, 7, 8 and 9) with polyanhydride films 
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composed of CPH:SA and CPTEG:CPH copolymers [6-9]. While several desirable 
protein/material and cell/material characteristics have been identified including preservation 
of protein structure, controlled release rate, low immune activation, enhanced cellular 
adhesion and differentiation [6-8, 10], the mechanical integrity and 3D scaffold design has not 
been demonstrated. Polymeric mechanical properties can be investigated using the 
combinatorial approach as described previously [11]. Both the mechanical integrity and 
scaffold design are dictated by the tissue in which the scaffold is being injected or implanted 
[5]. Hard tissue such as bone requires stiff polymeric structures; in contrast, soft tissue like 
nerves requires malleable polymers. Similarly, elastomeric tissue such as the skin or blood 
vessels requires flexible polymer scaffolds [5]. In addition to mechanical integrity, a 3D 
scaffold design is necessary for cellular integration into the construct. Several different 
approaches to 3D scaffold design have been reported including porous (Figure 13.1A), cell-
cleavable, and electro-spun networks (Figure 13.1B), nerve guiding conduits (Figure 13.1C), 
and elaborate grey and white matter track for spinal cord regeneration [5, 12-19]. Hence, it is of 
interest to investigate the mechanical properties of CPTEG:CPH and CPH:SA polymers in a 
combinatorial format and study their ability to be constructed into 3D networks. Further 
studies can then be conducted in high throughput to investigate protein/scaffold and 
cell/scaffold interactions as described in Chapters 4-10 and by other researchers [6-11, 20-27] and 
with the use of targeted strategies [28]. 
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13.2 Polyanhydride Particle Size and Shape Dependency on Cytotoxicity and Activation 
of Primary Murine Dendritic Cells 
A major focus of current research on polymeric adjuvants has been to investigate the use of 
nano- and microparticle adjuvants and how they influence the activation of APCs [7, 28-34]. 
Chapters 8 and 10 provided an in depth discussion of the adjuvant properties of 
polyanhydride nanoparticles composed of CPH:SA and CPTEG:CPH copolymers [7, 27]. 
While many of the mechanisms of particle internalization and activation are still unknown 
there appear to be several variables (particle size, roughness, shape, chemistry, etc.) that are 
likely to affect internalization by DCs and the subsequent immune response [7, 27-30, 35-42]. 
While much of the previous work has alluded to the effect of polymer chemistry on immune 
modulation [7, 27, 29, 30], particle size [42-44] and shape [41, 45] are known to play an integral role in 
uptake and are thus hypothesized to also play a role in immune activation. It has been 
reported previously that particles <10 μm but > 500 nm undergo internalization by 
phagocytosis, particles <500 nm but > 200 nm are internalized through endocytosis and are 
trafficked to early endosomal compartments with a pH of 6.0, and particles < 200 nm are 
internalized through endocytosis and are directed to late endosomal/lysosomal compartments 
with a pH of 4.5–5.0 [42]. Additionally, shape and orientation of PLGA and PS particles has 
been reported to affect uptake by macrophages and suggest internalization similarities 
between particles and bacteria of the same shape [41]. All reports of polyanhydride 
particle/cell interactions have been investigated with polydisperse polymer particles as seen 
in the SEM images and size distribution plots in several reports [7-9, 35, 46]. This makes it 
difficult to discern the effect of particle size and shape on immune activation.  
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Monodisperse poly(SA) particles have been fabricated by Berkland and co-workers utilizing 
precision particle fabrication technology [47]. An image of monodisperse poly(SA) 
microparticles fabricated with the precision particle fabrication technology [47] is shown in 
Figure 13.2. Additionally, shape varying particles based upon poly(lactic-co-glycolic) acid 
and polystyrene have been fabricated by Mitragotri and co-workers utilizing particle 
stretching technology employing PDMS [41]. These methods could be easily amenable to 
fabricate polyanhydride nanoparticles based upon CPH:SA and CPTEG:CPH copolymers 
varying in size and shape. It is therefore of great interest to investigate the effect of using 
monodisperse polyanhydride particles of various shapes on the internalization mechanisms of 
DCs and the subsequent immune response in a combinatorial format. Knowledge of the 
effect of particle size, particle shape, and polymer chemistry upon immune activation will 
allow for the rational design and development of more effective vaccine adjuvant/delivery 
vehicles able to better target intended immune responses. 
 
13.3 50:50 CPTEG:CPH Nanoparticle Adjuvants for the Single-dose Vaccination 
Against Anthrax, Pneumonia, and Influenza 
A major focus of research has been on the design of biocompatible polymeric adjuvants 
capable of controlling antigen release, providing a long-term antigen depot, and enhancing 
the immune response. Chapters 4 and 6 demonstrated that these polymer nanoparticles are 
capable of releasing encapsulated proteins in a chemistry dependent manner for weeks to 
months [8, 48], while Chapter 11 validated these findings in vivo [49]. Additionally, Chapter 11 
revealed mucoadhesive properties of 50:50 CPTEG:CPH and 50:50 CPH:SA nanoparticles 
and demonstrated that both CPTEG:CPH and CPH:SA nanoparticles provide a long-term 
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antigen depot in vivo. Chapters 5 and 6 revealed the effective protein stabilization capabilities 
of these polymer nanoparticles for several proteins [9, 48]. Several cell/materials interactions 
were investigated in Chapters 7, 8, 10, and 11 which indicate that these polymers are both 
biocompatible and immunomodulatory. Thus, it would be of interest to take this diverse 
knowledge of protein/polymer, cell/polymer, and host/polymer interactions for the design 
and optimization of respiratory vaccine adjuvants against pathogens such as anthrax, 
pneumonia, and influenza. Recently, long-term protection against a lethal challenge of 
Yersinia pestis was achieved with a single-dose intranasal vaccine composed of antigen-
encapsulated 50:50 CPTEG:CPH nanoparticles [50]. Based upon these findings and the 
superior mucoadhesive [49], protein stabilization [46, 48, 51], and adjuvant properties [7, 27, 30] of 
50:50 CPTEG:CPH nanoparticles, future studies designing respiratory vaccines would 
benefit by utilizing this adjuvant. Preliminary studies have indicated that elevated antibody 
titers against the pneumonia antigen, PspA, are achieved with the use of these nanoparticle 
adjuvants in a single dose administered subcutaneously, as shown in Figure 13.3. These 
studies provide insights for vaccination against respiratory pathogens including anthrax, 
pneumonia, and influenza with polyanhydride nanoparticles. Further studies could be 
conducted by varying the amount of soluble and encapsulated antigen to optimize antibody 
production and avidity and possibly reduce the amount of antigen required for protection. 
Additionally, since many of these pathogens infect via inhalation and replicate in the 
respiratory tract, it may be advantageous to deliver these nanoparticle adjuvanted vaccines 
intranasally [52-54]. Development of a single-dose, dose-sparing vaccine adjuvant capable of 
being delivered intranasally would provide a novel strategy for overcoming respiratory 
pathogen threats to public health in a patient-compliant and cost effective manner. 
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13.5 List of Figures 
 
Figure 13.1: Images of A) porous and B) electro-spun polymer networks and C) nerve 
regeneration conduits [5]. 
 
 
Figure 13.2: SEM image of 20 μm monodisperse poly(SA) particles [47]. 
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Figure 13.3: Total IgG anti-PspA concentrations from the serum of mice immunized with 
blank 50:50 CPTEG:CPH nanoparticles (blank nano), 1 μg soluble PspA + 2 μg encapsulated 
PspA into 50:50 CPTEG:CPH nanoparticles (soluble PspA + PspA nano), 1 μg PspA 
conjugated to alum (PspA + alum), and saline. Mice administered blank and PspA-loaded 
nanoparticles were only immunized once but mice administered PspA + alum were 
immunized 3 times. Error bars represent standard deviation and n=6. 
 
 
 
 
